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ABSTRACT  
HIV/AIDS is one of the most destructive health diseases of modern times, affecting 
approximately 45.5 million people worldwide. But the advent of the Highly Active 
Antiretroviral Therapy (HAART) in 1996 has significantly reduced HIV/AIDS-related 
mortality and morbidity and it has allowed many previously bed-ridden patients to live 
healthier and more productive lives. In order for the treatments to be successful, a very 
high level of adherence to HAART is required. It is estimated that at least 95% 
adherence to antiretroviral treatment is essential to reduce the replication of the virus 
and prevent the development of resistance to treatment. Generally, adherence is 
considered to be a complex clinical behaviour with a wide array of determinants. Thus, 
the aim of this study is to assess the level of adherence to HAART among HIV/AIDS-
positive patients in a major hospital in Malaysia as well as its determinants. 
 
Using prospective cohort study design, 925 participants who were on antiretroviral 
treatment were selected for the purpose of this study. Inclusion and exclusion criteria 
were also applied. The following three instruments for measuring the level of adherence 
to HAART were used in this study: self-reported adherence questionnaire, pharmacy 
refill records and Therapeutic Drug Monitoring (TDM) for testing drug in human 
plasma. Two blood samples were collected and tested for the presence or absence of 
three antiretroviral drugs, namely Efavirenz, Nevirapine and Lamivudine in human 
plasma using the LC-MS/MS machine. A test-retest reliability assessment was 
performed on a pilot test of 40 HIV/AIDS-positive patients. Three main data analysis 
techniques were used to analyze the collected data: descriptive analysis, comparative 
analysis of contingency tables, lastly logistic regression analysis.  This is the first study 
in South East Asia and Malaysia to analyze three antiretroviral treatment using LC-
MS/MS machine. It is also the first study in Malaysia to use three different methods for 
measuring the adherence level to Highly Active Antiretroviral Treatment (HART). 
 
The overall adherence level as measured by the self-reported questionnaire was 81.7%. 
The adherence levels using TDM for Efavirenz, Nevirapine and Lamivudine were 
71.2%, 69.6% and 60.3% respectively. Sensitivity was highest for Efavirenz (0.95; 95% 
CI 0.92, 0.96) and lowest for Lamivudine (0.89; 95% CI 0.85, 0.92). SRA specificity 
ranged between 0.56 and 0.63 and was highest for Nevirapine. Positive Predictive Value 
Positive (PPV) for Self-Reported Adherence (SRA) ranged between 0.76 (Lamivudine) 
to 0.84 (Efavirenz). Overall diagnostic accuracy ranged between 0.76 (Lamivudine) to 
0.84 (Nevirapine) while Area Under the Curve (AUC) ranged between 0.76 
(Lamivudine) to 0.83 (Efavirenz). In our findings of the logistic regression and cross 
tabulation analysis, we evaluated 48 variables which can be classified into four groups: 
reasons for missing medications, factors facilitating adherence, adverse effects of 
medications and alternative medications used for HIV treatment. Some of the factors 
associated with adherence include age, income, educational level, marital status, 
diarrhoea, vomiting, use of Alarm clock, acceptance of HIV status and use of herbal 
medicine. 
 
 In conclusion, according to the different methods of comparative analysis, it is evident 
that self-reported adherence is good enough for measuring adherence level in a poor 
resource setting and many factors have been found to be associated with adherence level 
to HAART.  
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ABSTRAK 
HIV/AIDS adalah salah satu penyakit zaman moden yang paling banyak memusnahkan 
nyawa, di mana seramai lebih 45.5 juta orang di seluruh dunia telah dijangkiti. Walau 
bagaimanapun, penemuan Terapi Retroviral Sangat Aktif (HAART) pada tahun 1996 
telah mengurangkan jumlah kematian dan morbiditi disebabkan oleh HIV/AIDS dengan 
kadar yang signifikan. Terapi ini telah membolehkan ramai pesakit yang sebelumnya 
hanya terlantar kembali sihat dan mampu hidup dengan produktif. Untuk membolehkan 
rawatan ini berjaya, tahap pematuhan yang sangat tinggi kepada rawatan adalah 
diperlukan. Sekurang-kurangya 95% tahap pematuhan terhadap rawatan antiretroviral 
diperlukan untuk mengurangkan replikasi virus dan mengelakkan perkembangan daya 
ketahanan terhadap rawatan. Secara umumnya, pematuhan dianggap sebagai 
tingkahlaku klinikal yang kompleks dan mempunyai pelbagai penentu. Oleh sebab itu, 
tujuan kajian ini ialah untuk menilai tahap pematuhan terhadap HAART serta penentu-
penentunya dalam kalangan para pembawa HIV positif dan pesakit AIDS di salah 
sebuah hospital utama di Malaysia. 
 
Dengan menggunakan rekabentuk kohort prospektif serta teknik pensampelan mudah, 
925 orang peserta yang ketika itu sedang menjalani rawatan antiretroviral telah dipilih 
dalam kajian ini. Kriteria serta dan kriteria singkir turut digunakan. Dalam kajian ini, 
ketiga-tiga instrumen berikut telah digunakan untuk mengukur tahap pematuhan 
terhadap HAART: soal selidik laporan kendiri, pengisian semula rekod farmasi dan 
Pemantauan Terapeutik Ubat (TDM) untuk menguji ubat-ubatan dalam plasma manusia. 
Dua sampel darah telah dikumpulkan dan diuji dengan menggunakan mesin LC-MS/MS 
bagi menentukan kewujudan atau ketidakhadiran tiga jenis ubat antiretroviral, iaitu 
Efavirenz, Nevirapine dan Lamivudine dalam plasma manusia. Penilaian 
kebolehpercayaan uji-uji semula telah dilaksanakan dalam ujian rintis terhadap 40 orang 
pembawa HIV positif dan pesakit AIDS. Empat teknik analisis data utama telah 
digunakan bagi menganalisa data yang telah dikumpulkan, iaitu analisis deskriptif, 
analisis perbandingan jadual kontingensi, tahap 3 jenis ubat daripada kaedah TDM 
dengan soal selidik laporan kendiri, dan analisis regresi logistik.  
 
Tahap keseluruhan pematuhan seperti yang diukur oleh soal selidik laporan kendiri 
adalah 81.7%. Tahap pematuhan yang menggunakan TDM untuk Efavirenz, Nevirapine 
dan lamivudine adalah 71.2%, 69.6% dan 60,3%. Sensitiviti adalah tertinggi untuk 
Efavirenz (0,95; 95% CI 0,92, 0,96) dan terendah untuk lamivudine (0,89; 95% CI 0,85, 
0,92). Spesifisiti SRA adalah antara 0,56 dan 0,63 dan tertinggi adalah untuk 
Nevirapine. PPV untuk SRA adalah antara 0,76 (lamivudine), dan 0.84 (Efavirenz). 
Ketepatan diagnostik keseluruhan adalah antara 0,76 (lamivudine), dan 0.84 
(Nevirapine) manakala AUC adalah antara 0,76 (lamivudine), dan 0,83 
(Efavirenz)Berdasarkan hasil dapatan bagi analisa regresi logistik serta penjadualan 
silang, kami telah menilai 48 pembolehubah yang boleh diklasifikasikan mengikut 4 
kumpulan, iaitu: sebab tidak mengambil ubat, faktor yang memudahkan pematuhan, 
kesan buruk ubat-ubatan dan penggunaan perubatan alternatif untuk merawat HIV. 
Beberapa faktor yang dikaitkan dengan kepatuhan termasuk umur, pendapatan, tahap 
pendidikan, status perkahwinan, cirit-birit, muntah-muntah, penggunaan jam Alam, 
penerimaan status HIV dan penggunaan perubatan herba 
Kesimpulannya, berdasarkan kepada kaedah analisis perbandingan yang berbeza, ia 
adalah jelas bahawa kepatuhan yang dilaporkan sendiri adalah cukup baik untuk 
mengukur tahap kepatuhan dalam suasana sumber yang miskin dan banyak faktor yang 
telah didapati akan dikaitkan dengan tahap kepatuhan kepada HAART. 
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CHAPTER 1  
 
In Malaysia, Human Immunodeficiency Virus (HIV) infection was first detected in 
1986(Jing & Ismail, 2001). It has continued to be one of the health problems affecting 
the country due to the increase in incidence rate especially among the high-risk groups. 
Through the past 25 years, the rate of new infections has always been on an upward 
trend and it only started to decrease in the past three years(Zhou, 2007). Currently, the 
rate of new infections has declined from its peak of 7000 cases in 2002 to 3080 cases in 
2009. In this chapter, we examine the background information of the epidemic, the 
problem statement and rationale for this study. We also list and describe the research 
question, objectives of this study and the contributions made by this study. 
 
1.1 Background 
HIV is a virus which infects humans, causing a disease known as the Acquired Immune 
Deficiency Syndrome (AIDS). In 2009, approximately 45.5 million people around the 
world were affected by the disease(Muangchan & Nilganuwong, 2009). AIDS continues 
to be a global health problem with the most number of infections in Africa and 
Southeast Asia(Garrett, 2007). In Southeast Asia, there were about 4 million people 
living with the disease by the end of December 2009 (prevalence of 5%) and an 
estimated 27,000 reported deaths. In Malaysia, the disease was mainly acquired 
through injecting drugs of abuse, but now the infection through heterosexual route has 
increased(Hamouda, 2011). Malaysia - with a population of over 28 million people and 
a multi-ethnic society - has an estimated 106,000 people living with HIV as of 
December 2009 (Kamarulzaman, 2009). Since the first case was detected in 1986, the 
disease has caused approximately 14,000 reported deaths and the prevalence rate
1
 is 
                                               
1 Estimated adult (aged 15-49 years) HIV prevalence 
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about 0.5% (87,710 cases) but may reach up to 20% in populations with high risk 
behaviours such as sex workers drug users (MOH, 2010) (W. Y. Low, 2009). 
 
The annual number of  new HIV reported cases in the country has declined from a total 
number of 7,000 in 2002 to 3, 931 cases in 2009 (Kamarulzaman, 2009).  Currently,  
there are about 9 new cases of HIV infections daily and the most common route of 
infection is through injecting drug use (70%) followed by the heterosexual route 
(19.6%) and the homosexual route which is about 2% (Choi et al.). Malaysia is a 
country with many different ethnic groups such as Malays, Chinese and Indians, with 
HIV most prevalent in the Chinese ethnic group. 
 
Most Malays become infected through injecting drug use and they are usually men aged 
between 20-29 years while the Chinese on the other hand usually acquire the infection 
through the sexual route via both heterosexual and homosexual route of infection 
(Kamarulzaman, 2009). The spread of the disease to both the Indian and Orang Asli 
populations (Orang Asli is the general Malaysian term used for any indigenous group 
found in Peninsular Malaysia which means “original people”) who used to be free from 
this infection need urgent attention from the Ministry of Health authorities.  
The benefit of new treatments which could be used these affected areas will go ahead in 
reducing the burden of the disease and help patients in improving and building their 
immune system.  
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With the increase in the number of cases, the Government responded in 2008 by 
providing the first line of Highly Active Antiretroviral Treatment (HAART) for free and 
subsidizing the second line of treatment. Today, not less than 10,000 infected patients 
are on HAART in different parts of the country. This is considered as a significant 
achievement. However, the biggest challenge is the level of adherence to treatment in 
Malaysia, which is not known as there are no published studies on adherence or non-
adherence to treatment. This could lead to the development of viral resistance resulting 
in treatment failure when the adherence level is less than 95%.   
 
1.2 Problem statement 
There are three classes of anti-retroviral drugs commonely  used for treating HIV in 
Malaysia(Altice, Kamarulzaman, Soriano, Schechter, & Friedland, 2010). These include 
the Protease Inhibitors (PI) which is used mainly for the second line of treatment; and 
the Nucleoside Reverse Transcriptase Inhibitors (NRTI) and Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI), both used in the first line of therapy (Alexander et 
al., 2003; Byakika-Tusiime, Orrell, & Bangsberg, 2008). Other new antiretroviral 
therapy such as Maraviroc, which belongs to the group of Entry Inhibitors or Fusion 
Inhibitors which has been recently produced with different mechanisms of action where 
the quality, reduced dose frequency and safety have been improved as compared to 
HAART [78, 79]. Is also available in the country but not commonly prescribed. WHO 
recommends first-line antiretroviral treatment that consists of two NRTIs and one 
NNRTI(Akileswaran, Lurie, Flanigan, & Mayer, 2005).  
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The effect of HAART in HIV-positive patients is assessed and evaluated by monitoring 
the viral load and measuring CD4+ cell count (Cambiano et al., ; Gutierrez et al., 2004). 
These  two parameters do not provide information  about  optimal prevention of 
development of resistance and cross resistance  to antiretroviral treatment, since viral 
resistance  has usually developed by the time an increase in viral load is observed (D. 
Murphy, K. J. Roberts, D. Hoffman, A. Molina, & M. Lu, 2003; PROCTOR, TESFA, & 
TOMPKINS, 1999). Non-adherence to treatment results in development of drug 
resistance and then treatment failure (Bangsberg et al., 2006; Bangsberg et al., 2000). 
 
Adherence of HIV/AIDS-positive patients to antiretroviral treatment is one of the most 
challenging issues affecting them in Malaysia. It is estimated that 95% adherence or 
more to antiretroviral treatment is essential for reducing replication of the virus thus, 
preventing the development of resistance to treatment (Bennett, Bertagnolio, 
Sutherland, & Gilks, 2008; de Olalla et al., 2002; Tuboi, Harrison, Sprinz, Albernaz, & 
Schechter, 2005). Adherence is considered to be a complex clinical behaviour with a 
wide array of determinants. A useful framework is to identify the factors which can lead 
to non-adherence to antiretroviral treatment. These factors can be classified into 
treatment factors such as side effects of treatment(vomiting and itching) and cost of 
treatment, service factors such patients waiting time for collection of medication and 
patient healthcare provider relationships , patient factors such forgetfulness to swallow 
tablets at prescribed time and depression, socioeconomic factors such as cost of paying 
for transportation to hospital for follow up and collection of medication, cultural factors 
such as use of tradional medicine as alternative treatment, clinical setting and the 
disease itself (Berg & Arnsten, 2006; M. A. Chesney, 2000; I. Escobar, M. Campo, J. 
Martin et al., 2003). 
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In addition, the development of resistance in patients with poor adherence to treatment 
can accelerate the progression of disease to AIDS status (Hirsch et al., 1998). More 
information on factors and circumstances, which affect HIV-positive patients’ 
adherence to treatment, is required. With the introduction of Antiretroviral Therapy 
(ART) and the possibility of patients developing resistance and infecting other 
individuals with the resistant virus, it is necessary to explore the factors and/or 
circumstances affecting adherence to ART (Attia, Egger, Müller, Zwahlen, & Low, 
2009).  
 
 Adherence counselling has emerged as an important component in HIV/AIDS 
counselling. However, little knowledge and information is available regarding this topic 
in most treatment centres in Malaysia (Ghailan et al., 2010). More knowledge with 
regards to the factors influencing HIV/AIDS patients’ adherence to ART will clarify 
circumstances or specific factors that should be considered in assessing patients for 
ART. This new knowledge could improve service delivery by means of relevant 
assessment and screening procedures that are responsive to the needs of patients in 
order to enhance adherence. 
 
The following research problem has been formulated: Factors affecting or associated 
with adherence to antiretroviral treatment in HIV/ AIDS-positive patients are unknown. 
There are insufficient guidelines for assessing the factors affecting adherence to 
antiretroviral therapy in HIV/AIDS-positive patients in Malaysia. Sufficient guidelines 
for assessment and screening could lead to enhanced adherence and thus minimize the 
development of resistance to antiretroviral drugs. Also, the adherence level to HAART 
is not known yet and there is no valid method for measuring adherence to antiretroviral 
therapy in Malaysia. Thus, it is necessary to identify the factors that should be assessed 
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when screening patients for ART. This is a study on adherence to antiretroviral drugs 
and it focuses on investigating factors related to HIV/AIDS, specifically those that 
influence adherence to antiretroviral therapy. It also focuses on measuring the adherence 
level by different methods and eventually identifies which methods are most valid and 
suitable for measuring adherence to HAART in Malaysia. 
 
1.3 Rationale for the study 
First line treatment has been provided for free by the Ministry of Health for all 
HIV/AIDS-positive patients since most of them cannot pay for antiretroviral treatment 
(Mazlan et al., 2006). However, the biggest challenge is the adherence level and factors 
affecting it are not known in Malaysia. Determining the adherence level and its 
determinants is very important since adherence level of less than 95% is associated with 
developing drug resistance which leads to unsuccessful treatment (Muñoz-Moreno et 
al., 2007). If treatment failure is confirmed, the patient has to be shifted from first line 
treatment - which is relatively cheap - to second line treatment which is very costly the 
cost will be doubled due to the high cost of second line treatment and patients may not 
be able to purchase such drugs even though the Ministry of Health in Malaysia 
subsidizes such treatment(Komatsu et al., 2010).  
 
When patients are prescribed second line antiretroviral therapy, their medication cost 
will be doubled due to the high cost of second line treatment(Komatsu et al., 2010). This 
will have serious economic implications on both the patient and the country due to the 
increase in the total number of patients testing positive for the virus on a daily basis (i.e. 
new cases). This will be the first study of its kind on measuring adherence level to 
HAART in HIV positive patients using three different methods namely self-reported 
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adherence questionnaire, use of pharmacy refill method and use of Therapeuitic Drug 
Monitoring (TDM) in Malaysia.  
 
Since there have not been any published studies on measuring adherence level or factors 
associated with it in this country, this study will be the first in measuring the adherence 
level by a self-reported method. It will also be the first study in Malaysia and Southeast 
Asia that aims at validating the accuracy of self-reported adherence to three 
antiretroviral therapy (efavirenz, nevirapine and lamivudine) with therapeutic drug 
monitoring using high-performance liquid chromatographic-mass spectrometry  (which 
combines the physical separation of liquid chromatography with the mass analysis of 
mass spectrometry) in Malaysia. More importantly, the factors associated with 
adherence level will be identified and taken into consideration in the treatment and 
follow-up of HIV-positive patients in this country. 
 
1.4 Research questions 
1. What are the adherence levels as measured by self-report, pharmacy records and 
therapeutic drug monitoring in HIV-positive patients on HAART in Sungai Buloh 
Hospital? 
2. What are the factors affecting adherence to highly active antiretroviral treatment in 
HIV/AIDS-positive patients in Sungai Buloh Hospital? 
3. How well does self-reported adherence compare to therapeutic drug monitoring in 
Malaysian patients? 
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1.5 Study objectives 
1.5.1 General objective 
To determine the adherence level to highly active antiretroviral treatments in 
HIV/AIDS-positive patients in a major hospital in Malaysia and its determinants 
 
1.5.2 Specific objectives 
1. To determine the level of adherence to antiretroviral treatment in HIV-positive 
patients in Sungai Buloh Hospital. 
2. To develop a method for determination of antiretroviral drug level in human plasma 
by high-performance liquid chromatographic-mass spectrometric (LC-MS-MS) method. 
3. To validate self-reported adherence to therapeutic drug monitoring method in HIV-
positive patients. 
4. To determine the factors affecting adherence to highly active antiretroviral treatments 
among HIV/AIDS-positive patients. 
5. To recommend policy measures that will be usefull for both physicians and 
pharmacists in the treatment of HIV positive patients. 
6. To recommend policy measures that will improve adherence and hence reduce 
transmission of HIV.  
 
1.6 Contribution of the study 
This is the first study of its type to be carried out in Malaysia on measuring the 
adherence level to Highly Active Antiretroviral Therapy in HIV-positive patients and it 
is also the first to describe and predict the factors affecting the adherence level to 
treatment. Regionally it is the first study in Southeast Asia to measure the adherence 
level objectively by detecting the drug levels for three highly active antiretroviral 
therapies (efavirenz, niverapine and lamivudine) in human plasma using therapeutic 
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drug monitoring via Liquid Chromatography Mass Spectrophotometry (LC-MS/SM) 
machine. 
 
We also developed and validated a self-reported study instrument (i.e. questionnaire) 
which can be used by other researchers in Malaysia and the region for measuring the 
adherence level and predicting the factors that affect the adherence level in HIV/AIDS-
positive patients. Another instrument for measuring the adherence level using pharmacy 
refill data was developed. This is a very simple instrument, which can be used by 
researchers in clinical pharmacology and medicine. The results of this study can be used 
in other developing countries where the HIV/AIDS are major health problems. 
 
In summary, this study gives the researchers in Malaysia a point from where they can 
start when they think about any study on adherence to antiretroviral treatment and on 
other medication for infectious diseases. Health policy makers can use the finding of 
this study to formulate a decision regarding the use of antiretroviral treatment and the 
management of HIV/AIDS in Malaysia. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Search Strategy 
In this chapter and based on our research questions under the title “Factors Affecting 
Adherence to Highly Active Antiretroviral Treatment”, the researcher searched through 
Science Direct, PubMed database and Google Scholar. The researcher decided not to do 
a full systematic review due to the availability of current systematic reviews conducted 
on this research topic (Attia et al., 2009; Falagas, Zarkadoulia, Pliatsika, & Panos, 2008; 
Mills et al., 2006; Wasti et al., 2011).  However, the researcher reviewed and refers to 
these systematic reviews throughout this chapter. The above-mentioned databases were 
reviewed for relevant studies similar to our study topic. Studies from two published 
systematic reviews as indicated in the Evidence Table 2.1 below were examined and 
referred to in this chapter. 
 
The search terms used were factors, adherence, compliance, Highly Active 
Antiretroviral Therapy and HIV/AIDS. We downloaded 239 journal articles (described 
in the flow chart, Figure 2.1 below) using the above databases and search terms. They 
were found to be relevant to the study topic based on the articles important contents 
which were relevant to this study and thus used in the review. The majority of the 
articles examined are survey studies on factors affecting adherence to antiretroviral 
treatment and other remaining examined qualitative studies on adherence to 
antiretroviral treatment. The retrieved data is from studies which were carried out in 
both developed and developing countries, with a few artiles from Malaysia on the 
epidemiology of HIV and other aspects of HIV treatment but not on measuring 
adherence to HAART. Table 2.1 below aslo shows the selected relevant studies used in 
the leterture review in this study. Summmary of the study population, focus of each 
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study and the country in which the study is carried out is highlighted in table 2.1 below 
for quick account of these important studies. 
 
 
 
 
 
 
 
 
 
 
                                                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Flow chart for studies included in the literature review 
 
 
 
 
 
 
 
239 Original studies 
182 Relevant studies 
19 excluded because they were 
not on HIV medication. 
165 studies included  
57 Studies excluded because 
they were on other diseases 
such TB and not HIV 
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Table 2-1: Selected relevant studies for the literature review 
Reference Population Focus of study 
 
Country Setting 
JOSE A MUNOZ 
MORENO 2007 
 
530 HIV out-patients on HAART Assessing Self-Reported Adherence to 
HIV Therapy Questionnaire the SERAD 
Study 
 
Spain 
Hospital 
based 
C.A.T. Pinheiro1, 
J.C.  2002 
A total of 195 patients participated 
in the study. 
Factors associated with adherence to 
antiretroviral therapy in HIV/AIDS 
patients 
Italy Hospital 
Hernado knobel 
2002 
 
3004 HIV patients on HAART  Validation of simplified medication 
adherence questionnaire in a large cohort 
of HIV 
US Hospital 
based 
Abel, 2003  100% women; (2 
African-American, 1 Hispanic, 3 
white 
Factors that influence adherence to ART 
were explored from perspective of women 
US Clinic 
Golin, 2002  16 men/8 women 
(12 African-American: 12 
white) 
To understand barriers to ART adherence 
faced by patients living with HIV in the 
south-eastern US 
US Clinic 
Brigido, 2001  126 men/56 women To assess if adherence to antiretroviral 
medication correlates to clinical and 
laboratory outcomes 
Brazil Clinic 
Hills, 2003  78 (no demographic/ ethnicity 
given specific to study; only 
general clinic population) 
To explore patterns and explanations of 
adherence to antiretroviral therapies from 
the patients’ perspective 
US Clinic 
Johnston-Roberts, 
2000  
100% women 
(50% Hispanic, 35% African- 
American, 15% white) 
To explore, from HIV-positive women’s 
own perspectives, the barriers they faced in 
adhering to combination antiretroviral 
therapies 
US Journal 
entries 
Kemppainen, 2004 46: 38 men/8 women (12 African-
American, 24 white, 5 Hispanic, 
and 5 mixed) 
To identify factors and circumstances that 
influence the ability of persons with 
HIV/AIDS and severe mental illness to 
comply with ART regimens 
US Hospital 
Meystre-Agustoni, 
2000  
37:25 men/12 women(no ethnicity 
information given) 
To explore patients’ perceptions of 
HAART 
Switzerlan
d 
Clinic 
 13 
 
Miller, 2002   30: 23 men/7 women (21 Latino, 7 
African- American, 2 white 
To assess barriers to adherence to 
antiretroviral regimens by conducting 
focus groups and asking patients about 
their preferences for different aspects of 
antiretroviral regimens 
US Clinic 
Murphy, 2003   81: 45 men/36 women (22% 
Central American, 61% Mexican, 
6% Mexican-American or Chicano, 
1% South American, 4% mixed, 
and 5% other 
Three aims: (1) to determine what barriers 
impede adherence, (2) what strategies 
facilitate adherence, and (3) investigate 
the health-care provider–patient 
relationship and how it may affect 
adherence 
US Clinic 
Murphy, 2000   39; 27 men/12 women 
(3% Asian/Pacific Islander, 44% 
African-American, 6% Latino, 3% 
Native American, 39% white, 6% 
other or mixed) 
To determine what strategies facilitate 
adherence, what barriers prevent 
adherence, and investigate the health-care 
provider–patient relationship and how it 
may affect adherence 
US Clinic 
Oggins, 2003   62; 40 men/22 women (21 African 
American, 7 Asian, 2 Haitian, 8 
Latino/Latina, 9 European 
American, 11 Native American) 
To explore the reasons for low adherence 
to HIV-medication regimens among ethnic 
minority groups 
US Private 
homes, 
health 
agencies, or 
via telephone 
Proctor, 1999  39; 27 men/12 women (19 white, 
16 African American, 4 Hispanic 
To understand the barriers to adherence to 
HAART faced by people living with 
HIV/AIDS 
US University 
medical 
centers and 
clinics 
Reback, 2003   23; 100% men (87% 
white, 19% Latino, 4% 
Native American 
To understand the meaning of reported 
HIV medication adherence among gay and 
bisexual men who are dependent on or 
abuse methamphetamine 
US Treatment 
center 
Source:  Systematic review for developed and developing countries 2006 and Systematic review 2011 for Asian countries
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2.2 Outline of HIV epidemic 
Since HIV virus was detected in Malaysia  in 1981, more than 32.2 million people are 
currently living with the disease(Rugalema et al., 2009). The prevalence rate was about 
0.5% in the reproductive age group 16-49 years. The prevalence rate is higher in the 
high risk group such as commercial sex workers and injecting drug users. The main 
route of infection was through injecting drug use but recently it has become increasingly 
through the heterosexual route, according to the 2010 Malaysian Ministry of Health 
report (W. Low, 2009). The 2010 report also predicted the injecting drug use to stabilize 
while infections via the sexual route (heterosexual and the homosexual route) would 
increase (W. Low, 2009).  
 
Human Immunodeficiency Virus (HIV), which can spread through body fluids such as 
blood, breast milk and semen, is the main virus that causes AIDS. Among drug addicts, 
contaminated needles are considered to be the main route of transmission while sexual 
route is the main route among high risk groups such as commercial sex workers. At the 
beginning of the virus infection, the host experiences flu-like illness and will then 
remain without any other symptoms for about eight years in some cases. Opportunistic 
infections such as Tuberculosis may start to infect the persons as soon as their immunity 
depresses.   
 
One of the key components of the immune system is the CD4 cells which measure the 
effect of the virus on an infected person and measuring the viral load may give the 
numbers of the HIV virus in the body (Gebo, 2008). When the CD4 count falls beyond 
300 to 1000 cells /ul, the person starts to have other opportunistic infections. A CD4 
count less than 350 cells will necessitate commencement of antiretroviral treatment. 
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AIDS patients suffer from many symptoms such as frequent diarrhoea, fever and weight 
loss which may result in wasting (Hladik et al., 2008).   
 
2.2.1 Virology of HIV 
HIV-1 is a retrovirus, which has a single RNA genome and contains about fifteen 
different types of proteins. There are three types of proteins in HIV-1 virus which are 
grouped into structural, regulatory and accessory proteins (Demeter et al., 2002). The M 
group of HIV-1 virus  accounts for almost 90% of HIV-1 infections while the other two 
classes N and O account for the remaining infections (Silvestri, 2008).  HIV virus binds 
its particle (known as virion) to the host cells, which starts when the surface envelope is 
attached to its receptor. The viral contents such as its genetic material and the protein 
(reverse transcriptase, or RT) enter the cytoplasm of the host cell resulting in copying of 
the viral genetic material (Demeter et al., 2002).  
 
2.2.2 Immunology 
People infected with HIV virus present two types of antibody immune responses to the 
virus, which will not stop the progress of infection.  The cellular response is mediated 
through CD4 and CD8 cells which stop the replication of HIV virus by destroying and 
killing infected cells (Papasavvas et al., 2006). CD4 cells on the other hand responed to 
the HIV virus through a very complex process resulting in a very low viral load 
(Seyoum et al., 2006).  When the HIV virus is in a resting state, the HAART cannot 
remove or destroy the virus in the cell leading to continuous infections (Huber & 
Trkola, 2007).  
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2.2.3 HIV transmission and risks 
In  developed countries, the main route of infection is through the homosexual route 
while 80% of the infection in developing countries is through the heterosexual route of 
infections with injecting drug use being the second route of infection (Taiwo & Murphy, 
2007). The risk of transmitting the virus through the sexual route is increased by the 
presence of injuries and ulcers in the genital area and it also depends on the viral load 
(Paltiel et al., 2006). Other methods of viral transmission include blood transfusion, 
needle injuries, mother-to-child transmission & through the use of infected needles by 
drug users (Korenromp et al., 2000; Titti et al., 1987).   
 
The risk of transmission from accidental needle injuries is estimated at about 0.4-0.6%. 
Mother-to-child transmission is very high in developing countries, accounting for 25% 
newborn babies of HIV infected mothers (Wu, 2008). The transmission in newborn 
babies is increased mostly during delivery and breast feeding (Kourtis, Bulterys, 
Nesheim, & Lee, 2001).  
 
2.2.4 Classification of the disease 
There are two types of Human Immunodeficiency Virus, namely HIV type 1 and HIV 
type 2. Both infect the immune system of the host cells which results in leaving the 
person vulnerable to a lot of opportunistic infections such Pneumonia and Tuberculosis 
(Ling et al., 2004). When the number of CD4 or helper T cells is less than 600 cells / ul, 
it means that the immune system is seriously damaged and the infected person is already 
at risk of opportunistic infection. A CD4 value of more than 1200 cells / ul indicates 
that the infected person still has a good immune system and such a person may not be 
required to start HAART. CD 4 of less than 350 cells / ul is a sign of immune 
impairment and ART can be started, while CD4 of less than 200 cells / ul necessitate 
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immediate start of the HAART (Lifson et al., 1997; van Baalen et al., 1997). Infection 
of an individual with the virus is normally followed by a period during which the virus 
continues to replicate in the body and may render the immune system less functional, 
resulting in a clinical disease progression. 
 
Untreated HIV disease is chronic and progressive. Primary HIV infection, often marked 
by a mononucleosis-like acute viral syndrome, is followed by a period of clinical 
latency typically lasting several years, during which high levels of viral replication and 
CD4 cells turnover lead to progressive immune dysfunction, eventually resulting in 
clinical disease progression. The progression of HIV virus in the body and a 
dysfunctional immune system lead to the development of AIDS which is considered to 
be the most destructive epidemic of the twenty first century (Goliber, 1999). 
 
2.2.5 Natural course and history of HIV infection 
The natural course of the HIV infection has six phases which comprise the acquisition 
of infection (when the person becomes infected), primary HIV infection, asymptomatic 
HIV infection, early symptomatic infection, late symptomatic infection (the stage with 
opportunistic infections) and advanced HIV disease (Lifson et al., 1997). Initial 
infection of HIV begins with a flu-like illness, which is usually about 3-5 weeks of 
infection. The infection at this stage is similar to any febrile infection such as Malaria, 
Typhoid or Dengue fever (Hubert et al., 2000).  
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About 87% of HIV infected patients come up with the above-mentioned symptoms. 
According to available data and diagnosis, this is possible only within one or two 
months after acquiring the infection. Infected persons may have few clinical signs and 
symptoms at this early stage (Jaffar, Grant, Whitworth, Smith, & Whittle, 2004). The 
period between HIV infection and the stage of HIV/AIDS may take as long as 10 years. 
Available data from Zimbabwe indicated that there was no difference in the duration of 
infection (from the early stage of infection to the stage of HIV/AIDS) between males 
and females as well as between developed and developing countries (Gregson et al., 
2002).  
 
When a patient progresses to AIDS, he or she may survive for about 10 months or more 
depending on whether he or she is treated or not. This may also vary from one patient to 
another due to multiple opportunistic infections at this stage (Sterling et al., 2001). 
HIV/AIDS is classified by either the World Health Organization (WHO) staging or the 
Center for Disease Control (CDC) classification. The CDC classification has been 
available since 1982 but has undergone several updates and it now includes 
measurements as one of its criteria. The WHO staging came to light in 1990 and is fully 
based on clinical manifestations such as the signs and symptoms of the disease. This 
staging of the disease is used mostly by poor developing countries in Africa and Asia 
(Who, 2009). 
2.2.6 The laboratory diagnosis of HIV 
The diagnosis of HIV is carried out by Enzyme-linked Immune-Sorbent Assay (ELISA) 
and confirmed by the use of Western blot assay, which can identify HIV antibodies. 
ELISA is a very specific test and can be used alone for the diagnosis of HIV (Fiscus, 
Cheng et al. 2006). In HIV infection, antibody production occurs within weeks of 
infection or less. As such, ELISA testing may be negative if used in the early stages (i.e. 
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the first few months of infection period, also called the "window period"). The viral 
load in the window period may be very high and HIV infection can be transmitted 
during this period (Gibellini, Vitone et al. 2004). HIV infection can be tested on both 
urine and saliva but this must be followed by serological confirmation.  
 
Home testing for the disease is also available using the HIV rapid serum testing which 
takes about 30 minutes with 99-100% sensitivity and specificity compared to ELISA 
testing (Fideli, Allen et al. 2001). In many developing countries, the CD4 count is used 
for HIV staging since it correlates with the risk of developing opportunistic infections 
and thus used for the clinical decision making (Finzi, Blankson et al. 1999). Many 
factors affect the CD4 count and can result in a lot of variation in this count since CD4 
is a subset of the white blood cells (T lymphocytes). These factors include other 
infections that may be available at testing time, malnutrition, use of medication and 
stressful conditions (Alimonti, Ball et al. 2003).  
 
To differentiate between depletion of the CD4 due to HIV infection and the effect of the 
above-mentioned factors, we use the CD4 percent and the inversion CD4/CD8 cell ratio 
(Blanco, Barretina et al. 2001). The viral load measurement in HIV-infected patients is 
usually made using the Reverse Transcription Polymerase Assay (RT-PCR) which is 
based on the fact that, the virus is detected when it binds to DNA sequences. The viral 
load testing results are usually shown in log units, thus a viral log of 10,000 is equal to 4 
log units (Mellors, Munoz et al. 1997).  
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2.3 Antiretroviral Therapy (ART) 
Antiretroviral Therapy was first introduced in 1990 and since then has continued to be 
used by HIV-positive patients worldwide(Shetty, 2008). It helped in reducing mortality 
in many hospital and treatment centres by improving patients survival rate (Mukherjee, 
Ivers, Leandre, Farmer, & Behforouz, 2006). In many developing countries, the 
provision of ART also require  patients to be well-educated about the disease, associated 
opportunistic infections and the need for constant adherence to treatment (C. E. Golin et 
al., 2002). Patients who have been prescribed ART need to take it for the rest of their 
lives. The ART if used properly can control and reduce the virus level in HIV patients 
(J. B. Nachega et al., 2007).  
 
Antiretroviral treatments help in rebuilding the immune system, preventing the virus 
from multiplying and increasing the duration of a patient’s life(Soares & Costa, 2011). 
The biggest challenges facing the use of antiretroviral in poor countries include poor 
healthcare infrastructure, high cost of second line treatment and the developing of drug 
resistance (Gilks et al., 2006; Richard et al., 2004). There are also concerns pertaining to 
the non-adherence to treatment which will result in failure of treatment and 
accumulation of strains of highly resistant virus that can promote the spread of drug 
resistance.  
 
The current treatment of ART is in a combination form known as the Highly Active 
Antiretroviral Therapy (HAART) (Severe et al., 2005). Three classes of HAART are 
used in most parts of the world. These include protease inhibitors, non‐nucleoside 
reverse transcriptase inhibitors (NNR‐TIs) and nucleoside reverse transcriptase 
inhibitors (NRTIs). All HAART classes have adverse effects which have severe impact 
on its usage and on patients’ adherence to treatment (Dybul, Fauci, Bartlett, Kaplan, & 
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Pau, 2002). First-line treatments are cheap and easy to use compared to second-line 
treatments which are very expensive and need to be used only when the first line of 
treatment fails (Urquhart, 1995).  
 
Some of the significant achievements attributed to HAART are reduction in HIV/AIDS-
related mortalities, keeping HIV-positive patients at their homes, helping them to 
continue with their jobs and emptying hospital wards of HIV/AIDS patients 
(Akileswaran et al., 2005). The high cost of HAART in many developing countries has 
made it unavailable to poor patients and necessitated the interventions of WHO and 
other international organizations to provide the  medication (De Cock & De Lay, 2008). 
The benefits of HAART are great despite its high cost, as it is one of the most useful 
medication in the fight against infectious diseases in the twenty first century. It is 
estimated that more than 790,000 deaths would be avoided if the coverage is up to 50%, 
while the 100% coverage model could avert up to 1,900,000 deaths over the same 
period (Guimarães et al., 2008).  
 
2.3.1 Type and combination of antiretroviral drugs 
HAART combination was developed for the first time in 1996 for the treatment of 
HIV/AIDS(Cooper et al., 2002). Since that date the combination has contributed 
significantly in reducing mortality and morbidity among HIV positive patients. The 
medications have also contributed in emptying hospital words from HIV positive 
patients. Antiretroviral therapy had the primary aims of improving duration and quality 
of life, reducing HIV transmission, as well as reducing HIV-related illnesses and deaths. 
Antiretroviral treatment also has the benefit of reducing the risk of Mother-to-Child 
HIV Transmission (MTCT) rate when used accurately  and at the requested time for the 
benift of both mother and child (Bogart et al., 2006).  
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Even though HAART has contributed significantly in fighting against the disease, 
eradication of the virus is impossible due to the fact that CD4 cells get infected during 
the acute HIV stage and continues on (Ledergerber, 2004). The goal of maximal viral 
suppression at the beginning of treatment in some cases may be very difficult due to the 
resistance strains of the virus. A successful HAART must combine at least two to three 
drugs from at least 2 different classes of treatment (Carpenter et al., 2000; Struble et al., 
2005). Changing from the first line to the second line of treatment may be due to failure 
of the first line of treatment (Gulick, 2003; Marks & Gulick, 2004).  
 
The most common combination of antiretroviral regimens for treatment in HIV patients 
generally consists of one NNRTI with two NRTIs or a PI (with or without ritonavir-
boosting) with two NR. The antiretroviral treatment (ART) combination of Efavirenz, 
Stavudine, Lamivudine and Nevirapine is the most frequently used initial regimen in 
many developing countries including Malaysia. In Malaysia, first-line HAART are 
provided at no charge by the Ministry Of Health to all patients. Malaysia spends more 
than USD 3.5 million on HIV/AIDS treatment since the majority of patients are drug 
users and cannot afford to pay for their medication (Sluis-Cremer & Tachedjian, 2008). 
 
2.3.2 Starting Antiretroviral Therapy 
Patients who suffer from an AIDS-defining disease and those whose CD4 cell counts 
below 200 cells/mm are classified at WHO stage 4 irrespective of their CD4+ cell 
count. Furthermore, the psychosocial considerations of the patient should be considered 
before patients are offered ART (Gilks et al., 2006). HIV-positive patients whose CD4 
counts are very low and whose clinical status showed progression towards AIDS require 
immediate start of HAART. In general, the decision to start HAART should be made for 
the benefit of the patients. Secondary aims of starting antiretroviral treatment include 
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relieving patients’ symptoms, rebuilding and improving the immune system and partial 
reduction of viral load  (Bradley-Springer et al., 2002; Nackchuay, 2009). One of the 
problems associated with starting or changing antiretroviral treatment is the 
development of toxicities or side effects to such treatment. 
 
2.3.3 Side effects of antiretroviral drugs 
Current HIV treatments need to be administered conteniously to suppress viral 
replication. HAART, like most other medication, comes with negative aspects such as 
unwanted drug interactions, drug toxicity, heavy pill burden, pill fatigue and side effects 
(Rudorf & Krikorian, 2005). Development of resistance to HAART has emerged in all 
countries worldwide(Mocroft et al., 2001). These toxicities affect most patients 
undergoing treatment and may result in non-adherence. Complications of HAART 
include diabetes, renal failure, abnormal blood lipids and liver damage. Other common 
adverse effects of antiretroviral treatment are vomiting, fever, skin rashes, headache, 
weight loss and diarrhoea (Bates, 1996). These side-effects of HAART can be classified 
as acute and long-term, and from mild to severe reactions(Borras-Blasco, Navarro-Ruiz, 
Borras, & Castera, 2008). This is due to the variability of absorption, distribution and 
elimination of drugs from patient to patient(Kiertiburanakul & Sungkanuparph, 2009).  
 
Side effects of treatment depend on the type and class of the medication used. NRTIs 
are commonly used in most countries including Malaysia and they are known to be 
associated with bone-marrow suppression with subsequent anaemia, peripheral 
neuropathy, pancreatitis and mitochondrial toxicity, manifesting as myopathy 
(weakening of the muscles)(Mkhize, 2007). These drugs include d4T, AZT and 3TC 
(Hofstede, De Marie, Foudraine, Danner, & Brinkman, 2000; Lee, Hanes, & Johnson, 
2003). In HAART group, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) is 
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the most commonly used group in Malaysia(Lapadula et al., 2008). Efavirenz is the 
most common drug used by HIV-positive patients in Malaysia and it is known to be 
associated mostly with adverse effects such as drowsiness, depression and anxiety, 
which usually results in the patient’s refusal of treatment(O'Connor et al., 2007).  
 
The NRTI may cause hepatic toxicity and nevirapine, in particular, is known for its 
association with skin rash and systemic hypersensitivity (Clarke et al., 2001; De Clercq, 
2004). Protease Inhibitors (PI) are known to be very costly and not provided for free in 
most developing countries including Malaysia and are associated with many side effects 
(d’Almeida et al., 2008). One of the most common side effects is hyperurisaemia 
leading to gout, increased risk of cardiovascular events like heart failure, anaemia and 
elevated liver enzymes (Carr et al., 1998; Riddle, Kuhel, Woollett, Fichtenbaum, & Hui, 
2001). Almost all known medications are associated with adverse effects including the 
new generation of antiretroviral therapy and these could be the main causes of drug 
resistance and treatment failure (Siripassorn et al., ; Wainberg, Martinez-Cajas, & 
Brenner, 2007). 
  
2.3.4 Antiretroviral drug resistance 
Resistance to treatment in general is a well-established biological process occurring 
with infectious agents such as viruses, parasites and bacteria (Laing, 2005; Stokes, 
2002). In Malaysia, the issue of resistance to HAART is not well studied and there are 
no published articles on this vital issue. This study will serve as a foundation since we 
are looking into adherence and also examining the common type of adverse effects to 
treatment. Resistance to medication in the HIV situation is mostly affected by the very 
fast replication of the virus and the fact that the virus can easily become inactive and 
does not respond to HAART (Fumero & Podzamczer, 2003). Adherence to HAART is 
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highly needed at the commencement of therapy due to high viral load. Non-adherence at 
the beginning of therapy is more highly associated with development of drug resistance 
than after six months of therapy due to the fact that the viral load would have been low 
at this time (Glass et al., 2006; Vlahov & Celentano, 2006). 
 
2.4 Adherence and drug resistance 
Adherence is “the extent to which a client’s behaviour coincides with the prescribed 
health care regimen as agreed through a shared decision‐making process between the 
client and the health care provider” (KITSO Manual, 2004; Carter, 2004). The 
definition of adherence used by the World Health Organization (WHO) is “the extent to 
which a person’s behaviour – taking medication, following a diet, and/or executing 
lifestyle changes – corresponds with agreed recommendation from a health care 
provider”. The term adherence is viewed to be less judgemental compared to 
compliance which is the agreement with the recommendations or advice.  
 
Adherence or compliance is still used interchangeably in research although they are not 
different in definition. Adherence can also be divided into dose, timing and food 
restriction adherence in the same way as compliance (Södergård, 2006). When drug 
resistance develops, patients start to suffer from opportunistic infections due to failure 
of treatment and they transmit the virus with resistance strains to their close contacts. 
The biggest obstacle that affects patients after they have developed drug resistance is 
the very expensive second line of treatment that they must undergo, instead of the first 
line of treatment which is cheaper. The cost of second-line treatment is about 10 times 
the cost of the first line which is available for free in Malaysia (Cameron, Ewen, Ross-
Degnan, Ball, & Laing, 2009). Thus, when the issue of developing drug resistance and 
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treatment failure is put into consideration, the patient’s best option is to ensure a 95% 
adherence level as recommended by WHO (J.B. Nachega et al., 2007).  
 
2.4.1 Changing Antiretroviral Therapy   
Antiretroviral therapy should be changed when there is evidence of treatment failure 
which is detected in three categories: virological, clinical and immunological. It is well-
established that the effects of antiretroviral therapy decrease over time and the main 
causes of treatment failure are the development of resistance to one or more drugs 
followed by cross-resistance (Amoroso, Davis, & Redfield, 2002). Non-adherence to 
treatment is considered to be the most important contributing factor in treatment failure 
(Jevtovic et al., 2005; van der Ende et al., 2003; Yeni et al., 2002).  
 
Stopping HIV replication using antiretroviral therapy may not be possible due to many 
reasons and factors which include poor drug absorption, non-adherence leading to drug 
resistance, low drug dosage due to increased adverse effects and low potency of the 
antiretroviral used (Sharland, Blanche, Castelli, Ramos, & Gibb, 2004). When there is 
evidence that viral replication is not in progress despite using HAART, switching from 
one line of antiretroviral treatment to another should be considered(Colebunders et al., 
2006). The most common reasons for changing HAART in any patients are non –
adherence, adverse effects of treatment and development of resistance to 
HAART(Mocroft et al., 2001). Patients who were non-adherent and subsequently 
developed drug resistance may require more complicated combinations of HAART with 
different dosing frequencies than the one which he or she had used before (D.A. 
Murphy, Wilson, Durako, Muenz, & Belzer, 2001). Changing from one antiretroviral 
therapy to another may be  justified if patients prove to have developed some adverse 
effects to that treatment (Moyle et al., 2008). 
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2.4.2 Importance of adherence to HAART 
Many studies conducted around the world have stated the significance of HAART in the 
treatment of HIV/AIDS(Uzochukwu et al., 2009). The main objectives of using 
HAART are to stop the progression of the disease, reduce viral replication hence 
reducing the viral load, build and restore the immune system thereby increasing the 
patient’s survival rate as well as reduce mortality and morbidity, and in general improve 
the patient’s quality of life by reducing and fighting against opportunistic infections 
(Wang, Masho, & Nixon, 2006). Many published studies in both developed and 
developing countries have shown and confirmed the fact that antiretroviral treatment 
has reduced mortality and improved the quality of life of most patients who adhere to it. 
In order for treatments to be successful, a very high level of adherence to HAART is 
required and the combinations of the treatment must be used in the correct quantities as 
in the prescribed doses (Stewart, Padarath, & Bamford, 2004). Development of drug 
resistance is always a consequence of increased viral load as a result of either taking the 
wrong drug at the wrong time, or non-adherence to the prescribed medication.  
 
Adherence also means that the health care provider’s instructions for taking the 
medication are followed. For example, some of the HAART combinations need to be 
taken with or without food. The right type of food is very important, as avoiding food 
with excessive amount of fat may play an important role in drug metabolism and drug 
absorption. Patients on HAART must avoid using other medication - such as alternative 
or traditional medication - along with their prescribed antiretroviral treatment, as such 
combinations could have very serious or even fatal interactions (A. Nakiyemba, D. A. 
Aurugai, R. Kwasa, & T. Oyabba, 2006). Ninety-five percent adherence level can be 
achieved if patients do not miss more than one dose a month if he is taking once-daily 
treatment, or missing not more than 3 doses a month if he is taking HAART twice a 
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day, or missing not more than 4 doses a month if he is taking HAART three times a day 
(Metcalfe, 2005). 
 
However, most HIV-positive patients on antiretroviral therapy do not achieve 95% 
adherence level and they end with sub-optimal adherence level, which could be very 
low. Evidence suggests that greater than 95% adherence level may be necessary to 
adequately suppress viral replication, produce a durable response and halt disease 
progression(A. Nakiyemba, D.A. Aurugai, R. Kwasa, & T. Oyabba, 2006). This means 
that missing more than one dose of a regimen per week may be enough to cause 
treatment failure. In addition to leading to disease progression, this may result in the 
development and transmission of drug‐resistant viruses, which cannot be treated with 
first‐line (i.e. lower cost) medicines. This will require treatment with second‐ and/or 
third‐line medicines, which are more expensive, associated with many side‐effects and 
are complex to manage. 
 
The challenge of adherence in the face of potential viral resistance, treatment failure, 
disease progression and the spread of drug‐resistant virus to sexual partners are of great 
concern. Patients on long‐term ART with undetectable levels of HIV still harbour 
replication‐competent virus. For this reason, with current medication, ART is a lifelong 
process. It should be recognized that adherence to ART is a critical issue, and it is clear 
from the literature that the factors which influence a patient’s ability to adhere are 
multiple and complex (Fogarty et al., 2002). The consequences of non-adherence are 
not limited to the patient, which is usually the case in most chronic diseases. If a patient 
with resistant virus infects another person, the resistant virus is transmitted. This is 
hence a risk for society in a wider sense, since these patients have limited treatment 
options (Gazzard, Bernard, & Boffito, 2006). 
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Among the factors that affect the virological response to HAART are the consequences 
of previous antiretroviral treatment. Patients with prior treatment are therefore at higher 
risk for the development of resistance. The time for treatment initiation with 
antiretroviral therapy has been debated and different approaches have been used for 
starting HAART in HIV-positive patients (Egger et al., 2002; Paredes et al., 2000). 
 
2.4.3 Theories used to explain adherence 
Adherence to HAART remains a significant problem in the clinical reality of the HIV 
treatment as in other chronic treatments.  The theories mainly used have not been well-
developed to explain adherent behaviour to drug treatment but rather more on health 
behaviour in general (Ryan, Patrick, Deci, & Williams, 2008). One of the theories used 
is the Health Model Theory which states the fact that patients will take action to prevent 
ill-health conditions, if they feel that they are prone to the vulnerable complications of 
the disease condition (i.e. they feel that low adherence will result in treatment failure). 
This is also true if the condition is believed to have serious consequences for the patient 
(i.e. treatment failure is perceived as bad), and if the patient feels that the action they 
take will reduce their susceptibility to the condition (i.e. they feel that adherence will 
reduce the risk for treatment failure). The theory also states that the situation in which 
the patient feels that the expected barriers ( physical, psychological or financial 
obsticles ) to taking the action are more than the perceived benefits  and “the conviction 
that one can successfully execute the behaviour required to produce the outcome” are 
other concepts that have been added to the model (Becker & Maiman, 1975). 
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Intention is however influenced by patients’ attitudes toward the behaviour and his 
subjective norms. Attitudes toward the behaviour are a result of weighting (by the 
individual) the possible outcomes of the action and whether the patient finds these 
outcomes positive or not. If a patient strongly believes that the outcomes of the 
behaviour will be negatively valued, this will result in  negative attitudes toward the 
behaviour (Sheeran, 2002). 
 
The Theory of Planned Behaviour deals with the concepts of attitudes toward the 
behaviour and subjective norms(Ajzen, 2006). It also includes the concept of perceived 
behavioural control since not all factors influencing behaviour are under the control of 
the individual. Perceived behavioural control is influenced in turn by control beliefs and 
perceived power. Control beliefs concern factors that can facilitate or impede the 
planned behaviour and these factors are weighted by their perceived power (Ajzen & 
Madden, 1986). 
 
2.4.4 Factors affecting adherence 
A range of factors has been found to be related to adherence towards chronic diseases 
(Ediger et al., 2007). WHO has suggested taxonomy for grouping these factors. The 
factors are divided into patient-related factors, treatment-related factors, health system-
related factors, social and economic factors and condition-related factors (Ismael 
Escobar et al., 2003). Factors specifically influencing adherence to HIV therapy 
corresponds well to these categories. Age, gender, marital status and educational level 
are part of the socio-demographic factors associated with adherence(Arrivillaga, Ross, 
Useche, Alzate, & Correa, 2009). Other demographic factors include income and 
educational level which were found to be significantly affecting adherence by some 
studies. Higher educational level and increase in patient’s income have been positively 
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associated with his adherence level to antiretroviral treatment, which mean patients with 
a master degree is more adherent to treatment than other with diploma (Kumarasamy et 
al., 2005).  On the other hand ethnicity and religious were found not to affect adherence 
by other studies(Debra A. Murphy, Roberts, Martin, Marelich, & Hoffman, 2000). 
  
The health care team and health care system can affect adherence levels especially the 
patient-health care provider relationship together with their access to health care(M. 
Carrieri et al., 2003). Good nursing care, excellent patients –doctor relationship and 
good counselling service at some hospitals in western countries were positively 
affecting the adherence level and resulting in high adherence (Mohammed et al., 2004). 
On the other hand poor nursing care and non availability of counselling in some poor 
resource setting led to very low adherence to medications (Loubiere et al., 2009). The 
complexity of the therapy and adverse effects to treatment are therapy-related factors. 
Treatment resulting in severe adverse effects such as itching may discharge patients 
from taking their tablets resulting in low or non-adherent to medication (S. g. n. Duran 
et al., 2001) When patients run out of pills or high cost of treatment has also been found 
to be associated with low adherence level. Some other treatment factors such as few 
prescribed pills, patient’s belief in the efficacy of the pills had been found to increase 
the patient’s adherence level (Ammassari et al., 2002). 
  
Health service factors such as long patients waiting time for seen his doctor or 
collecting his medication and travelling long distances to hospital for treatment and 
follow up had been shown to discharge patients from visiting these hospital and can 
cause low adherence level (Hardon et al., 2007). Other important factors such cultural 
factors (patient’s needs to care for other relative) may encourage patients to adhere his 
treatment, this corresponds with the theory of Health Behaviour Model (Gore-Felton & 
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Koopman, 2008). The Health Behavioural Model individual tends to adopt a new 
behaviour when he is faced by a threat, thus patients will adhere to his treatment rather 
than face the choice of death due to not adhering to his medication. Patient-specific 
factors such as being busy with other things or being away from home (which results in 
missing medication), drug or alcohol abuse- related factors, together with motivation are 
also associated with adherence (Barclay et al., 2007) 
 
2.4.5 Strategies for improving adherence 
According to Cochrane reviews which have focused on adherence in chronic disease, 
several individual interventions or factors have a positive impact on adherence to long-
term treatment (Sabaté, 2003). Many adherence-promoting interventions have also been 
tested in the HIV-infected population. Some randomized controlled trials have 
evaluated the impact of interventions on adherence (Peterson, Takiya, & Finley, 2003). 
Two of these studies found no improved adherence, namely Medication Adherence 
among Community-Dwelling Older Adults: Current Practices and Potential Technology 
Solution and Cost-related Non-Adherence To Prescribed Medication Therapy Among 
Medicare Part D Beneficiaries With End-Stage Renal Disease (D.A. Murphy, Lu, 
Martin, Hoffman, & Marelich, 2002; Ozok, Patel, Wu, & Gurses, 2011). 
 
in 2002 used a multidisciplinary intervention focusing on social support, information 
and behaviour, while the latter attempted to improve self-efficacy. One of the 
interventions used cues-dose training (i.e. counsellors trained the patients to find 
personalized cues for their medicine intake) and money incentives. This intervention 
enhanced adherence during the intervention but not during the follow-up (Sorensen et 
al., 2007). An intervention focusing on couples where education about treatment and 
adherence was the main focus had an impact on adherence during the first period after 
 33 
 
the intervention, but showed no difference after 6 months (Haddad et al., 2003). Factors 
which may contribute and influence an individual’s adherence to ART can be divided 
into the following main categories: Socio-demographic factors, patient factors, 
treatment factors, factors associated with clinical setting, disease characteristics and 
patient-provider relationship (García & Côté, 2003; D. A. Murphy, K. J. Roberts, D. 
Hoffman, A. Molina, & M. C. Lu, 2003; Reynolds et al., 2004). 
 
2.4.6 Conceptual framework 
The conceptual framework (Figure 2) below shows factors affecting adherence to 
HAART. The factors include Socio-demographic factors, patient factors, treatment 
factors, service factors and cultural factors. In this study, the researcher aims to examine 
which of the above-mentioned factors affect the adherence level to antiretroviral 
treatment in Malaysia. 
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Figure 2-2 Factors affecting adherence to HAART in Sungai Buloh Hospital 
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2.4.7 Financial constraints 
It is logical that the patient’s financial status should affect adherence level. Being poor 
for example, may seriously prevent a patient from either obtaining medication, or 
transporting oneself to hospital to get treatment. The high cost of medication in some 
African countries has been found to be a major reason for non-adherence to treatment 
(Creese, Floyd, Alban, & Guinness, 2002). In Botswana, it was reported that 70% of 
patients believe that the high cost of treatment is a major reason for non-adherence 
while 44% of patients believe that the cost of therapy, to some extent, affects their 
adherence level to HAART(Protopopescu et al., 2009).  Apart from the cost of 
treatment, other costs such as transportation to hospital or health centres and the cost of 
buying food to be taken along with medication are financial problems which affect most 
HIV patients in developing countries. In Malaysia, the first-line treatment for HIV is 
given for free by the Ministry of Health Malaysia in most treatment centres, but the 
second-line treatment is costly and patients have to pay for their treatment. Other costs 
such as transportation, hospital charges and food cost definitely play a significant role in 
adherence to medication in Malaysia. 
 
2.4.8 Social support 
Social support is essential for any patient regardless of the type of disease he or she 
suffers from. Most patients who are surrounded by their loved ones during illness 
respond better to treatment than those who are staying alone without any social or moral 
support. Being non–adherent to medication may or may not be associated with  social 
class as shown by some (M. P. Carrieri et al., 2003). Patients who live with their 
families, sons and very supportive family members are shown to be more adherent than 
those who do not have children or family support (Given, 2007). 
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2.4.9 Treatment factors 
HIV-positive patients who are on HAART usually face the issue of having to take many 
pills (up to 5 pills a day), high dosing frequency in one day (ranging from one dose to 
three doses a day) and also having to comply with particular types of fluids and food. 
The above-mentioned instructions are always very difficult to follow and can result in 
non-adherence if patients fail to comply  (Brigido et al., 2001). Some studies reported 
about patients getting tired of taking too many pills. Such patients may refuse to take 
their medication, resulting in poor or non-adherence (Kleeberger et al., 2001). Adverse 
effects to HAART such as vomiting, diarrhoea, dry mouth and skin rashes have been 
shown to lead patients to stop taking  medication regularly or even stop taking them 
completely (Ammassari et al., 2001; S. Duran, M. Sav s et al., 2001). Patients’ 
adherence level decreases with increased dosing frequency, increased amount of pills 
per day and increase in the severity of side effects to HAART (Ingersoll, 2004). The 
taste or size of antiretroviral medication may also affect a patient’s adherence level 
(Pontali, 2005). Embarrassing situations in public such as severe itching or sweating and 
other side effects may result in patients refusing to take medication, leading to non-
adherence to treatment. 
 
2.4.10 Patient factors 
Studies have shown socio-demographic factors to be associated with adherence level to 
HAART [150, 151]. For example, a patient’s income or completed educational level can 
positively affect the adherence level. However, some studies showed inconsistent 
association between adherence level and other factors such as religious belief, use of 
traditional medicine and use of alternative medicine [152, 153]. Age may influence 
adherence to highly active therapy; some studies found that elderly patients are more 
adherent to treatment than their younger counterparts [154]. 
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 Another important factor that may affect adherence to treatment is educational level. 
Some studies showed that those who are highly educated, for instance university 
graduates, are more adherent to treatment than those with low level of education such as 
those with merely primary or secondary school education [155]. This is because 
educated individuals can easily understand the benefit of adherence to HAART and the 
complications associated with non-adherence. Other socio-demographic factors have 
also been shown to affect adherence to HAART, such as income, marital status [156]. 
Patient factors include stigma as a result of disclosure of their HIV status, avoidance of 
taking prescribed HIV medication in public places, change in daily routine, the feeling 
of depression, hopelessness, or overwhelmed, falling sick, or being away from home. 
Other barriers include high costs of treatment and wanting to avoid adverse effects of 
treatment (Spire et al., 2002). It is important to state that when patients feel that their 
health condition is getting better or improving, it may negatively affect adherence level 
since some patients may stop taking their medication (Tuldrà et al., 2000). 
 
2.4.11 Patient provider relationship 
Responsibility for successful long-term treatment and adequate viral suppression must 
lie with the individual who is on antiretroviral therapy. It is equally vital that the 
selection criteria for antiretroviral therapy be set up and communicated by providers to 
patients who are in need of such treatment. The relationship between patients and their 
doctors must be very good for the patients to be satisfied. The best relationship is the 
one in which patients are included in the decision making process with their care 
providers (Schneider, Kaplan, Greenfield, Li, & Wilson, 2004). The relationship in 
which sensitive issues such as race and ethnicity are looked into very carefully by the 
health care providers when dealing with HIV-positive patients is very important 
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especially in a country with a multiethnic society like Malaysia (Hasanah, Zaliha, & 
Mahiran, 2011). In general, a good patient–provider relationship is very important in 
motivating HIV patients to take their HAART medication, therefore improving the 
adherence level to treatment. 
 
2.4.12 Health service factor 
Hospital setting or service provision has a tremendous effect on a patient’s adherence to 
medication. Among the most important aspects are short waiting time for medication 
collection, friendly relationship between hospital staff and the patient, warm welcoming 
by hospital staff, short distance between the hospital and patients’ residences, 
availability of supportive staff and most importantly, the patient’s appointment for 
follow-up should be short and convenient (Architects, 2004; Merten et al.). Likewise, 
high adherence level of HIV-positive patients on HAART is also associated with 
maintaining their privacy and confidentiality during interviews, examinations and 
investigations carried out on patients. Judgemental, unsympathetic and untrained staff 
with poor human relation may be associated with non-adherence to antiretroviral 
treatment (G. C. Stone, 1979). 
 
2.4.13 Disease characteristics 
Disease characteristics include the impact and severity of HIV on the patients, the effect 
of other diseases and opportunistic infections on the patient and the ability of the 
patients in accepting and living with HIV as a disease that has no cure (Tawfik & 
Kinoti, 2003). 
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2.4.14 Beliefs and knowledge 
Good adherence to antiretroviral therapy could be predicted by a patient’s awareness, 
knowledge, beliefs about the disease and the effectiveness of HAART. It is known that 
HAART does not cure HIV, but despite this, patients’ understanding and belief that 
HAART can prolong and improve the quality of life is essential in the management of 
HIV (J. B. Nachega et al., 2005). On the other hand, patients’ lack of interest in 
understanding the disease and being equipped with the knowledge about antiretroviral 
treatment may eventually lead to non-adherence to treatment. When patients become 
non-adherent, development of drug resistance and treatment failure will follow. 
 
2.4.15 Depression 
Depression is a major predictor of sub‐optimal and in most cases non-adherence to 
prescribed medication. HIV-positive patients suffer from psychiatric illness at one time 
or another and about 70% of the patients experience depression or anxiety-related 
illness (Ammassari et al., 2004). This could be due to the fact that HIV/AIDS affect the 
nervous system, dementia and several forms of central nervous system disorders may 
even be present in HIV patients. Patients may lose cognitive functions and consequently 
forget to take medication as prescribed by their health care providers. This will have 
negative impact of adherence to medication and patients will have sub-optimal 
adherence or non-adherence to treatment (Tozzi et al., 1999). 
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2.5. Measuring adherence 
Measuring adherence is a problematic and complex procedure, and even though there 
are many known methods for measuring adherence, there is no ‘Gold Standard’ (M. A. 
Chesney, 2006). All of the methods for measuring adherence have their own advantages 
and disadvantages, and it will be good to use more than one method to measure 
adherence(Quittner, Espelage, levers-Landis, & Drotar, 2000).  
 
Adherence to antiretroviral therapy can be done either through the direct method or the 
indirect method. The direct method is more objective and depends on measuring the 
plasma concentrations of the antiretroviral drugs using therapeutic drug monitoring, 
whereas the indirect methods rely on less objective measures. The indirect methods 
mainly include self-reported adherence, such as pill count, pharmacy refill records, 
Medical Event Monitoring Systems (MEMS), and assessment of adherence by a doctor 
or nurse (Hugen et al., 2002).  
 
Other indirect methods include reviews of patient charts (documented patient report of 
adherence to provider), missed clinic visits, Direct Observed Therapy (DOT) and 
therapeutic outcomes (i.e. viral load, CD4 lymphocyte count and stage of disease 
progression). The most widely used approach is, however, self-reported adherence, 
which has its advantages and disadvantages (Knobel et al., 2002; Muñoz-Moreno et al., 
2007). 
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2.5.1 Self-reported adherence   
In this method, patients report their adherence level using questionnaires, interviews or 
diaries, by which a patient reports the number of doses he/she had taken or missed 
during a specified time interval(Wiener, Riekert, Ryder, & Wood, 2004). This interval 
differs from one study to another and may be two days, four days, two weeks, four 
weeks and six weeks. A trusting and very good patient–doctor relationship plays a very 
important role when using self-reported adherence method to measure adherence level 
in HIV-positive patients (V. E. Stone et al., 2001). Inquiring about the most recent days 
of taken and missed doses will give accurate results.  
 
Measuring adherence with self-reporting adherence is used in many countries but it 
tends to overestimate adherence, and inaccuracies may result from patients’ 
forgetfulness or patients’ desires to provide answers which will suit their physicians 
(Ammassari et al., 2001). Self-reported adherence is believed to be very cheap, fast and 
easy to administer and more importantly, many studies show an association between 
self‐reported adherence and HIV RNA, which suggests that self‐reports may be a valid 
indicator of adherence (Kerr et al., 2008). Patients reporting to be non-adherent are 
usually non-adherent indeed (i.e. high specificity) according to pill count. The 
sensitivity is the probability that patients who are actually being adherent will be 
categorized as adherent according to the assessment. The disadvantages with the method 
are that the results are easily affected by recall error (i.e. patients do not remember how 
many doses they have taken) and social desirability (i.e. patients report the behaviour 
they think is correct according to the social norms, or in other words they report the 
behaviour that their health-care personnel want to hear) (Hergenrather, Rhodes, & 
Clark, 2004). 
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2.5.2 Pill counts 
Using pill counts to measure adherence level is carried out by counting the number of 
medication remaining in the patients’ drug container / bottle during unannounced visits 
to patients’ homes or during patients’ hospital visits for follow-up. The adherence level 
is calculated using the remaining pills, which is assumed to be missed doses(Kalichman 
et al., 2008). This is easily done if a patient uses a pill organizer in this method of 
measuring adherence level (Pearson, Simoni, Hoff, Kurth, & Martin, 2007). From 
another perspective however, patients’ privacy and confidentiality may be affected 
when unannounced visits are conducted, and it may also negatively affect the patient-
health care provider relationship(Negash, 2011). Additionally, more human resources 
are required for home visits and more importantly, patients may even forget to bring 
their medication with them when visiting the hospital or clinic. 
 
2.5.3 Pharmacy refill data 
Measuring adherence to antiretroviral treatment does not depend on physicians or 
patients alone but also pharmacists who play an important role in supporting HIV 
patients to adhere to their medication. When patients suffer from problems in their 
prescribed medication, pharmacists can help in educating them and solve problems 
associated with taking their prescribed medication (Golin, Isasi, Bontempi, & Eng, 
2002). Adherence to treatment can also be measured by pharmacy refill data in which 
adherent patients are patients who collect their prescribed medication regularly and on 
due date. Pharmacists help in calculating the adherence level by providing the date in 
which the antiretroviral medications were dispensed and also the exact number of days 
between each consecutive refill. If the health care provider obtains the refills according 
to the prescribed time and medication are collected on the due date, patients are 
assumed to be taking their medication regularly. On the contrary, if patients have not 
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taken the prescribed medication as scheduled by their physicians, they are assumed to 
be missing their medication dose(R. B. Haynes, Ackloo, Sahota, McDonald, & Yao, 
2008).  
 
Pharmacy refill data is used in many international studies to calculate adherence level to 
HAART (J. B. Nachega et al., 2006). A reliable and effective medical record system 
plays an important role in calculating the adherence level by pharmacy refill data. 
Calculating the adherence through pharmacy refill data requires patients to obtain their 
prescribed medication from the same pharmacy all the time. This method is considered 
to be a non-measure of medication intake by the patients (i.e. patients might not 
swallow the tablets he collected from the pharmacy, for instance) and therefore have its 
disadvantages in measuring or calculating adherence (Grossberg, Zhang, & Gross, 
2004). 
2.5.4 Biological markers 
Biological markers such as plasma viral load and CD4 have been used as a very 
effective indicator of a patient’s medication usage in many developing countries 
including Malaysia. The main objective of antiretroviral treatment is to reduce the 
plasma viral load, however some studies showed that patients may be taking all of their 
medication every day and yet their viral load may remain very high (Liu et al., 2001). 
Using biological markers to monitor adherence in resource-poor settings is found to be 
very expensive. Other disadvantages of using biological markers such as viral load level 
is the fact that it causes malabsorption and affects metabolic conditions of the patients. 
The availability of other infectious diseases and drugs interactions can also lower the 
plasma viral load, thus giving a false impression that it is due to the antiretroviral 
treatment. It will be fair to state that these markers are rough indicators of a patient’s 
adherence to HAART and of very limited use(Shiras, 2006). 
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2.5.5 Medication Events Monitoring System (MEMS) 
This method consists of an electronic chip embedded in the lid of the medication bottle. 
The chip records the opening and closing of the bottle. A computer program downloads 
the information from the lid and gives a written report. The report shows the exact date 
and time for each opening of the cap and assumes that the opening concedes with 
HAART intake. Adherence level is calculated by dividing the number of time-
appropriate bottle openings by the number of expected doses over the study period 
(Samet, Sullivan, Traphagen, & Ickovics, 2001). One of the major disadvantages of this 
method is it can only access the adherence level on one medication and does not assess 
the components of the combination therapy such as HAART, other than the fact that the 
method is expensive. This system is not used in measuring adherence in Malaysia, 
where most centres depend mainly on physicians using plasma markers as a main 
method for measuring patients’ adherence. 
 
2.5.6 Therapeutic Drug Monitoring (TDM) 
There are many ways to measure adherence level, but Therapeutic Drug Monitoring 
(TDM) is the best objective method for measuring adherence by indicating the 
concentration of drugs in the serum. TDM has not been used for assessing and 
measuring adherence level due to the high cost involved in conducting TDM, short half-
life of the commonly used HAART medication and the physiology of drug metabolism 
and drug absorption which affect the use of TDM in measuring the adherence level. At 
the present time, TDM is only limited to research settings. Many studies have used this 
method for measuring adherence level. However, this method is very sensitive and 
expensive to use. It will be discussed in greater detail in chapter three of this thesis. 
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2.5.7 Combination methods for measuring adherence 
Most of the studies conducted on adherence to HAART in HIV-positive patients agree 
that there is no gold standard for measuring adherence. In addition, most of the methods 
used for measuring adherence level to antiretroviral treatment have their advantages and 
disadvantages. For example, the self-reported adherence questionnaire method has the 
advantage of being cheap and easy to administer, but  is associated with recall bias 
(Muñoz-Moreno et al., 2007). Likewise,  pharmacy refill method does not actually 
prove that the patients actually swallow the pills, rather it merely shows whether a 
patient has collected the medication or not (C. Golin et al., 2002).  
 
As a result of the above advantages and disadvantages and also the lack of gold standard 
method for measuring adherence, most studies use a combination of different method 
(Hill, Kendall, & Fernandez, 2003).  Meaning two or more of the above methods are 
used to assess the adherence level. The most common combination used consists of both 
the direct and indirect methods for measuring HAART. In this study, we used the self-
reported adherence questionnaire, pharmacy refill method and Therapeutic Drug 
Monitoring (TDM) for measuring the adherence level in HIV-positive patients. 
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CHAPTER 3 VALIDATION OF LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY (LC-MS-MS) METHOD FOR THE ANALYSIS OF THREE 
HIGHLYACTIVE ANTIRETROVIRALTREATMENT (HAART) IN HUMAN 
PLASMA OF HIV/ AIDS POSITIVE PATIENT 
 
 
3.1 The principle of LC-MS-MS 
LC-MS-MS is a combination of two techniques to identify and analyze chemical 
compounds(Kosjek, Heath, Petrović, & Barceló, 2007). Liquid chromatography can 
separate a component of a mixture into separate compounds and then characterize them 
by using mass spectrometry according to their molecular weights. The separation of a 
mixture by liquid chromatography can be achieved by using a column. A column is 
normally packed with certain materials from different types of phases, such as the 
normal phase, reverse phase, ion exchange.  
 
After separation in the column, the samples transferred into the mass spectrometer ion 
source, where the molecular components are ionized. The mass spectrometer will 
separate these ions according to the types of their ion charge ratio. For the purpose of 
simplicity, assume that all ion forms are singly charged; therefore the denominator of 
the mass-to-charge ratio (m/z) is always 1. Consequently, any ion observed at a 
particular mass has that mass. Therefore, a compound can be identified either to confirm 
the presence of the compound, for quantitation by using standard curve or determine the 
elements within the sample, if unknown. 
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3.1.1 Experimental 
3.1.2 Chemicals 
All chemicals obtained for this study are HPLC-grade or reagent-grade. Format and 
formic acid, ammonium and acetonitrile were obtained from Fisher Scientific, Malaysia. 
Human plasma which do not contain any drugs was obtained from the University of 
Malaya Medical Centre blood bank. Antiretroviral drugs such as lamivudine, efavirenz 
and nevirapine were purchased from Labchem Sdn. Bhd., all with United States 
Pharmacopeia (USP) grade. 
 
3.1.3 Apparatus 
The LC-MS/MS system consisted of an LC-10A UFLC system with a SIL-HT 
automatic sample injector (Shimadzu, Kyoto Japan) and an API 3200 Q-Trap LC-
MS/MS system (Applied Biosystems, Lincoln Centre Drive, Foster City, CA, USA). 
The LC-MS/MS system was controlled with the Analyst 1.42 software (Applied 
Biosystems). 
 
3.1.4 Mass spectrometer parameters 
The analysis of the drugs in this study was conducted using a mass spectrum with 
Model API 3200 Q-Trap triple quadrupole mass spectrometer, and operated in ESI 
mode with positive and negative mode ionization. Analytes were then quantified by 
Multiple Reactions Monitoring (MRM) (refer to Table 1 for MRM transitions). MRM 
allows for enhanced selectivity through the measurement of parent and daughter ions 
simultaneously for each compound of interest. The protonated ion (M+H
+
) and 
deprotonated ion (M-H
-
) of the analytes were then chosen and placed into the collision 
cell where they separated into product ions. The intensity of the ion was processed and 
finally maintained and kept by a selected computer system. 
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Table 3-1: summarised the MRM transition ions and the mode of mass spectrometer 
analysis  
Drug Ionization mode MS/MS transition 
Lamivudine Positive 230.20/111.90 
Nevirapine Positive 267.08/226.10 
Efavirenz Negative 313.90/68.90 
Zalcitabine Positive 212.08/112.00 
 
3.2 Chromatographic system 
The parameters of the liquid chromatography used in this analysis were a C18 Zorbax 
column with a diameter of 4.6 mm ID x 100 mm length with 3.5 µm particle sizes 
packing and Gemini-NX C18 4 mm ID x 2.0 mm length guard column. The assay flow 
rate was maintained at 0.8 mL/min throughout the process. The mobile phase A was 
0.05% formic acid in water and mobile phase B was 10mM ammonium formate in 
acetonitrile with a pH of 5.8. At the beginning of the assay, the flow gradient was 80:20 
v/v of A: B for 0.1 minutes, linearly ramped to 35 % B over 0.5 minutes, and then held 
at 35% B until 0.8 minutes. The gradient then ramped again to 95% B until 2 minutes 
and remained for 0.50 minutes. The gradient then returned to 20% B at 2.51 minutes 
and this condition was maintained and kept constant for about 3.5 minutes.  
 
3.3 Preparation of Mobile Phase 
The mobile phase had two phases: Phase A and Phase B. Phase A consisted of 0.05% 
pure formic acid in deionised water that was well mixed and filtered, and then degassed 
under vacuum. Mobile phase B was formed by mixing 770 mg ammonium formate in 
acetonitrile; the pH was adjusted to 5.8 with formic acid before filtration using a 0.45 
um membrane and then degassed under vacuum. 
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3.4 Preparation of standard and control 
To prepare lamivudine, nevirapine, and efavirenz stock solution, 2.0 mg of each analyte 
was weighed and then dissolved in a 10 mL methanol to produce 200µg/mL of each 
analyte. A diluted concentration was used in spiking the calibration standard. 10mL 
aliquots of drug-free plasma were spiked with each to obtain a range of concentration 
from 10 to 500 ng/mL. Frozen Quality Control (QC) pools were prepared at five 
different concentrations of each analyte using stock solution of each analyte. The 
analytes contain 200ug/mL in methanol.  Zalcitabine was prepared in acetonitrile at 
500ng/mL.  All samples obtained were kept at -20 
0
C in a fridge for future batch 
analysis.  
 
Table 3-2 Preparation of calibration standards 
Analyte concentration 
(ng/mL) 
Volume mix plasma 
(1ug/mL) µL 
Volume free drug 
plasma (µL) 
Total volume (uL) 
10 50 4950 5000 
25 125 4875 5000 
50 250 4750 5000 
100 500 4500 5000 
250 1250 3750 5000 
350 1750 3250 5000 
500 2500 2500 5000 
 
Table 3-3 Quality control sample 
Analyte concentration 
(ng/mL) 
Volume mix plasma 
(1ug/mL) µL 
Volume free drug 
plasma (µL) 
Total volume (uL) 
    
30 150 4850 5000 
240 1200 3800 5000 
400 2000 3000 5000 
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3.5 Extraction procedures  
Five hundred microliters of internal standard in acetonitrile solution was mixed with 
100uL of plasma (containing an analyte) in 1.5 mL micro centrifuge tubes and vortexed 
for 20s at high speed. The tube was centrifuged at 14800 rounds per minute for 10 min 
to turn precipitated proteins into pellet and produce a clear supernatant. Five hundred 
microliters supernatants was filtered using PHENEX RC 0.25µm syringe filter and 
transferred to  a vial  which was inserted and placed in the auto sampler tray which 
injected it onto the LC column. 
 
3.6 Analyte quantitation 
The quantitation of an analyte were achieved using the calibration curve plotted using 
the area ratio of analyte to internal standard versus known concentration analyte from 
10 to 500 ng/mL of plasma with 7 calibrators. All the results were calculated using the 
y= Ax+B linear regression. The regression coefficient for all the calibration curves 
obtained were greater than 0.99.  
 
3.7 Method Validation 
All the validation procedures and the acceptance criteria used in this study were adapted 
from the European Agency for the Evaluation of Medicinal Products (EMEA) guideline 
for method validation  (Surapaneni, 2012)and USFDA guideline(Mistri et al., 2007). 
The frozen plasma samples obtained from HIV positive patients, calibration standards 
and the quality control samples were first made available for the process and thawed as 
required. All samples were prepared with the same procedure. The following parameters 
were studied during method validation. 
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3.7.1 Specificity 
Specificity can be defined as non-interference  process between antiretroviral drugs 
used  and internal standard using  a pre-determined  extraction procedure, LCMS/MS 
conditions and no cross interference at the retention time when testosterone appear from 
the endogenous plasma(Owen III, Hidalgo, Li, & Zhang, 2012). Assay specificity was 
determined by analyzing double blank (plasma sample without analyte and internal 
standard), blank (plasma sample spike with internal standard only), LLOQ (Lower 
Limit of Quantification) and ULOQ (Upper Limit of Quantification) sample. 
 
 
3.7.2 Calibration / linearity 
The calibration consists of seven non zero, calibrators assayed in duplicate (nominal 
values 10, 25, 50, 100,250, 350 and 500ng/mL. Two analyte free samples were 
analysed, one with the internal standard and one without the internal standard; neither 
being included when fitting the calibration line. The correlation coefficient (r) between 
concentration and peak area ratio should be equivalent to, or better than, 0.98. The 
simplest mathematical model that adequately describes the concentration-response 
relationship was used. 
 
The following conditions should be met in developing a calibration curve: 
 No more than 20% deviation of the LLOQ from nominal concentration. 
 No more than 15% deviation of standards other than LLOQ from nominal 
concentration. 
 
At least 66% of the non-zero standards must meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. Excluding any 
calibrators should not change the model used. 
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3.7.3 Inaccuracy and Precision 
Inaccuracy was tested by determinations of low, medium and high quality control 
samples, together with the LLOQ and ULOQ samples. The nominal values for low, 
medium and high control samples were 30, 240 and 400ng/mL, respectively. The 
nominal values for the ULOQ and LLOQ were the same nominal concentration as the 
highest and the lowest calibration standards, respectively. 
 
Assay precision were measured both within-batch and between-batch by the analysis of 
the three control samples, the LLOQ and the ULOQ. Precision was evaluated as the 
relative standard deviation of the mean expressed as a percent (coefficient of variation: 
(CV %). Inaccuracy was expressed as the absolute percent deviation from the 
theoretically determined concentration (% difference) for within-batch and between-
batch precision the LLOQ, ULOQ and the three control samples was each assayed six 
times in three separate assays. Each assay has an individual calibration curve. 
 
The within- and between-batch mean inaccuracy for the high and medium control 
sample concentration must be within ±15% of the expected or nominal concentration 
and within ±20% of the expected or nominal concentration for the lowest control 
sample. The within-batch and between-batch precision for the high and medium control 
sample concentration must be within ±15% and within ±20% for the lowest control 
sample. 
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At the LLOQ, the mean inaccuracy and imprecision must be within ±20% of the 
expected or nominal concentration for at least five of the six control samples. At the 
ULOQ, the mean inaccuracy and imprecision must be within ±15% of the expected or 
nominal concentration for at least five of the six control samples. At least 66% of the 
controls must meet the above criteria. 
 
3.7.4 Recovery 
Absolute recovery of the three antiretroviral drugs namely Efavirenz, Lamivudine and 
Nevirapine was tested using human plasma spiked with other three samples of the above 
drugs at the same concentrations of the QC samples. Absolute recovery of zalcitabine 
was obtained at a concentration of 500 ng/mL Peak area measurements produced from 
the extracted samples were compared to the peak area measurements which were 
obtained from injection of the test compounds. Statistical parameters such as Mean & 
SD were calculated from the three measurements at each level. 
 
3.8 Validation Results 
3.8.1 Selection of operating protonated ions 
Figure 3.1 shows the chemical structure and the protonated ions of efavirenz 
lamivudine, nevirapine, and zalcitabine used in this study related to their mass. Major 
fragment ions at m/z 93.9, 94.9, 100.9, 112.0 and base peak at m/z 229.9 were observed 
for lamivudine. Whereby, for nevirapine some major fragments ions at m/z 92.9, 104.9, 
107.0, 197.7 and base peak at m/z 225.9 were observed. The major fragments ions at 
m/z for efavirenz were 199.0. 230.0.244.0 and peak at m/z 314.1. The mass spectrum 
scans for the above two analytes are shown in Figure 3.2, 3.3 and 3.4 
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4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
N
N
O
O
S
HO
NH2
4-amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
N
N
O
OHO
NH2
11-cyclopropyl-4-methyl-5,11-dihydro-6H- dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
NH
N
N
N
O
Scheme 1: Structures of the drugs
(Nevirapine)
(Zalcitabine)
(Lamivudine)
 
 
Figure 3-1 chemical structure efavirenz, lamivudine, nevirapine, and zalcitabine 
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3.8.2 Specificity 
No significant interfering peaks were found at the retention time of efavirenz, 
lamivudine, nevirapine, and zalcitabine.  The signal to noise ratio for all the drugs were 
both greater than 5. Figure 3.2, 3-3 and 3.4 shows the chromatogram obtained from the 
blank plasma, blank plasma spiked with 10 ng/mL efavirenz, lamivudine, Nevirapine 
(The 10 ng/ml was selected because it is the least value at which the LC-MS/MS 
machine can detect any of the three drugs tested for. This value was determined during 
the development and validation of the method used for the drug analysis) and blank 
plasma spiked with 500ng/mL zalcitabine. 
 
 
 
Figure 3-2 Efavirenz 
 
 
 
Figure 3-3 Lamivudine 
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Figure 3-4 Nevirapine 
3.8.3 Calibration 
The concentration range of efavirenz, lamivudine, nevirapine, measurement was 10 to 
500ng/mL to correctly weight the liner regression line for this 500 fold range the 
residuals were weighted by the reciprocal of the nominal concentration value squared. 
This achieves an allocation of equal importance to each standard value. That is, a 
constant coefficient of variation is assumed across the calibration range. The peak area 
ratio, regression coefficient and the slope of the calibration line etc. were calculated 
from the peak area data by the analyst program. The regression coefficient for all the 
calibration curves were greater than 0.99. Mean results obtained from three curves are 
summarized in Table 3.4 
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Table 3-4 Regression parameters for three calibration curves during validation 
Batch (C) (A) Intercept(B) r
2
 
1 6.12 E-6 0.00743 0.000394 0.9965 
2 7.75 E-6 0.00772 0.000682 0.9972 
3 7.51 E-6 0.00783 0.000210 0.9987 
BAXCxy   
 
3.8.4 Imprecision and Inaccuracy 
 
Within-assay reproducibility 
 
The CV% and the percentage for within assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted range with ranging from 1.7 to 13% and 
0 to 10%, respectively. 
 
Between assay repeatability 
The CV% and the percentage for between assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted ranges of between 1.9 to 8.3% and 1 to 
5%, respectively. Table 3.5 and Table 3.6 summarises the within and between assay 
imprecision and inaccuracy achieved during the validation study. All the results 
obtained were below than the limit accepted for validation. 
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Table 3-5 Within assay imprecision and inaccuracy of efavirenz in plasma 
Batch # Nominal 
concentrations 
Mean n=6 SD CV Mean  
accuracy 
 (ng/mL) (ng/mL)  (%) (%) 
 10 
(S/N* ratio > 5) 
8.848 
 
0.236685 
 
2.675016 
 
88.48 
 
 30 32.08  1.561089 
 0.09 
4.866239 
 
106.9333 
 
1 240 242 
 
5.787918 
 
2.391702 
 
100.8333 
 
 400 401.4 
 
5.029911 
 
1.253092 
 
100.35 
 
 500 535.6  37.32693 
 
6.969181 
 
107.12 
 
 10 
(S/N ratio > 5) 
11.02 
 
0.438178 
 
3.976207 
 
110.2 
 
 30 31.64 
 
1.681666 
 
5.314999 
 
105.4667 
 
2 240 205.8 
 
10.28105 
 
4.995651 
 
85.75 
 
 400 333.4 
 
15.25778 
 
4.57642 
 
83.35 
 
 500 470.8 
 
41.32433 
 
8.77747 
 
94.16 
 
 10 
(S/N ratio > 5) 
11.4 
 
0.158114 
 
1.386964 
 
114 
 
 30 34.24 
 
1.346477 
 
3.932468 
 
114.1333 
 
3 240 241 
 
16.77796 
 
6.96181 
 
100.4167 
 
 400 409.2 
 
7.395945 
 
1.807416 
 
102.3 
 4 
 500 510.6 
 
19.28212 
 
3.776364 
 
102.12 
 
* S/N: Signal to noise ratio 
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Table 3-6 Between assay imprecision and inaccuracy of efavirenz in plasma 
Nominal  
concentration 
Mean (n=15) SD CV Mean 
inaccuracy 
(ng/mL) (ng/mL)  (%) (%) 
10 10.42267 
 
1.196719 
 
11.48188 
 
104.2267 
 
30 32.65333 
 
1.845406 
 
5.651509 
 
108.8444 
 
240 229.6 20.5871 
 
8.966506 
 
 95.66667 
 
400 381.3333 36.48418 
 
9.567529 
 
95.33333 
  
500 505.6667 
 
41.89386 
 
8.284876 
 
101.1333 
  
 
 
Table 3-7: Within assay imprecision and inaccuracy of Lamivudine in plasma 
Batch # Nominal 
concentrations 
Mean n=6 SD CV Mean  
accuracy 
 (ng/mL) (ng/mL)  (%) (%) 
 10 
(S/N* ratio > 5) 
10.074 
 
0.465167 
 
4.617497 
 
100.74 
 
 30 30.56 1.532319 5.014131 101.8667 
1 240 237.4 7.635444 3.216278 98.91667 
 400 427.6 17.358 4.0594 106.9 
 500 535.6 21.00714 3.92217 107.12 
 10 
(S/N ratio > 5) 
10.77 
 
1.174521 
 
10.90549 
 
107.7 
 
 30 29.96 2.12791 7.102503 99.86667 
2 240 233 7.905694 3.393002 97.08333 
 400 377.6 15.1096 4.001483 94.4 
 500 499 30.11644 6.035359 99.8 
 10 
(S/N ratio > 5) 
11.008 0.786333 7.143289 110.08 
 30 34.58 0.460435 1.331505 115.2667 
3 240 264.6 11.58879 4.379738 110.25 
 400 452 6.442049 1.425232 113 
 500 540.4 33.50821 6.200631 108.08 
* S/N: Signal to noise ratio 
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Table 3-8: Between assay imprecision and inaccuracy of Lamivudine in plasma 
Nominal  
concentration 
Mean (n=15) SD CV Mean 
inaccuracy 
(ng/mL) (ng/mL)  (%) (%) 
10 10.61733 0.894926 8.428914 106.1733 
30 31.7 2.555945 8.062919 105.6667 
240 245 16.79711 6.855963 102.0833 
400 419.0667 34.50562 8.233922 104.7667 
500 525 32.74577 6.23729 105 
 
 
Table 3-9: Within assay imprecision and inaccuracy of nevirapine in plasma 
Batch 
# 
Nominal 
concentrations 
Mean n=6 SD CV Mean  
accuracy 
 (ng/mL) (ng/mL)  (%) (%) 
 10 
(S/N* ratio > 5) 
10.62 
 
0.342053 
 
4.617497 
 
100.74 
 
 30 28.62 
 
2.148721 
 
5.014131 
 
101.8667 
 
1 240 222 
 
15.01666 
 
3.216278 
 
98.91667 
 
 400 385.8 
 
15.73849 
 
4.0594 
 
106.9 
 
 500 516.6 
 
47.65816 
 
3.92217 
 
107.12 
 
 10 
(S/N ratio > 5) 
12.42 
 
0.725948 
 
5.844989 
 
124.2 
 
 30 29.62 
 
1.30269 
 
4.398007 
 
98.73333 
 
2 240 199.4 
 
8.619745 
 
4.322841 
 
83.08333 
 
 400 332.6 
 
19.33391 
 
5.812961 
 
83.15 
 
 500 493.2 
 
50.30606 
 
10.19993 
 
98.64 
 
 10 
(S/N ratio > 5) 
10.64 
 
0.750333 
 
7.052004 
 
106.4 
 
 30 29.84 
 
0.835464 
 
2.799812 
 
99.46667 
 
3 240 246.8 
 
4.438468 
 
1.798407 
 
102.8333 
 
 
 400 407.6 
 
4.97996 
 
1.221776 
 
101.9 
 
 500 541.8 
 
16.6343 
 
3.070192 
 
108.36 
 
* S/N: Signal to noise ratio 
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Table 3-10: Between assay imprecision and inaccuracy of nevirapine in plasma 
Nominal  
concentration 
Mean (n=15) SD CV Mean 
inaccuracy 
(ng/mL) (ng/mL)  (%) (%) 
10 10.64 
 
0.750333 
 
7.052004 
 
106.4 
 
30 29.84 
 
0.835464 
 
2.799812 
 
99.46667 
 
240 246.8 
 
4.438468 
 
1.798407 
 
102.8333 
 
400 407.6 
 
4.97996 
 
1.221776 
 
101.9 
 
500 541.8 
 
16.6343 
 
3.070192 
 
108.36 
 
 
 
3.8.5 Recovery 
The absolute recovery of efavirenz, lamivudine, nevirapine, and zalcitabine ranged from 
84 to 89% and 82 to 86%, respectively. All the values are summarised in Table 3.11 and 
Table 3.12 
 
3.8.6 Stability 
Table 3.13, 3.14, and 3.15 lists the stability data for efavirenz, lamivudine and 
nevirapine in plasma after three freeze and thaw cycles, after 48 hours at room 
temperature, and after 48 hours at 4ºC, respectively.Efavirenz, nevirapine and 
lamivudine were found to be stable at all the conditions tested. 
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Table 3-11: Percentage of Nevirapine and Lamivudine recovery from plasma 
                                              Nevirapine                         Lamivudine 
Nominal 
concentration 
Mean area    Recovery Nominal 
concentration 
Mean area Recovery 
Extracted 
samples 
Non extracted 
samples 
Extracted 
samples 
Non extracted 
samples 
(ng/mL) Peak area Peak area (%) (ng/mL) Peak area Peak area (%) 
30 45178 53912 82.5 30 44879 50069 89.6 
        
240 1334923 1499488 89.0      240 1284757 1298722 83.6 
        
400 3866636 4067952 95.1 400 4005169 4309874 92.9 
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Table 3-12: Percentage of Efavirenz and Zalcitabine recovery from plasma 
Efavirenz                 Zalcitabine 
Nominal 
concentration 
Mean area Recovery Nominal 
concentration 
Mean area Recovery 
Extracted 
samples 
Non extracted 
samples 
Extracted 
samples 
Non extracted 
samples 
(ng/mL) Peak area Peak area (%) (ng/mL) Peak area Peak area (%) 
30 45145 53922 83.8     
        
240 1184957 1399421 84.7 500 3228421 4959878 86.0 
        
400 4166863 4567946 91.2     
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Table 3-13: Results of stability tests carried out on efavirenz: values expressed in percentage  
of the concentration difference between, before and after the test 
  Concentration (ng/mL) 
  30 240 400 
Time 0 stability data. Mean (n=4) 28.5 235 385 
In plasma, after three freeze-thaw cycles. Mean (n=4)  27.1 231 392 
Difference (%) -4.9 -1.7 1.8 
    
In plasma after 48 hours room temperature. Mean (n=4) 25.6 239 380 
Difference (%) -10.1 1.7 -1.3 
    
In plasma after 48 hours at 4ºC. Mean (n=4) 25.9 231 388 
Difference (%) -9.1 0.4 0.8 
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Table 3-14: Results of stability tests carried out on lamivudine: values expressed in percentage  
of the concentration difference between, before and after the test 
  Concentration (ng/mL) 
 Time 30 240 400 
Time 0 stability data. Mean (n=4) 29.9 238.7 398.4 
In plasma, after three freeze-thaw cycles. Mean (n=4)  27.5 241.0 401.9 
Difference (%) -8.03 0.96 0.88 
    
In plasma after 48 hours room temperature. Mean (n=4) 32.3 239.1 396.9 
Difference (%) 8.03 0.17 -0.38 
    
In plasma after 48 hours at 4ºC. Mean (n=4) 30.56 239.9 400.45 
Difference (%) 2.21 0.50 0.51 
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Table 3-15: Results of stability tests carried out on nevirapine: values expressed in  
percentage of the concentration difference between, before and after the test 
  Concentration (ng/mL) 
  30 240 400 
Time 0 stability data. Mean (n=4) 31 239.9 399.67 
In plasma, after three freeze-thaw cycles. Mean (n=4)  30.68 240.97 398.34 
Difference (%) -1.0323 0.44602 -0.3328 
    
In plasma after 48 hours room temperature. Mean (n=4) 29.86 239.26 401.34 
Difference (%) -3.6774 -0.2668 0.41784 
    
In plasma after 48 hours at 4ºC. Mean (n=4) 32.4 241.32 397.43 
Difference (%) 4.51613 0.59191 -0.5605 
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Table 3-16: Autosampler stability data for efavirenz 
Sample type Expected concentration Measured concentration Elapsed time 
 (ng/mL) (ng/mL) (h) 
  27.91 0 
  29.63 4.3 
QC1 30 31.50 8.7 
  30.30 17.0 
  33.13 22.1 
  28.64 24.5 
  239.86 0 
  241.98 4.3 
QC 2 240 238.13 8.7 
  236.98 17.0 
  240.61 22.2 
  242.32 24.6 
  398.47 0 
  398.99 4.3 
QC 3 400 400.57 8.7 
  401.09 17.0 
  403.00 22.1 
  399.52 24.5 
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Table 3-17: Autosampler stability data for nevirapine 
Sample type Expected concentration Measured concentration Elapsed time 
 (ng/mL) (ng/mL) (h) 
  31.32 0 
  30.56 4.3 
QC1 30 29.63 8.7 
  32.45 17.0 
  30.17 22.1 
  27.91 24.5 
  239.89 0 
  241.52 4.3 
QC 2 240 240.28 8.7 
  243.04 17.0 
  240.17 22.2 
  237.18 24.6 
  399.03 0 
  398.07 4.3 
QC 3 400 403.16 8.7 
  400.29 17.0 
  401.83 22.1 
  398.46 24.5 
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Table 3-18: Autosampler stability data for lamivudine 
 
Sample type Expected concentration Measured concentration Elapsed time 
 (ng/mL) (ng/mL) (h) 
  29.81 0 
  30.83 4.3 
QC1 30 33.56 8.7 
  29.13 17.0 
  28.71 22.1 
  29.91 24.5 
  240.63 0 
  238.41 4.3 
QC 2 240 239.04 8.7 
  238.99 17.0 
  242.67 22.2 
  241.13 24.6 
  399.62 0 
  397.09 4.3 
QC 3 400 398.73 8.7 
  401.18 17.0 
  400.47 22.1 
  403.54 24.5 
 
 
3.9 Analysis of plasma samples obtained from HIV patients 
Blood samples were obtained from 925 patients for analysis. The blood was collected in 
2 groups’ namely first blood sample and second blood sample. First blood sample was 
collected with the administration of the self-reported questionnaire, second blood 
sample was obtained one month after the first sample when patient come to collect his 
antiretroviral  medication.  Six ml of blood was drawn from the vein of each patient by a 
phlebotomist using lithium heparin tube and centrifuged within one hour of collection 
time. It was then transferred to 2 plain bottles (3ml each) for storage at -80 degrees in 
the Department of Pharmacology for future batch analysis using the Liquid 
Chromatography Mass Spectro-Photometery (LC-MS/MS) machine. The number of 
second blood sample collectd were less than the number of the first blood samples this 
due to the fact that some patients did not come to give second blood sample. The 
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researcher has made several telephone calls and sends text massages to ask patients to 
come for providing second blood sample but still there were some that did not show up. 
 
3.10 Results 
Table3.19. below shows the results of lamivudine analysis in the first and second blood 
samples obtained from HIV-positive patients. Out of 925 samples analysed, 299 
(32.3%) of the first blood samples had lamivudine detected while the remaining 197 
(21.3%) samples were lamivudine-free. Fifty seven of second blood samples were 
analyzed. The remaining 868 participants did not provide second blood samples for 
analysis.  
 
Table 3-19 Analysis of lamivudine in HIV positive plasma samples using LC-MS/MS 
Drugs Plasma concentration (ng/mL) Detection of the drugs in the 
plasma samples 
 Mean Maximum Minimum  Positive (%) Negative (%) 
Lamivudine      
1st sample 12±1.1 43029±308 1534.3±31 299 (60.3%) 197 (37.7%) 
2
nd
 sample 38±1.7 21057±423 4917.1±27 38 (66.7%) 19 (33.3%) 
Note: Sample were diluted prior to analysis from 10 to 100 times dilution 
 
 
Table III.20 below presents different concentrations of the 243 first blood samples and 
38 second blood samples containing lamivudine as detected by LC-MS/MS machine. 
Thirty one participants’ first blood samples had lamivudine concentrations greater than 
6001 ng/mL while 12 participants’ second blood samples had concentrations greater 
than 6001. Ninety two or 37.9% of the participants’ first blood samples had 
concentrations ranging from 1 -1000 ng/mLwhile only 6 or 15.8% of the second blood 
samples contained efavirenz concentrations ranging between 1 ng/mL to 1000 ng/mL.  
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Table 3-19: Detected Lamivudine concentration in human plasma using LC-MS/MS 
Lamivudine in first blood sample Lamivudine in second blood sample 
Con( ng/mL) N            (%) Con( ng/mL) N                 (%) 
1--1000 92         37.9 1-- 1000 6                  15.8 
1001-- 2000 35         14.4 1001-- 2000 4                 10.5  
2001--3000 33         13.6 2001-- 3000 6                  15.8 
3001--4000 19         07.8 3001-- 4000 3                    7.9 
4001--5000 14         05.8 4001-- 5000 3                    7.9 
5001—6000 19         07.8 5001-- 6000 4                   10.5 
> 6001 31         12.8 > 6001 12                31.6 
Total 243       100 Total 38                1000 
N = Number of patient.      LC-MS/MS = Liquid Chromatography Mass-Spectro-photometry   Con = Concentration 
 
 
Table3.21 below shows the results of efavirenz analysis in the first and second blood 
samples obtained from HIV-positive patients. Out of 925 samples analysed, 445 
(71.2%) first blood samples had efavirenz detected while the remaining 180 (28.8%) 
samples were negative and three participants did not provide blood for analysis.  One 
hundred and thirty two second blood samples were analyzed. The remaining 793 
participants did not provide second blood samples for analysis.  
 
Table 3-21 Analysis of Efavirenz in HIV positive plasma samples using (LC-MS/MS) 
Drugs Plasma concentration (ng/mL) Detection of the drugs in the 
plasma samples 
 Mean Maximum Minimum  Positive (%) Negative (%) 
Nevirapine       
1st sample 19±1.4 32100±134 4350.90±91 445 (71.2%) 180 (28.8%) 
2
nd
 sample 146±6.1 23450±35 4342.10±29 119 (90.2%) 13 (9.8%) 
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Table 3.22 presents different concentrations of efavirenz detected in the 346 first blood 
samples and 119 second blood samples. More than 24% or 84 of the participants’ first 
blood samples had efavirenz concentration above 6001 ng/mL while 21% or 25 of the 
participants’ second blood samples had concentration above 6001 ng/mL. Forty one of 
the participants’ first blood sample had efavirenz concentrations ranging from 1-1000 
ng/mL while only 13 participants’ second blood samples contained efavirenz 
concentrations ranging from 1-1000 ng/mLs. 
Table 3-20: Detected Efavirenz concentration in human plasma using (LC-MS/MS) 
machine 
Efavirenz  in first blood sample  Efavirenz  in second blood sample 
Con( ng/mL) N            (%) Con( ng/mL) N           (%) 
1—1000             41        11.8 1-- 1000 13           10.9 
1001-- 2000 45         13.0 1001-- 2000 10            8.9 
2001--3000             59         17.1 2001-- 3000 28            23.5 
3001--4000             52         15.0 3001-- 4000 22             18.5 
4001--5000             32         09.2 4001-- 5000 10             8.4 
5001--6000             3309.5 5001-- 6000 11             9.2 
> 6001             84          24.3 > 6001 25              21.0 
Total 346        100 Total 119             100 
N = Number of patient.      LC-MS/MS = Liquid Chromatography Mass-Spectro-photometry    Con = concentration 
 
Table 3.23 below shows the results of nevirapine as analyzed in the first and second 
plasma samples obtained from HIV-positive patients. Out of 925 samples analyzed, 394 
(69.6%) first blood samples had nevirapine detected while the remaining 172 (30.4%) 
samples were negative and two participants did not provide blood for analysis. Ninety 
five second blood samples were analyzed. The remaining 830 participants did not 
provide second blood samples for analysis. 
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Table 3-21: Analysis of Nevirapine in HIV positive plasma samples using (LC-
MS/MS) 
Drugs Plasma concentration (ng/mL) Detection of the drugs in the 
plasma samples 
 Mean Maximum Minimum  Positive (%) Negative (%) 
Nevirapine      
1st sample 11±1.2 11650±12 2734.17±121 394 (69.6%) 172 (30.4%) 
2
nd
 sample 44±2.3 12566±40 3853.3±29 82 (86.3%) 13 (13.7%) 
 
Table 3.24 below presents the different concentrations of 269 first blood samples and 82 
second blood samples containing nevirapine as detected by the LC-MS/MS machine. 
Thirty six participants’ first blood samples had nevirapine concentrations greater than 
6001 ng/mL while 15 participants’ second blood samples had concentrations greater 
than 6001. Ninety five or 35.3% of the participants’ first blood samples had 
concentrations ranging from 1-1000 ng/mL while only 12 or 14.6% of the second blood 
samples contain nevirapine concentrations between 1 ng/mL to 1000 ng/mL.  
 
Table 3-22: Detected Nevirapine concentration in human plasma using (LC-MS/MS) 
machine 
Nevirapine  in first blood sample Nevirapine in second blood sample 
Con( ng/mL) N            (%) Con( ng/mL) N                 (%) 
1--1000 95         35.3 1-- 1000 12                   14.6 
1001-- 2000 34         12.6 1001-- 2000 7                       8.5 
2001--3000 41          15.2 2001-- 3000 13                    15.9 
3001--4000 24          08.9 3001-- 4000 15                    18.3 
4001--5000 22          08.2 4001-- 5000 13                    15.9 
5001--6000 17          06.3 5001-- 6000 7                       8.5 
> 6001 36   13.4 > 6001 15                   18.3 
Total 269          100 Total 82                    100 
N = Number of patient.      LC-MS/MS = Liquid Chromatography Mass-Spectro-photometry Conc = Concentration 
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Figure 3-5 Spectra for Efavirenz 
 
 
Figure 3-6 Spectra for Lamivudine 
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Figure 3-7 Spectra for Nevirapine 
 
 
Figure 3-8 Spectra for both Nevirapine and Lamivudine 
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Figure 3-9 Spectra for Efavirenz 
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CHAPTER 4 METHODOLOGY 
4.1 Study design 
This section provides the overall plan of the study; it briefly covers the following four 
main issues: the strategy of the study, its conceptual framework, data collection and the 
methods of analysis used. This study is intended to describe factors affecting adherence 
to antiretroviral treatment in HIV-positive patients in Malaysia. The best method that 
was selected to carry out this study and address the research question is through a 
bidirectional cohort (both prospective and retrospective) study, which consists of two 
components. Prospective cohort study design usually describe a group of patients and 
follow them from the present time to the future while in retrospective cohort patients 
records are obtained from the present time to specific years in the past. 
 
First, patients were monitored for a period of one year (Nov 2009 – Oct 2010). During 
this period, blood samples were collected twice after the administration of the self-
reported questionnaires, and pharmacy record data were collected for the preceding six 
months from online hospital record data. All investigation results such as biological 
marker (viral load), immune reconstruction makers (CD4, CD8), liver function tests and 
other haematological investigation results had been collected. These two components 
were carried out simultaneously and at the end of the first year, all of the blood samples 
collected was analyzed in the pharmacology lab using the LC-MS-MS machine.  
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The machine determined the antiretroviral drug levels in the plasma using Therapeutic 
Drug Monitoring method. The LC-MS/MS was used because it is more accurate and has 
the ability to analyze more than one drug in a very short time compared to the old 
Liquid Chromatography machine. The research team (i.e. researcher and data collectors) 
administered a self-reported adherence questionnaire to collect information about the 
reasons that facilitate patients to adhere to treatment as well as barriers for missing 
medication. We collected pharmacy data and results of clinical tests done at the same 
time from online clinical records. Cohort studies have several advantages. They are 
useful to ascertain both incidence and natural history of a disease. In addition, they are 
also important in investigating multiple outcomes that might occur after a single 
exposure. The cohort study design is suitable for studying rare exposures, and it reduces 
the risk of survivor bias. Cohort studies also allow calculation of incidence rates, 
relative risks, and other outcome measures such as survival analyses.  
 
However, cohort studies also have their own disadvantages. These include selection bias 
which happen when patients were selected to participate in the study. Moreover, loss to 
follow-up can be a problem, and cohort studies are not suitable for studying rare 
diseases. Before-after cohort studies have significant limitations. An investigator takes a 
measurement, exposes participants to an intervention, repeats the measurements, and 
then compares them. The first limitation is regression to the mean (which refers to a 
phenomenon where if a variable is extreme on the first measurement, later 
measurements may tend to be closer to the centre of distribution) because lower mean 
values will arise at follow-up. The second limitation is that secular trends - such as 
seasonal changes in disease frequency - can affect results. In principle, a cohort study 
could be used to estimate average risks, rates, or occurrence times. This requires that the 
whole cohort remain at risk and under observation for the entire follow-up period. In 
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practice, patients may be lost, transferred, or die of competing causes. When losses or 
competing risks occur, one may still estimate the incidence rate using survival methods. 
 
Figure 4.3 illustrates the conceptual framework of the study. It outlines the different 
ways of analyzing factors affecting adherence to antiretroviral treatment among HIV-
positive patients. As shown by the figure, three different measures of ‘adherence to 
antiretroviral treatment’ were used: first is through self-reported adherence 
questionnaire, second is through pharmacy refill from online electronic records and the 
last one is by obtaining the drugs level using Therapeutic Drug Monitoring (TDM).  
 
The self-reported questionnaire consists of 48 dichotomous questions that can be 
divided into four main groups as follows:  
1) Risk factors of HIV treatment;  
2) Alternative medications to HIV patients; 
3) Reasons facilitating the adherence to treatment; and  
4) Reasons for missing HIV medications.  
 
With the exception of ‘reasons for facilitating’ variables, all variable groups have a 
negative relationship with adherence.   
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AUC = Area under the curve 
PPV = Positive predictive value 
NPV = Negative predictive value 
 
Figure  4 2 Conceptual framework 
 
As we would see in the data analysis and modeling section, the study uses different 
methods of analyzing factors affecting adherence to antiretroviral treatment in HIV. 
They include logistic regression analysis, contingency table analysis (descriptive/odd 
ratio), and screening & diagnostic test analysis. In order to achieve the desired results, 
this study was executed in the following phases: 
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Phase 1: Instrument Development and Validation, June 2009 – Oct 2009 
During this phase, a self-reported study instrument for measuring overall adherence was 
developed. This involved pre-testing on fifteen participants with different educational 
level and backgrounds, forward and backward translation into Bahasa Malaysia, 
Mandarin and Tamil as well as a test-retest to check for reliability. Figure 4.3 outlines 
the translation process of the modified AACTG questionnaire from English languages 
into Malay, Chinese and Tamil languages.  
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Figure 4-1 Forward and backward translation from English into Bahasa Malayu and 
Chinese. 
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Phase 2: Data Collection and Refinement, Nov 2009 – Oct 2010 
The pharmacy refill instruments were applied to the study population over a 1-year 
period (Nov 2009 –Oct 2010). This was accompanied by blood taking in order to check 
for therapeutic drug concentration. Blood was frozen at between -20 to -80 degrees 
Celsius for future batch analysis. 
 
Phase 3: Method Development and Validation using LC-MS/MS, Oct 2010 – March 
2011 
All chemicals and drugs for the LC-MS/MS therapeutic drug monitoring machine 
(Nevirapine, Lamivudine, Efavirenz and Zalcitabine) were obtained from Labchem Sdn. 
Bhd. in Kuala Lumpur. They were used in human plasma to develop standards for 
checking therapeutic drug concentration. This method was developed and validated 
using the LC-SM/MS machine first; then, the frozen plasma obtained from HIV-positive 
patients was used to check for the concentration of the drugs. Drugs tested for were 
Lamivudine, Efavirenz, and Nevirapine which are used by the Ministry of Health as part 
of the HAART regimen. The batch anlaysis and testing for drugs in human plasma was 
completed by April 2011. 
 
Phase 4: Data Analysis and Report Writing, March 2011 – April 2012 
The researcher culturally adopted, developed and validated the Adult AIDS Clinical 
Trials Group (AACTG) adherence questionnaire. The pharmacy refill counts were 
obtained from the online pharmacy records in Sungai Buloh Hospital.  The collected 
data was entred into SPSS between Nov 2010- Feb 2011.Then, the findings were 
analysed (Feb 2011- June 2011) and presented in a few conferences. IT illustrates the 
flow chart of the study process starting from the proposal development through data 
collection till the report writing. It showed the duration for each step. 
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4.2 Study area and population 
This study was carried out in Hospital Sungai Buloh, (a tertiary-level hospital in the 
Malaysian state of Selangor) which is located about 25 km from Kuala Lumpur, the 
capital of Malaysia. The hospital covers an area of 130 acres and has a capacity of 620 
beds.  It was built to meet the needs of the growing and crowded population in the 
district of Gombak, providing various medical services and tertiary services. Sungai 
Buloh Hospital has been identified as a centre of excellence for Infectious Diseases such 
as HIV/AIDS.  The infectious diseases clinic operates 3 days a week from 8 a.m. to 5 
p.m., catering for the treatment and follow-up of HIV/AIDS patients. It is the largest 
infectious disease hospital in Malaysia.  Most of the data in this hospital are entered into 
an online electronic medical record system for all the patients and thus the data stored 
are easy to access and more accurate than the traditional medical record system and 
filing used in other hospitals. 
 
The study population consists of patients who visited the HIV /AIDS clinic in Sungai 
Buloh Hospital for treatment and follow-up between November 2009 and October 2010. 
Prior to the establishment of this hospital in 2006, most of these patients went to 
Hospital Kuala Lumpur for their treatment and follow-up. The HIV patients came from 
three districts – Gombak, Petaling and Kuala Selangor. These three catchment areas 
have a total population of almost one million residents. A few other HIV patients came 
from the other areas of Kuala Lumpur. 
 
4.3 Sample size 
Researchers rarely survey or analyze the entire population; instead, they select a sample 
which is expected to explain the phenomenon under study for the entire population. 
Determining sample size is a very important issue, since samples that are too large may 
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waste time, resources and money, while samples that are too small may lead to 
inaccurate results. The sample size in this cohort study is based on their exposure status. 
The study subjects should be at risk of the outcome under investigation (adherent or 
non-adherent) at the beginning of the cohort study and as the cohort is followed through 
time to assess their later outcome. 
 
The sample size for this research was calculated by using the Formula 3.1 below 
(Araoye, 2003) . The following assumptions were considered: first, the sample was 
representative; second, the sampling error was small; third, the sample was viable in the 
context of funds available for the research study; fourth, systematic bias was controlled 
in a better way; and finally, results from the sample study will be generalizable. 
 
          
     
  
 ------------- 3.1         
Where: z= standard variate (1.96) which corresponds to 95% confidence interval 
 p = proportion of HIV and AIDS patients on ARV treatment who did not adhere 
 q = 1 – p  
 e = the desired marginal error (precision of measurement) 
 p = 0.20 (was found from previous similar studies (Talam et. al., 2008 and 
Aroaye, 2003). 
 q = 0.80 
 e = 0.026 (e is the margin of error which is the tolerable amount of error and 
usually standard of error of equal or less than 0.05 is acceptable). 
  
                   
        
 = 909 ≈ 925 
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Thus, based on the values z = 1.96, p = 0.20, q = 0.80, and e = 0.026.  The sample size, 
denoted by n, equals to 909 patients which is almost equal to 925. 
 
4.4 Sampling procedure 
Convenience sampling technique was applied and it was drawn from a group of patients 
undergoing antiretroviral treatment in Hospital Sungai Buloh, Malaysia who satisfied 
the inclusion criteria. Convenience sampling was used considering the problem of 
consent and poor response rate in HIV/ AIDS studies. 
 
4.4.1 Inclusion criteria 
The inclusion criteria were Malaysian nationals, adults (18 years and above) of either 
sex who were HIV-positive (person detected to have the human immunodeficiency 
virus HIV), used HAART for at least two month, obtained their treatment from the 
hospital pharmacy and gave written consent to participate in the study. Patients must 
actually be taking the following antiretroviral treatment drugs: lamivudine and /or 
efavirenz and /or nevirapine. They were selected based on the fact that most of the 
patients in Sungai Buloh Hospital were prescribed this combination by their physicians. 
 
4.4.2 Exclusion criteria 
Individuals who were either very ill or unable to complete the study questionnaire, those 
who are less than 18 years of age, pregnant women (due to changes in a pregnant 
woman's mental and physical health from pregnancy through six months postpartum), 
patients who refused to give a written informed consent, eligible patients who 
participated in the pre-testing and test-retest of the questionnaire, patients who were not 
on the three selected HAART medications used in this study and patients who were not 
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Malaysian by nationality were excluded from this study since we wanted to restrict 
generalize our results within the  Malaysian populations only. 
 
4.4.3 Ethical consideration  
This study is approved by both the University of Malaya Medical Centre Research 
Ethics Committee and Ministry of Health Malaysia (Reference number 714.14, see 
Appendix J). Individual written informed consent form (Appendix F) was distributed to 
each participant in their preferred language and it was clearly stated that participation 
was voluntary and that the participant could withdraw from this study at any time. The 
consent form was signed after the purpose & benefits of the study had been explained to 
the participants. Privacy & confidentiality were maintained throughout the study period. 
 
4.5 Study variables 
This study on factors affecting adherence to antiretroviral treatment has 48 variables 
which can be categorized into two main groups: dependent variables and independent 
variables.  
 
4.5.1 Dependent variable 
The dependent variable of this study is called ‘Adherence to antiretroviral treatment’. It 
is defined as having adherence level of more than 95% as measured by either of the 
following methods. The adherence level was assessed within aperiod of two weeks, four 
weeks and sex weeks respectively using overall self-reported adherence. Patients with 
95% adherence level mean those patients had missed 5% of their prescribed dose. 
Adherence will then be categorized into high adherence (>95%), moderate adherence 
(75% to 95%) and lower adherence (<75%). The researcher used the WHO standard 
which requires a minimum adherence level of 95% or more for patients to be adherent 
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& avoid treatment failure [222, 223].  This variable was measured using self-reported 
adherence questionnaire, pharmacy refill from online electronic records and objectively 
by obtaining the drug level using Therapeutic Drug Monitoring (TDM).  
 
4.5.2 Independent variables 
Table 4-1: Independent variables 
Group Variables 
Demographic  age, race, ethnicity, marital status, employment status, income 
level and level of education 
Disease factors (side 
effects) 
HIV transmission route, duration of HIV infection, Age, Sex, 
Marital Status, Vomiting, Diarrhoea, Loss of appetite, Dry 
mouth, Itching, Tiredness, Rashes, Fever, and Headache. 
Treatment factors duration of treatment, medication side effects, drug dose 
frequency and number for missed doses in preceding 
4days.number of missed doses in 2 weeks, 4 weeks and 6 weeks. 
Reasons for missing 
medications 
distance to hospital too long and costly, was busy with other 
things, treatment and drug collection time in hospital too long, 
had a change in daily routine, felt well did not want others to 
notice you taking medications, simply forget was, away from 
home,  felt depressed / over whelmed,  religious belief,  had 
problem taking pills at specified times, felt a sleep through dose 
time,  cost of treatment too high,  felt like drug was toxic,  
wanted to avoid side effects, poor relationships with health 
provider,  ran out of pills,  beliefs and preference for traditional 
medicine, felt sick or ill and had simply many pills 
Reasons facilitating 
adherence to treatments 
acceptance of one HIV status, use of Alarm/ clock, belief in the 
efficacy of pills, the needs to care for others, social support, self 
efficacy to take and adhere to ART, to avoid paying for new 
drugs, afraid of my health condition getting worse, afraid of 
developing resistance to drugs, disclosure revealing disease 
status). 
 
Patients were asked to report the adverse effects of treatment such as itching, loss of appetite if such symptoms were 
felt only after taking their medications (this is to distinguish between symptoms due to disease and symptoms due to 
medication side effects) 
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4.6 Description of the study instruments used in this study 
4.6.1 Self-reported questionnaire 
Instead of choosing to develop and validate new instruments to use in this study, the 
researcher decided to translate, culturally adapt and use an instrument which is already 
validated in many developed countries and used in many international studies on 
measuring adherence to antiretroviral treatment. This is to avoid the high cost, huge 
resources and long time required for the development and validation of a new 
instrument. The researcher used the Adult AIDS Clinical Trials Group (AACTG)  
adherence questionnaire (see Appendix 1)  which is designed and tested by the Center 
for AIDS Prevention Studies (CAPS) and  made available free of charge at the 
following website: http://www.caps.ucsf.edu/tools/surveys/. This is for the benefit of 
HIV researchers, evaluators, prevention program planners and designers.  
 
The AACTG questionnaire has been translated and used in some developing countries 
such as India, South Africa, Kenya, Pakistan and some other African countries 
(Balakrishnan et al., 2005; J. Nachega et al., 2004). Before translating the study 
instrument into Malaysian languages, the study team - after reviewing all items in the 
questionnaire - decided to exclude some items from the questionnaire and modified 
others that are not suitable to be used in Malaysia. The team members applied their 
clinical experience of working with HIV/AIDS-positive patients for many years in 
modifying the AACTG questionnaire and obtaining the final version to fit in the context 
of Malaysian society. 
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The AACTG questionnaire used in this study consists of two parts. The first part 
contains the introduction and questions about socio-demographic characteristics such as 
age, sex and marital status. The second part of the questionnaire includes questions 
related to the number of missed doses in the preceding days, 2 weeks, 4 weeks and 6 
weeks, twenty questions on the reasons for missing medications and ten questions on 
reasons facilitating adherence to antiretroviral treatment. It also contains questions on 
prescribed medications as well as the number of doses taken and missed.  
 
The total number of doses missed was assessed by first asking the patients to state 
whether or not they had missed any medication. Those who had missed medication were 
asked to choose the number of doses they missed (between one, two or three doses) over 
the specified period of four days, two weeks, four weeks and six weeks. Other questions 
on the adverse effects of treatment, use of alternative medicine such as yoga and use of 
traditional medicine are also included (see Appendix A). All questions are closed-ended 
questions. The True or False choices represent the frequency of experiencing a specific 
item during the last one month and answers are assigned a rating of 1 and 2 
respectively. 
 
Based on the study population in Sungai Buloh Hospital (study area), the study team 
decided to translate the new instrument into three languages - Malay, Chinese and Tamil 
- in addition to the English version. The guidelines used by WHO for translating and 
adapting study instruments in health was used. This guidline consisted of foreword 
transilation, backword transilation, pre-testing of the questionnaire and cognitive 
interviewing before obtaining the final version of the questionnaire.  Three very well-
experienced independent bilingual translators (who speak English and Malay, English 
and Chinese and English and Tamil) were selected to make a forward and backward 
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translation from English to Malay, Chinese and Tamil languages. The translators did a 
semantic translation and the instrument was then checked for the accuracy of 
translation.  After this initial step, three bilingual translators and two monolingual 
reviewers participated in a back-translation process. Two of the back translators were 
 from the original transilators who performed the forword transilation. After a repetition 
of the back-translation process to correct errors in translation, the target version of the 
final questionnaire was obtained. The questionnaire was then pretested on fifteen 
participants (due to the constraints in the available resources and the fact that there is no 
specific number for testing a questionnaire on) with different educational backgrounds 
and levels. They included three teachers, four general workers, two unemployed 
individuals and six students. The purpose of pretesting was to explore the feasibility of 
using this new instrument in the HIV/AIDS population in Sungai Buloh Hospital, and 
more importantly for accuracy, interpretability and to identify any problem associated 
with the new version of the questionnaire.  
 
The researcher and two research assistants performed a test-retest reliability assessment 
on 40 HIV/AIDS-positive patients in the Infectious Disease Clinic of Sungai Buloh 
Hospital three months before the commencement of the main study. The questionnaire 
was administered twice with a two-week interval between the first and second sessions 
to avoid recall bias. A two-week interval was considered not too long enough for 
changes that could potentially affect responses to occur and not too short enough to 
enable the recall of previous responses (Brazier et al., 1992; Jackson et al., 1996). 
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 All of the participants’ identification numbers were listed and kept for future exclusion 
from the main study. The questions listed in the questionnaire were delivered in Malay, 
Chinese and English. Subjects were asked to attempt to answer all of the questions. The 
results were entered into the SPSS version 16 for analysis (Carver & Nash, 2006). 
 
4.6.2 Pharmacy refill data instrument 
In Sungai Buloh Hospital, HIV/AIDS-positive patients visit the pharmacy departments 
monthly to collect their prescribed medications. We decided to obtain information on 
the patients’ last six visits to the pharmacy to collect their medications using the 
instrument (see Appendix E). A patient’s most recent visit to obtain his/ her medication 
from the pharmacy is considered to be the last refill visit. This is for the purpose of 
comparison with other instruments used in this study. The research assistant retrieved 
data on the preceding six refill visits for each patient from the Pharmacy Information 
System and filled in the information on the instrument for each visit and medication. 
 
The form used was designed by the researcher to collect data from the online pharmacy 
record in the pharmacy department of Sungai Buloh Hospital. The form was completed 
by a research assistant who was working in the above-mentioned department and had 
the experience of obtaining such information for other studies in the past. Data collected 
includes the patient’s hospital number and date of visit. Each instrument was labelled 
with a number for the purpose of identification.  
 
On each patient’s refill visit, information such as the refill status (whether or not the 
patients collected a particular medication), number of pills prescribed per day, number 
of pills dispensed on each refill visit, specific date on which medication was dispensed 
and the exact number of days between each refill visit and its consecutive refill visit was 
  93 
calculated. Since all participants in this study must be on one of the three drugs 
(Lamivudine, Efavirenz, or Nevirapine) a table was provided for each medication with a 
space for the above-mentioned information.  
 
The adherence level for each medication was calculated using the following formula 
which is used in many international studies (Grossberg & Gross, 2007; Saberi, Caswell, 
Amodio-Groton, & Alpert, 2008). 
 
Adherence = (pills dispensed/pills prescribed per day) / (days between refills) x 100% 
 
4.6.3 Instrument for collecting investigation results 
The test results for all the investigations carried by HIV/AIDS-positive patients 
participating in this study were obtained from the Laboratory Information System (LIS) 
by a research assistant, who completed the specific designed instrument (see Appendix 
E). The instrument contains the following information: patient’s hospital number, date 
of collection, instrument number, patient’s age and date of birth as well as method of 
exposure to the disease. 
 
Investigation results that were obtained from the patient’s electronic records include the 
baseline (after diagnosis of the disease), pre-treatment investigations (before the 
commencement of HAART) and most recent investigations done (at most six months 
before or during the current index visits) for each patient. Test results included 
haemoglobin level, white blood cells, CD4, CD8, viral load and detailed liver function 
test such as total protein, albumin and bilirubin levels. Other clinic information obtained 
includes the patient’s baseline, pre-treatment and most recent weight (in kg). The 
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patient’s disease history and past medical history were also obtained and filled in the 
instrument. The date for each of the above tests is filled in the space provided. 
 
Table 4-2: Instruments used in the study  
# Description  Appendix 
1 AACTG) questionnaire in English language  Appendix A 
2 AACTG) questionnaire  in Malay language  Appendix B 
3 AACTG) questionnaire  in Chinese language  Appendix C 
4 Instrument for data collection from online records  Appendix D 
5 Instrument designed for collection of data from hospital electronic 
medical records for both drugs and investigations tests results 
Appendix E 
6 Written inform consent form  for obtaining patients consent Appendix F 
7 First blood collection instrument for Therapeutic Drug Monitoring Appendix G 
8 Second blood collection instrument for TDM Appendix H 
9 Pharmacy refill data instrument for number of  drugs doses, time, 
date of collection and drug side effects 
Appendix I 
10 University of Malaya Medical Centre Research Ethics Committee 
approval form for conducting the study 
Appendix J 
 
4.6.4 Therapeutic Drug Monitoring (TDM) instrument 
Monitoring drug concentration in humans to optimize efficacy and reduce toxicity is not 
a new concept in clinical pharmacology. It is also considered the most objective method 
for measuring adherence to antiretroviral treatment. In this study, blood samples were 
drawn by a phlebotomist after the patient had completed the self-reported questionnaire, 
and was on any of the following HIV drugs: Lamivudine, Nevirapine, and Efavirenz. 
The data collection instrument used for this procedure provides information such as 
detailed instructions for the blood sample collection, patient hospital number, date of 
collection, time of blood collection and time it was centrifuged.  
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Other information includes the name of the prescribed medications, dosage, date and 
time when the last dose was taken and number of doses administered per day (See 
Appendix D).  Six ml of blood was drawn from the vein of each patient by a 
phlebotomist using lithium heparin tube and centrifuged within one hour of collection 
time. It was then transferred to 2 plain bottles (3ml each) for storage at -80 degrees in 
the Department of Pharmacology for future batch analysis using the Liquid 
Chromatography Mass Spectro-Photometery (LC-MS/MS) machine. The process of 
development and validation of the method for analysis of the above drugs is discussed 
in detail in Chapter 2 of this thesis. 
 
4.6.5 Overall self-reported adherence 
The self-reported questionnaires were then administered to patients who satisfy the 
inclusion criteria by two well-trained data collectors. Atrained interviewer was not 
employed to collect the data so as to reduce the cost which may arise since the sample 
size was large and extra-funding was required for the expensive labrotory work.   The 
data collectors were two counsellors who attended a two-day training course given by 
the researcher on how to introduce the study to participants, administer the self-reported 
questionnaires, and fill in the blood forms. All of the information collected was based 
on the patient’s self-report. The primary adherence measure is based on patients recall. 
Mean adherence level was calculated by asking participants to answer the following 4 
questions (A to D) with a Yes or No response: A- Do you sometimes find it difficult to 
remember to take your medicine?; B-When you feel better, do you sometimes stop 
taking your medicine?; C-Thinking back over the past four days, have you missed any 
of your doses?; D-Sometimes if you feel worse when you take the medicine, do you 
stop taking it? 
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We then assessed adherence by counting the number of No answers to questions A to D. 
If all 4 answers were No, the patient was classified as being highly adherent, but if there 
was 1 Yes answer, the patient was classified as being moderately adherent. If there were 
2 or more Yes answers, the patient was classified as having low adherence level (T. 
Barfod, Hecht, Rubow, & Gerstoft, 2006; TS Barfod, Sørensen, Nielsen, Rodkjær, & 
Obel, 2006).  
 
The 4 questions were designed so that an adherent patient would need to give a No 
response since it has been observed that in many studies participants tended  to answer 
Yes to questions posed to them by their health care providers in order to please them 
(Nieuwkerk & Oort, 2005; G. Wagner & Miller, 2004). In order to measure the 
adherence level over longer periods of time (such as the preceding two weeks, four 
weeks and six weeks) from the day the questionnaire was administered, the percentages 
of medication actually reported to have been taken by the patients were calculated and 
regarded as the adherence level for each patient at the stated period of two weeks, four 
weeks and sex weeks accordingly. Adherence level was then categorized into high 
adherence (>95%), moderate adherence (75% to 95%) and low adherence (<75%). For 
analysis by logistic regression we dichotomized adherence level to define high 
adherence as >95% and lower adherence as <95%. 
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4.7 Data collection and entry 
The following four methods were used to collect the data: 
1- A self-reported questionnaire to measure adherence to therapy. 
2-  Collecting data from pharmacy records of drugs dispensed. 
3- Instrument to obtain measure of response to therapy such as viral loads, CD4 cell 
counts, adverse events, nutritional status (i.e. BMI, body fat), and biochemical 
measures like haemoglobin, white blood cells and liver function tests. 
4-  Therapeutic drug monitoring using the LC-MS/MS method. 
 
The above-listed methods were used to collect the required data for this study. 
Qualitative and quantitative data were collected using a pretested self-reported 
questionnaire (Appendix A-D) which was developed and culturally adapted for this 
purpose. The questionnaires were administered to eligible patients by two research 
assistants on their appointment days (usually on Mondays, Wednesdays and Fridays) 
after the patients’ vital signs and weight had been recorded by the nurses. The 
questionnaire was administered in a private room after each patient had completed a 
written informed consent form (Appendix F).  
 
The research assistants explained the importance and significance of the study to the 
participants. Participants were informed of their right to continue or withdraw from the 
study at any time and were asked to answer all the questions in the questionnaire and 
reminded that there were no right or wrong answers. The participants were encouraged 
to choose the most suitable questionnaire based on their language preference (i.e. 
English, Malay, Chinese or Tamil). Most participants completed their questionnaires in 
an average of five to ten minutes after which they were sent to an adjacent laboratory 
room.  
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Six ml of blood was drawn from each patient by a trained phlebotomist under a safe and 
sterile condition. The blood sample was collected in a lithium heparinised tube, labelled 
as the first blood sample and the blood collection instrument (Appendix G) was filled. 
The collected blood was then sent to the Haematology lab within one hour for 
centrifuging. It was stored in a refrigerator at -20 degrees Celsius and kept for batch 
transportation by the research officer to the Pharmacology Department. There, the blood 
was kept at a temperature of -80 degrees Celsius for future analysis using the Liquid 
Chromatography - Mass Spectrometry (LC-MS-MS) machine to determine the drug 
level. 
 
Before each patient left the phlebotomy room, a second form (see Appendix H) for 
providing the second blood sample (one month after the first one) was given to them.  
For convenience, the second blood sample was collected when the patients came to 
collect their medications from the hospital pharmacy in the following month. Before 
starting the data collection, the researchers had conducted a training workshop for the 
data collectors to train them on aspects such as introducing the study to participants, 
administering the self-reported questionnaire, etc. Thus, a trained research assistant used 
the pharmacy refill data instrument (Appendix I) to obtain information on the type of 
drugs used, dosing frequency, number of pills taken per day and adverse drug effects) 
from the online electronic medical record. This was done in a private room in the 
Pharmacy Department three times a week after obtaining the hospital registration 
number of each patient who participated in the study in the previous week. 
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The completed instruments were collected by the researcher who compared the hospital 
number and instrument number of each patient and added them to the patients’ self-
reported questionnaires which were stored for future use. Another trained medical 
record clerk collected investigations and test results twice a week after obtaining the 
patients’ hospital numbers from the list of patients who participated in the study using 
the provided instrument (Appendix E). All three of the above-mentioned instruments 
were kept by the researcher for data entry purpose.  
 
Data was entered into an SPSS version 16 data file. Every categorical variable in the 
study instrument was given a name that identified its place in the data set, and for each 
variable every possible value is coded with a number. To ensure accuracy, the 
researcher did a double data entry at different times, making two complete sets of data 
with a similar structure. The two sets were then exported to Epi-Info for Windows 
version 3.4.3 and were validated using Epi-Info Compare. Some differences in the two 
sets of variables were noticed and the researcher went back to the original source of data 
to check for the correct answers and corrected them accordingly. Thirty five participants 
(3.6% from a total of 978 participants) had missing variables in the data and had to be 
removed from the data sets since their presence could have adversely affected the 
analysis. A final data set which was used for the analysis was then generated. 
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4.8 Data management 
The data set was then imported into SPSS version 16 for analysis. Before analysis, data 
was cleaned and pre-processed which involved accuracy checking, treatment of missing 
values, recategorization and recoding of fields. Data was checked for accuracy and 
missing values were identified and rechecked for value correction based on the 
questionnaire which the participants had previously completed. Missing values of less 
than 5% were found, and this was due to a data entry error. The missing values which 
could not be corrected were removed from the data sets so as to avoid the analysis from 
being adversely affected. Finally, a total of 48 variables related to adherence among 
HIV-positive patients were analyzed. 
 
4.9 Test- Retest, Reliability and Validity  
The researcher and two research assistants performed a test-retest reliability assessment 
on 40 HIV/AIDS-positive patients in the Infectious Disease Clinic of Sungai Buloh 
Hospital three months prior to the commencement of the main study. The questionnaire 
was administered twice with a one week-interval between the first and second sessions 
to avoid recall bias. One week is considered not too long enough for changes that could 
potentially affect responses to occur and not too short enough to enable the recall of 
previous responses (Kalton & Schuman, 1982; Nieuwkerk & Oort, 2005). Questions 
listed in the questionnaire were delivered in Malay, Chinese and English. Subjects were 
asked to attempt to answer all of the questions. The results were entered into the SPSS 
version 16 for analysis (Carver & Nash, 2006). 
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The items in the questionnaire were binary-item scales to measure the level of 
adherence to antiretroviral treatment among HIV-positive patients in Malaysia. The 
questionnaire consists of 48 dichotomous questions, which measured the level of 
adherence to antiretroviral treatment among HIV-positive patients in Malaysia. These 
48 questions were subdivided into the following 4 main groups: (1) Adverse effects of 
HIV treatment (9 questions); (2) Use of alternative medicine by HIV-positive patients (9 
items); (3) Reasons facilitating adherence to treatment (10 questions); and (4) Reasons 
for missing HIV medication (20 items). All items in the questionnaire were binary-item 
scales. 
 
To determine the accuracy and trustworthiness of the data, Cronbach and Split-half tests 
were used to test for internal consistency in order to check the repeatability of the scale 
as a whole. The face validity and construct validity were used to check if items in the 
instrument are right and valid. 
 
4.9.1 Reliability Analysis 
Reliability is the instrument’s ability to provide consistent results in repeated uses 
(Rahman, 2001). Another way to look at reliability is by the following analogy: two 
people who are equal in terms of the construct being measured should get the same 
score. There are so many ways to test reliability but this study uses only the most 
common measures for reliability which are Cronbach’s alpha, split-half reliability and 
inter-rater reliability (Grilo et al., 2001).  
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Cronbach’s alpha is the basic measure for reliability; it is used to determine internal 
consistency between questionnaires. The value of the Cronbach Alpha coefficient 
ranges between 0 and 1. The closer the value is to 1, the higher the level of consistency 
is among the items. A commonly accepted rule of thumb is that 0.7-0.8 is an acceptable 
value for Cronbach’s Alpha; values less than 0.7 are considered weak and unreliable; 
and reliabilities of higher than 0.95 are not necessarily desirable (Baessler, O’Neill, 
Maher, & Battistutta, 2010). 
 
Split-half methodology is one of the measures to test internal consistency. This method 
splits the items in the data into two sets. A score for each instrument is calculated based 
on each half of the scale. If there is consistency in the data, the mean value between the 
two split parts should be similar, and the two halves of the questionnaire should also 
correlate perfectly – with large correlation being a sign of reliability. The final method 
for testing reliability of our data is by using inter-rater reliability (interclass correlation) 
on the binary items in the questionnaire that checks whether or not two or more raters 
are consistent (Boyer & Verma, 2000). 
 
4.9.2 Validity Analysis 
After reliability test, the next step is to test validity of the instrument measurements. 
This is important because it provides confidence that the empirical findings accurately 
reflect the proposed constructs. This study uses several measures of validity of the self-
reported adherence questionnaire. The first one is the face validity which concerns the 
appearance of the questionnaire measurements. Several people who are well-versed in 
the field were  asked about the validity of instruments in the questionnaire (S. N. 
Haynes, Richard, & Kubany, 1995). The second method for testing the validity of the 
data is convergent validity, which checks whether or not the items in an instrument 
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converge to the same intent. (Blackburn, Donnelly et al. 2004). The final method for 
testing the validity of instruments in the self-reported adherence questionnaire is 
Cronbach validity which is simply the square of the Cronbach reliability. 
 
4.9.3 Test retest analysis 
Test-retest analysis is one of the simplest ways of testing the stability and reliability of 
an instrument over time. As mentioned in above the data collection was performed 
twice in two different occasions. This is to check the stability and reliability of an 
instrument over time, if the results of the two periods differed by a great deal, then it is 
suspected that the measure was inaccurate. If the Spearman rank correlation (which is 
used for binary items) between separate administrations of the test is high (0.7 or 
higher), then it has good test-retest reliability (Rousson, Gasser, & Seifert, 2002). 
 
4.10 Data analysis 
After gathering data through the questionnaire, the researcher analyzed the data using 
SPSS version 16. All statistical values were considered significant at P ≤ 0.05 with the 
exception of entry into the logistic regression model. For the latter, we chose p-value < 
0.25 (Bendel & Afifi, 1977 and Mickey & Greenland, 1989). The researcher made sure 
the data were normally distributed. The following were used in analysing the collected 
data: descriptive analysis, comparative analysis of contingency tables, sensitivity, 
specificity, positive predictive value, negative predictive value, and receiver operating 
characteristic (ROC) curves to compare between SRA and TDM and logistic regression 
analysis. Four multivariate regression models between the dependent variables and 
independent variables were developed. Paired t –test was use to determine the factors 
affecting adherence. Cross tabulation of the HIV adherence predictors (independent 
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variables) with overall self-reported adherence questionnaire was prefored and odd ratio 
was used to report the results.  
 
4.10.1 Descriptive statistics:  
Descriptive statistics were used to analyze socio-demographic characteristics, calculate 
percentages of adherent and non-adherent patients (using the self-reported adherence 
questionnaire) for overall adherence level and calculate adherence level for individual 
medication using pharmacy records. Calculation of percentages of reasons for missing 
medication, reasons facilitating adherence, medication side effects, as well as the type 
of alternative medicine used for the treatment of HIV/AIDS was described by means of 
descriptive statistics such as calculation of frequency distributions and percentages as 
well as the use of appropriate statistical graphs. 
  
The overall adherence level calculated by the self-reported questionnaire was then 
dichotomized into adherent for participants with adherence level equal to or greater than 
95% and not adherent for participants with adherence level less than 95%. The 
operational definition of adherence level as adherent and not adherent was based on the 
fact that WHO requires 95% adherence level to antiretroviral therapy for successful 
treatment, avoidance of resistance development and treatment failure.  
 
4.10.2 Comparative analysis of contingency tables:  
This section is on comparison of adherence level to the different independent variables 
using cross tabulation analysis with odds ratio and chi-square analysis. A cross 
tabulation analysis is useful to show how respondents answered to two or more 
questions at the same time; hence, this would give us greater insights. The Crosstabs 
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procedure forms two-way and multiway tables and provides a variety of tests and 
measures of association for two-way tables.  
 
Specifically, we would make a cross tabulation of four different classification schemes 
in adherence to antiretroviral therapy (overall adherence level measured by self-reported 
questionnaire, adherence to HIV medication as measured by TDM for Efavirenz, 
adherence to HIV medication as measured by TDM for Nevirapine, and adherence to 
HIV medication as measured by TDM for Lamivudine) versus HIV adherence to 
HAART predictors (socio-demographic characteristics, adverse effects of treatment, 
alternative medication used for HIV treatment, reasons facilitating adherence to 
HAART and reasons for missing HAART medication). 
 
4.10.3 Sensitivity, Specificity and Predictivities of Self Reported Adeherence versus 
TDM  
To be certain about the results of our instrument and tests (TDM levels for three 
medications vs Self-reported adherence level) we need to do evaluation of screening or 
diagnostic test using sensitivity, specificity, positive and negative predictive values as 
well as diagnostic accuracy (all with 95% confidence intervals). Contingency table of 2 
x 2 serves as a basis of our analysis of diagnostic tes; Table 4.3 which is 2 x 2 
contingency table provides the outcome of two test on a sample of n subjects. 
According to the table, test positive people would be a+b, and test negatives would be 
c+d. The true positive were in cell ‘a’ and those true negative were in cell d. From this 
table, we calculated the sensitivity, specificity, and predictive value using the formulas 
bellow the table.  
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Table 4-3: 2 x 2 contingency table 
 Test 2 positive Test 2 negative Row total 
Test 1 positive a b a + b 
Test 1 negative c d c + d 
Column total a + c b + d n 
 
From the above table, we calculated the sensitivity, specificity, and predictive value 
using the formulas bellow the table.  
 
 Sensitivity is the proportion of test positives and is found by = a/(a+c). 
 Specificity is the proportion of test negatives in those who are without disease 
and is found by = d/(b+d). 
 Positive Predictive value (PPV) is the proportion of people who tested positive 
on the screening test who are actually sick = a/(a+b). 
 Negative predictive value is the proportion of people who are tested negative on 
the screening test who are actually not sick = d/(c+d 
 
4.10.4 Multiple logistic regression techniques:  
Four logistic regression models were used to determine the effect of independent 
variables on the dichotomized adherence level measured by: 1) self-reported adherence 
questionnaire; 2) TDM level for Efavirenz using the LC-MS/MS machine; 3) TDM 
level for Nevirapine using the LC-MS/MS machine; and 4) TDM level for Lamivudine 
using the LC-MS/MS machine. In this modelling, 48 independent variables were used to 
determine the predictors of adherence to treatment such as ‘reasons facilitating 
adherence’, ‘reasons for missing medications’, ‘socio-demographic characteristics’, 
‘adverse effects of treatment to antiretroviral medications’ and ‘use of alternative 
medicine for HIV/AIDS treatment by HIV-positive patients on HAART’. The 
researcher would make a comparison between the outcomes of the four regression 
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models besides indicating which independent variables may be good predictors of HIV 
patients’ adherence to HAART. 
 
The specification method of prediction was “Enter” by which the researcher specifies 
the variables that will go into the regression equation and the stage at which they go in. 
The results were interpreted using the odds ratios and 95% confidence intervals  
(Bendel & Afifi, 1977; Greenland, 1989). P-values of <0.25 were used to decide 
variables for initial entry into the model; the last category was used as a reference for all 
binary variables. Overall, this study uses the identification scheme and modelling 
techniques of Hosmer-Lemeshow. 
 
The logistic regression model is expressed as follows [3]:   
  bXa
Y
Y
ODDS 









ˆ1
ˆ
lnln
 
Where:  
Yˆ  is the predicted probability of the event which is coded with 1 (Adherent) 
rather than with 2 (Non-Adherent),   
Yˆ1  is the predicted probability of the other decision, and   
Xi is our predictor variables. 
 
Logistic regression predicts the log odds of the dependent event. The "event" is a 
particular value of y, the dependent variable. By default, the event is y = 1 for binary 
dependents coded 0, 1, and the reference category is 1. The natural log of the odds of an 
event equals the natural log of the probability of the event occurring divided by the 
probability of the event not occurring:  
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ln(odds(Adherence)) = ln(prob(adherence)/prob(non-adherence)). The logistic 
regression equation itself is:  
 
      Log(y) = β0 + β1* X1 + β2* X2 + β3* X3 + βi* Xk. 
     
 
    
                          
 
   
                              
 
   
                            
                              
 
 
                   
 
Where y is the log odds of the dependent variable = ln(odds(adherence)); 
β0 is the constant; and  
there are k independent (X) variables. 
The "y" is the logit, also called the log odds. 
The " β " terms are the logistic regression coefficients/ parameter 
estimates.  
Exp(b) = the odds ratio for an independent variable = the natural log base e 
raised to the power of b. The odds ratio is the factor by which the 
independent increases or (if negative) decreases the log odds of the 
dependent. 
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In Multivariate Linear Regression, the model (b coefficients) is determined by the 
“least-square” method but in logistic, the model is determined by the “maximum 
likelihood” method. Therefore, in logistic, b coefficients are called maximum likelihood 
estimators (MLE). The logistic and linear regression models differ in assumptions. In 
linear regression, we interpret b coefficients but in logistic regression, the exp (b) which 
is Odds Ratio is interpreted. An odds ratio of 1 indicates no difference in risk between 
the groups, i.e. the odds in each group are the same. If the odds ratio of an event is >1, 
the rate of that event is increased in patients who have been exposed to the risk factor. If 
<1, the rate of that event is reduced. Odds ratios are frequently given with their 95% CI 
– if the CI for an odds ratio does not include 1 (no difference in odds), it is statistically 
significant. 
 
The following are the steps that the researcher had followed for modelling logistic 
regression. The first step was to explore the data (Descriptive Statistics). Next, the 
researcher did a simple (binary) logistic regression modelling, and the third step was to 
conduct variable selection & checking “linearity in the logit”. Then, in the fourth step, 
the researcher checked whether there was an interaction & multicollinearity effect. The 
fifth step was to check model assumptions and outliers. Lastly, the final step was the 
interpretation of the final model.  
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Initial model building starts with a model of intercept and one explanatory variable. 
Then, the construction of multivariate model starts by adding variables into the model 
one by one until the newly added variable does not improve to the prediction power of 
the model. This is tested through the G statistic (difference in -2 Log likelihood ratio for 
the overall model with a nested model), Hosmer-Lemshow test, Omnibus test, and Wald 
statistic. For more information and discussion on the practical model building steps, see 
Chapter Four and Five, the results and discussion. 
 
G statistics is analogous to the F test of linear regression models (Chow, 1960). G 
statistic is compared with the chi-square table, and if the G > the Chi-square, the null 
hypothesis is rejected and it is concluded that at least and perhaps all p coefficients are 
different from zero at α = 0.05. 
 
This means that the inclusion of the new variable into the model has improved it. 
Another statistic of the measure of goodness of fit is Hosmer and Lemeshow chi-square 
test; this test is the recommended test for overall fit of a binary logistic regression model 
(Hosmer, Hosmer, Le Cessie, & Lemeshow, 1997).  
 
A finding of non-significance corresponds to the conclusion that the model adequately 
fits the data. Another way to justify the fitness of the model is by looking the Omnibus 
test; which tests whether or not the explained variance in a set of data is significantly 
greater than the unexplained variance. A finding of significance corresponds to the 
conclusion that there is adequate fit of the data to the model, meaning that at least one of 
the predictors is significantly related to the response variable. 
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Checking linearity in logit for numerical independent variables:  
In our independent variables in the model, only age is a numerical variable. Here, the 
researcher tested whether age is linear in logit (of outcome) or not. There is more than 
one method to check this assumption. However, the researcher used the design variable 
based quartiles method. The following steps were followed to check the linearity 
problem: First, the researcher categorized the variable in quartiles (4 levels); second, he 
calculated the midpoints of the quartile groups; third, he fit the model with the 4-level 
categorical variable and finally, the researcher plotted the midpoints to observe the 
linearity. If non-linear, the assumption of "linear in logit" is not satisfied. This means 
that the numerical variable is not appropriate. The solution to this problem is to use 
categorized variable instead of using numerical variable. However, as you would see in 
the results chapter, we found the age variable as linear. 
 
Checking Interactions:  
An interaction occurs when the effect of one independent variable on the dependent 
variable is influenced by (or depends on, or interacts with) another independent 
variable. To assess whether an interaction is present or not, all possible two-way 
interactions were checked (one at a time), then the researcher added the created 
interaction terms to the "main effect model" as additional independent variables and ran 
the model again using the “Enter” method. If an interaction term is significant (P<0.25), 
it means that there is an interaction between the two variables. Thus, the appropriate 
model is the main effect variables plus the significant interaction term.  
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CHAPTER 5 RESULTS 
 
5.1 Sample information 
Figure 5.1 is a flow chart for the sample information during the study period. Those who 
had complete data and included in the analysis were a total of 925 or 94.6% of the all HIV-
positive patients recruited for the study. More than 381 patients or 41.8% had been on 
HAART for more than three years while 238 or 25.8% of the patients had been on HAART 
for one year or less. 
                                                  
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Flow chart of study participants (n=925) 
 
 
5950 HIV positive patients on 
HAART in Sungai Buloh Hospital 
Met the inclusion criteria 
978 or  (93.14%) of total 
925 or (94.6%) the 
final sample size 
used 
306 or (33.1%) 1-3 
years on HAART 
238 or (25.8%) 
<1 year on 
HAART 
5 or (0.5%) 
Died 
 13 or (1.3%) was 
lost to follow up 
35 or (3.6%) had 
incomplete data 
Thus excluded 
381or (41.8%) 
>3years on HAART 
1050 were screened 72 or (6.86 %) did not 
meet the inclusion 
criteria & excluded 
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5.2 Socio -demographic variables 
This section provides a description of demographic variables included in the logistic 
regression analysis and contingency table analysis to investigate the research questions. At 
the beginning, a total of 5950 patients were identified as having HIV infection. Out of 
these, 1050 patients were screened, of which 978 patients met the inclusion criteria and 
responded to the distributed questionnaires, the remaining 72 patients did not met the intial 
screening and were excluded.  
 
The socio-demographic and baseline characteristics of the participants are shown in Table 
5.1 and 5.2 below. Out of the 978 patients who fulfilled the inclusion criteria, 925 patients 
had correctly filled the questionnaires. A total of 53 (5%) patients were identified as having 
incomplete data, 13 (1.3%) of the participants were lost to follow up while 5 (0.5%) of the 
participants died. The remaining 35 or 3.6% respondents had missing values in their data 
and had to be removed in order to not affect the analysis, since the study has a big sample 
of 925 patients. 
 
The highest percentage of the participants consists of those who were educated with 
secondary school level and above (658 or 71.2%), while 49 or 16% had primary school 
education.The educated with secondary school level  is noticed to be high this could be due 
to bias since the questionnaire is self-administered.  Only 118 or 12.8% of the participants 
had no formal education. More than half of them (505 or 54.6%) were employed, 193 or 
20.9% were unemployed and 58 or 6.3% were retired. About 366 or 39.6% of the 
participants had an average monthly income of less than RM1500 (USD480) per month, 
242 or 26.2% had a monthly income between RM 1501 and RM2500 (USD480-USD800) 
per month, while only 26 or 2.3% had an average monthly income of more than RM6500 
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(USD2080) per month. Less than half of the participants (451 or 48.8%) were exposed to 
HIV infection through the heterosexual route, followed by 278 (30.1%) who were infected 
through injecting drug use. 140 (15.1%) of them were infected via the homosexual route. 
 
Table 5-1: Socio-Demographic characteristics (n =925) 
Variable N % 
Gender   
   Female 219 23.68 
   Male  706 76.32 
 Race / Ethnicity   
   Malay 250 27.03 
   Chinese 585 63.24 
   Indian 72 7.78 
   Others (Dayak , Kadazan) 18 1.95 
Age group in years   
 18—30 330 35.68 
 31—44 338 36.54 
 45 or more 257 27.78 
Religion   
   Islam  258 27.89 
   Buddhism  448 48.43 
   Hinduism  53 5.73 
   Christianity 97 10.49 
   Taoism 55 5.95 
   Others  14 1.51 
 Completed Education   
   No formal schooling 118 12.8 
   Primary  school 149 16.1 
   Secondary school up to form 3 251 27.1 
   Secondary school up to form5 215 23.2 
   High school( form 6 / A level) 60 6.5 
   Diploma 41 4.4 
   Degree 91 9.8 
Current job status   
   Not employed 193                  20.9 
   Employed 505                  54.6 
   Self employed 146                  15.8 
   Retired 58                       6.3 
   Retired but re-employed 23                        2.5 
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Table 5-2 : Socio-demographic characteristics (continued) 
   Variable  N                                % 
Average monthly income   
  < RM 1500 366 39.57 
  RM1501—2500 242 26.16 
  RM2501 – 3500 152 16.43 
  RM3501—4500 60 6.49 
  RM4501—5500 50 5.41 
  RM5501—6500 29 3.14 
  RM6501 or more 26 2.81 
Marital status   
  Single 373 40.32 
  Married 440 47.57 
  Separated (Married but not living together) 21 2.27 
  Divorced 39 4.22 
  Widow / Widower 52 5.62 
Number of children   
  0 (No child) 500                      62.5 
  1—3 279                    30.2 
  4—6 127                       13.7 
  >6   19                         2.1 
Number of children living with patients   
  0 (No child) 58                        62.9 
  1—3 265                      28.6 
  4—6  68                        7.4 
  >6   10                        1.1 
 
 
 
Table 5.3 shows the exposure risk of HIV-positive patients on HAART. The most common 
exposure risk was through the heterosexual route, followed by injecting drug use. The least 
common exposure risk was through received blood or blood products. Nine out of the 925 
participants’ exposure risks were unknown.  
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Table 5-3: Exposure risk of HIV positive patients (n = 925) 
Variable  N    % 
  Bisexual     7                            0.8 
  Homosexual 140                       15.1 
  Heterosexual 451                       48.8 
  Heterosexual / Homosexual through IDU   35                           3.8 
  Injecting drug use 278                       30.1 
  Received blood / blood product     1                              0.1 
  Unknown     9                               1.0 
  Others     2                                0.2 
 
5.3 Test, test-retest, reliability and validation 
This section is about findings of the test-retest, reliability and validity of the study. 
Reliability test consists of the following three different ways of testing: Cronbach alpha, 
split-half and inter-rater reliability. For the validity test, the study uses three types of testing 
validity of the study: face validity, convergent validity and Cronbach validity. The last part 
of this section provides findings of the test-retest 
 
5.3.1 Reliability 
A) Cronbach Alpha 
This test was employed to determine internal consistency between items within each 
domen. Table 5.4 provides the values of Cronbach's alpha of the above-mentioned four 
item groups (adverse effects of HIV treatment, alternative medicine used by HIV-positive 
patients, reasons facilitating adherence to treatment, and reasons for missing HIV 
medication).  The results show that the Cronbach’s Alpha reliability coefficient for all 
variables were above the acceptable limit of 0.70 and only one alpha is slightly above 0.8.  
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Table 5-4: Reliability Statistics: Internal consistency by Alpha Cronbach  
 
 
Group of Variables 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on 
Standardized Items N  
Adverse effects of HIV treatment .826 .828 9 
Use of alternative medicine .777 .779 8 
Reasons facilitating adherence .813 .812 10 
Reasons for missing HIV medications .873 .875 20 
N =  Number of iteams in each category  
Tables 5.4 to 5.7 provide a column labelled ‘Cronbach’s Alpha if Item deleted’. This refers 
to the value of the overall alpha if that item is not included in the calculation. It was found 
that each of the 47 items on the adherence level scale has a smaller Cronbach’s Alpha value 
than its corresponding calculated scale alpha mentioned in Table 5.4. This implies that no 
single item in the scale suppresses its corresponding alpha level. Therefore, the self-
reported questionnaire of this study can be considered as a reliable measure of adherence 
level to antiretroviral treatment in HIV-positive patients. 
 
Table 5-5: Item-Total Statistics of Adverse effects of HIV treatment  
 
Scale Mean if 
Item Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Vomiting 1.45 4.151 .517 .342 .810 
Diarrhoea 1.43 3.789 .745 .760 .783 
Appetite 1.38 3.984 .507 .380 .811 
Dry Mouth 1.40 3.836 .653 .680 .793 
Itching 1.43 4.251 .394 .276 .822 
Tiredness 1.33 4.020 .430 .385 .822 
Rash 1.40 4.195 .397 .321 .823 
Fever 1.40 3.990 .540 .442 .806 
Headache 1.40 3.887 .615 .591 .798 
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Table 5-6: Item-Total Statistics of Use of alternative medicine  
 
Scale Mean if 
Item Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Alcohol 1.22 2.846 .532 .468 .745 
Alternative med 1.22 3.051 .351 .228 .773 
Herbal med 1.22 2.999 .395 .242 .766 
Yoga 1.12 2.830 .408 .383 .768 
Acupuncture 1.20 2.779 .544 .623 .742 
Dietary 1.22 2.897 .485 .636 .752 
Mind 1.20 2.779 .544 .469 .742 
Religious treatment 1.20 2.728 .589 .444 .734 
 
Table 5-7: Item-Total Statistics of Reasons facilitating adherence 
 
Scale Mean if 
Item Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
RFA_Acceptance 7.23 4.999 .476 .308 .798 
RFA_Discosure 7.28 4.871 .497 .297 .796 
RFA_Alam 7.25 4.859 .529 .545 .792 
RFA_Beleif 7.20 5.036 .487 .425 .797 
RFA_Care 7.25 4.654 .653 .640 .777 
RFA_Social 7.23 4.794 .601 .525 .784 
RFA_Afraid 7.23 5.102 .415 .273 .805 
RFA_Resistance 7.18 5.071 .505 .432 .795 
RFA_paying 7.20 5.138 .423 .268 .803 
RFA_Efficacy 7.20 5.292 .330 .379 .813 
RFA = Reason Facilitating Adherence. RFA – Acceptance = Acceptance of HIV Status as a 
Reason facilitating adherence to treatment 
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B) Inter-rater Reliability 
The values of inter-rater are reported in Table 5.8. This table provides a single measure of 
Inter-rater Correlation for each of the four item groups. It was found that the intra-class 
correlation of each of the four item groups of adherence has a correlation score of 0.3 
which is acceptable; this indicates reproducibility of the data (Fleiss, et al. 1979).  
 
The following is the intra-class reliability of the four variable groups. On average, ‘Adverse 
effects of HIV treatment’ has an intra-class correlation of 0.827 with an interval of 0.744 to 
0.897 and 95% confidence level while the ‘Use of alternative medicine’ has an intra-class 
correlation of 0.780 with an interval of 0.659 to 0.870 an 95% confidence. The variable 
group ‘Reasons facilitating adherence’ has an average intra-class correlation of 0.815 and 
an interval of 0.716 to 0.890 and 95% confidence. Next, ‘Reasons for missing medication’ 
has an average intra-class correlation of 0.875 with an interval of 0.811 to 0.925 and 95% 
confidence. In summary, the reliability estimates produced under the intra-class correlation 
models are numerically identical, suggesting a moderate agreement of the data. 
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Table 5-8: Intra-class Correlation Coefficient 
 
 Variable  groups Intra-class 
Correlation 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound Value 
Adverse effects of HIV treatment 
      Single Measures 
      Average Measures 
 
.347 
.827 
 
.234 
.734 
 
.493 
.897 
 
5.733 
5.733 
Use of alternative medicine 
      Single Measures 
      Average Measures 
 
.307 
.780 
 
.194 
.659 
 
.455 
.870 
 
4.490 
4.490 
Reasons facilitating adherence 
      Single Measures 
      Average Measures 
 
.305 
.815 
 
.202 
.716 
 
.448 
.890 
 
5.343 
5.343 
Reasons for missing medications 
      Single Measures 
      Average Measures 
 
.259 
.875 
 
.176 
.811 
 
.381 
.925 
 
6.224 
6.224 
 
 
C) Split half methodology 
The final method of testing reliability of the questionnaire instrument is the split-half 
methodology. This methodology splits items into two groups and then compares these 
groups as if they were two separate administrations of the same survey. Table 5.9 below 
provides the results for split-half reliability. For each of the four item groups, the scale of 
the first half split (Part 1) is similar to the other half split (Part 2) as their mean scores and 
alpha did not differ much; besides that, for each of the two, half splits show a high 
correlation coefficient, which suggests a high internal consistency of the instruments.  
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Table 5-9: Results for split-half reliability  
Description 
Part 1 Part 2  
Mean  Alpha Items Mean  Alpha #  Correlation 
Adverse effects of treatment 0.80 0.761 5 0.77 0.629 4 0.692 
Use of alternative medicine 0.70 0.542 4 0.67 0.720 4 0.626 
Reasons facilitating adherence 3.93 0.730 5 4.10 0.632  0.682 
Reasons for missing  1.92 0.756 10 1.95 0.762 10 0.855 
 
5.3.2 Validity Analysis 
The validity of the adherence level of HIV medication scale was measured through face 
validity analysis and Cronbach validity analysis. 
 
A) Face validity: The study instruments were checked by three public health consultants in 
the department who believed that the self-reported adherence questionnaire appears to 
measure what it is supposed to measure and because of this, it is valid (Nevo 1985). In 
summary, as seen in the different methods of reliability analysis and validity statistics of 
the above tables, all items seem to be contributing well to the scale’s reliability and 
validity. 
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B) Cronbach validity: The third approach that is used to test the validity of the 
questionnaire instrument is the Cronbach validity. This test is the square root of Cronbach 
Alpha that was previously mentioned. Table 5.10 provides the results of Cronbach Validity 
(square root of the alpha) which is a measure of the extent to which the results and findings 
can be generalized. As the table shows, each of the four item groups that measure 
adherence level of antiretroviral treatment in HIV-positive patients has an acceptable 
coefficient alpha.  
 
Table 5-10: Reliability Statistics: Internal consistency by Alpha Cronbach  
 
 
Group of Variables 
Square root of 
Cronbach's 
Alpha 
Sqrt Cronbach's 
Alpha Based on 
Standardized Items 
N of Items 
Adverse effects of HIV treatment 0.909 0.910 9 
Use of alternative medicine 0.881 0.883 8 
Reasons facilitating adherence 0.902 0.901 10 
Reasons for missing HIV medications 0.934 0.935 20 
 
5.3.3 Test retest analysis 
Test-retest analysis is the simplest method of testing the reliability of a study. In this 
analysis, the survey is administered twice to the same group of people and then the two sets 
of results are correlated. In other words, test-retest reliability is the correlation between the 
same tests administered at two time points (Weir 2005). The following table provides the 
correlation coefficient of the test-retest variables. As shown in Table 5.11, almost all of the 
test-retest Spearman correlations of the 4 group variables (side effects of treatment, use of 
alternative medicine, reasons facilitating adherence and reasons for missing HIV 
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medication) are greater than 0.3, thus the instrument is said to have a good test-retest 
reliability (Fleiss, et al. 1979). 
Table 5-11: Spearman Correlation analysis of test-retest data  
 Adverse effects of HIV treatment  Use of alternative medicine 
# Variables Value # Variables Value 
1 Vomiting 1 and 2 0.314286 1 Alcohol 1 and 2 0.899735 
2 Diarrhoea 1 and 2 0.315063 2 Alternative med 1 and 2 0.359313 
3 Appetite 1 and 2 0.218750 3 Herb med 1 and 2 0.688033 
4 Dry Mouth 1 and 2 0.263181 4 Yoga 1 and 2 0.341882 
5 Itching 1 and 2 0.411765 5 Acupuncture 1 and 2 0.307359 
6 Tiredness 1 and 2 0.404226 6 Dietary 1 and 2 0.215686 
7 Rash 1 and 2 0.427669 7 Mind 1 and 2  0.480519 
8 Fever 1 and 2 0.382088 8 Relig_treatment 1 and 2 0.653680 
9 Headache 1 and 2 0.263181 9   
    
 Reasons facilitating adherence  Reasons for missing HIV medications 
# Variables Value # Variables Value 
1 RFA_Acceptance 1 and 2 0.188982 1 RMM_Away 1 and 2 0.539650 
2 RFA_Disclosure 1 and 2 0.290929 2 RMM_busy 1 and 2 0.329276 
3 RFA_Alam 1 and 2 0.382088 3 RMM_forget 1 and 2 0.452061 
4 RFA_Beleif 1 and 2 0.134199 4 RMM_manypills 1 and 2 0.375000 
5 RFA_Care 1 and 2 0.628619 5 RMM_effects 1 and 2 0.518476 
6 RFA_Social 1 and 2 0.218750 6 RMM_stigma 1 and 2 0.359313 
7 RFA_Afraid 1 and 2 0.098693 7 RMM_routine 1 and 2 0.653680 
8 RFA_Resistance 1 and 2 0.359313 8 RMM_toxic 1 and 2 0.223814 
9 RFA_paying 1 and 2 0.359313 9 RMM_asleep 1 and 2 0.359313 
10 RFA_Efficacy 1 and 2 0.263181 10 RMM_sick 1 and 2 0.264628 
   11 RMM_depressed 1 and 2 0.427669 
   12 RMM_well 1 and 2 0.490098 
   13 RMM_nopills 1 and 2 0.592157 
   14 RMM_specific 1 and 2 0.665133 
   15 RMM_religous 1 and 2 0.250000 
   16 RMM_waiting 1 and 2 0.375000 
   17 RMM_distance 1 and 2 0.375000 
   18 RMM_relation 1 and 2 0.134199 
   19 RMM_cost 1 and 2 0.458333 
   20 RMM_tradional 1 and 2 0.427669 
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5.4 Measuring Adherence Level 
The adherence level was measured subjectively by the overall self-reported adherence 
questionnaire and pharmacy records method, and objectively by testing for HAART drug 
level in human plasma through Therapeutic Drug Monitoring (TDM) using the LC-MS/MS 
machine. 
5.4.1Measuring adherence using over all self-reported adherence questionnaire 
Figure 5.2 below shows the number of HIV-positive patients who missed their medication 
in the last 2 weeks, 4 weeks, and 6 weeks before the study as well as the number of 
medication doses they had missed. In the last 2 weeks before the study, only 22 or 2.3% 
patients missed two or more doses, compared to 48 or 5.2% in the last 4 weeks and 62 or 
6.7% participants in the last 6 weeks before the study. The results in this table revealed that 
participants missed more doses of their medication as the number of weeks increased. 
 
 
 
Figure 5-2 Number of HIV positive patients missing their medications (n =925) 
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Table 5.12 displays the adherence level to antiretroviral treatment using the self-reported 
questionnaire. Four questions (A to D, as mentioned below) were designed to obtain 
information on the time of taking HAART medication, number of doses missed over the 
past days and whether or not a patient will stop taking medication when he/she feels better 
or worse.  
 
Table 5-12: Assessing adherence to Highly Active Antiretroviral Treatment in HIV 
positive patients in Sungai Buloh Hospital using overall self-reported adherence 
questionnaire (n =925) 
Questions YES   (%) NO   (%) 
A 123 (13.3) 802 (86.7) 
B   28 (3.0) 897 (97.0) 
C   40 (4.3) 885  (95.7) 
D   37 (4.0) 888  (96.0) 
A-Do you sometimes find it difficult to remember to take your medicine? 
B-When you feel better, do you sometimes stop taking your medicine? 
C-Thinking back over the past days, have you missed any of your doses? 
D-Sometimes if you feel worse when you take the medicine, do you stop taking it? 
 
 
Table 5.13 below reveals the results of adherence level as measured using the overall self-
reported adherence questionnaire. Out of 925 participants, 756 or 81.7% of them had 
adherence level equal to or greater than 81.7% and were classified as adherent, whereas 169 
or 18.3% were classified as not adherent. This means that the adherence level is high, 
although the figure is less than the required 95% adherence level by the World Health 
Organization (WHO). 
 
 126 
 
 
Table 5-13: Adherence level measured by overall self-reported adherence questionnaire (n 
= 925) 
Adherence status N % 
Adherent( ≥95%  adherence level) 756 81.7 
Not adherent (<  95% adherence level) 169 18.3 
Total 925 100 
95% adherence level is operational definition used because it is WHO requirement for the 
definition of adherent to HAART. 
 
5.4.2 Measuring adherence using pharmacy records 
Table 5.14 below describes the type of HAART used by each HIV-positive patient based 
on the information obtained from the online electronic pharmacy record. The results show 
that patients were on combined medication. The most common type of drug used was 
Efavirenz, followed by Nevirapine. The least commonly used drug was Lamivudine. 
 
Table 5-14: Number of HIV positive patients on each antiretroviral drug used in HAART 
(n =925) 
Drug name Yes (%) No (%) 
Efaviranz (DMP-266) 791 (85.5) 134 (14.5) 
Nevirapine 653 (70.6) 272 (29.4) 
Lamivudine (3TC) 594 (64.2) 331 (35.8) 
 
Table 5.15 below shows the group of HAART used by participants, the HAART 
medication used, the number of medication taken per day, number of pills or tablets taken 
per day and the duration of HAART used (in years). The results reveal the following: 872 
out of 925 participants were on NRTI+NNRTI; the most common combination used 
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contained ZDV-3TC-EFV (431 out 925 participants); the highest number of medication 
taken per day was 3-4 medications (522 or 56.4% of the participants); the highest number 
of tablets or pills taken per day was 4-6 pills per day (557 or 60.2%); and the longest 
duration on HAART was < 3 years (380 or 44.1%).  
Table 5-15: Description of HAART used by HIV patients during study period (n=925) 
HAART DETAILS N                                 % 
HAART group   
  1= NRTI 35                               3.8 
  2=NNTRI 18                            1.9 
  3=NRTI+NNRTI 872                         94.3 
  Total 925  
HAART medications used   
  1= ZDV-3TC-EFV 431                       46.6 
  2= ZDV-3TC-NVP 192                       20.8 
  3=ZDV-3TC-d4T    9                                1.0 
  4=d4T-3TC-EFV 170                       18.1 
  5=d4T-3TC-NVP   61                         6.6 
  6= ZDV-3TC   11                            1.2 
  7= Others  51                               5.5 
  Total 925  
Number of HAART medications taken per day   
  1—2 401                          43.4 
  3—4 522                          56.4 
  >4 02                              0.2 
  Total 925  
Number of HAART pills / tablets taken per day   
  1—3 361                         39 
  4—6 557                          60.2 
  >6    7                              0.8 
  Total 925  
Duration of HAART used in years   
  < 1 238                         25.8 
  1—3 307                          33.1 
  >3 380                         44.1 
  Total 925  
Eventhough ZDV is the most common in the above HAART combination, but it is not 
commonly used in Sungai Buloh that is why it is not analysed in this study 
HAART= Highly Active Antiretroviral Treatment, ZDV = Zidovudine 
NNRTI= Non-nucleoside Reverse Transcriptase Inhibitor, 3TC = Lamivudine 
 NRTI = Nucleoside Reverse Transcriptase Inhibitor, EFV = Efaviranz 
 NVP = Nevirapine, d4t = Stavudine 
 128 
 
 
 
Figure 5.3 below describes the dispensation of Lamivudine and Nevirapine based on the 
online pharmacy record in the previous 6 months from the interview date for HIV-positive 
patients. The results revealed the number of patients who had collected their prescribed 
medication, patients who missed their prescribed medication and the number of patients 
who are not prescribed any of the two types of medication mentioned above.  
 
The results describe the 6 refill statuses, starting from the interview date as the first refill 
and going retrospectively to the 6
th
 refill as the last refill from the pharmacy record. In the 
first refill for Nevirapine, out of 925 patients, 610 (65.9%) patients collected their 
prescribed medication, 43 (4.6%) patients did not collect their medication and 272 (29.5%) 
were not prescribed Lamivudine by their doctors. For the first refill for Lamivudine, 559 
(60.8%) patients had collected their prescribed medication, 30 (3.2%) did not collect their 
medication and 333 (36%) out of the total 925 patients had been prescribed Lamivudine by 
their doctors. As seen in the graph, the number of patients collecting their prescribed 
medication decreases with time, while the number of missed medication shows an 
increasing trend as time passes.  
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Yes = Patient has collected prescribed medication 
No = Patient missed their prescribed medication 
PNM= Patient is Not on this Medication 
 
Figure 5-3 Online pharmacy records for Lamivudine and Nevirapine dispensation in the 
last 6 month for HIV positive patients (n= 925) 
 
Figure 5.4 below describes the dispensation of Nevirapine and Efavirenz in the past 6 
months from the interview date based on the online pharmacy record for HIV-positive 
patients. The results reveal the number of patients who had collected their prescribed 
medication, patients who missed their prescribed medication and the number of patients 
who were not prescribed any of the two medications above.  
. 
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Figure 5-4 Online pharmacy record for Nevirapine and Efaviranz dispensation in the last 6 
month for HIV positive patients (n= 925) 
Yes = Patient has collected prescribed medication 
No = Patient missed prescribed medication 
PNM= Patient is Not on this Medication  
 
 
Table 5.16 shows the adherent and non-adherent patients for each medication listed below 
as measured by the pharmacy refill data.Participants on Efavirenz (73.2% adherent) and 
Nevirapine (68.5% adherent) were mainly adherent to their medication. Patients on 
Lamivudine had the lowest adherence level (53.1%) as calculated by pharmacy refill 
method and they were the most likely to switch drugs. 
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Table 5-16: Adherence level for antiretroviral drug in HIV positive patients based on 
pharmacy refill data 
 
 
Drug name 
                            Adherence level   
 
Total 
(≥ 95%) Adherent (≤95% )Not –adherent 
Efaviranz 579 (73.2) 212 (26.8) 791 (100) 
Nevirapine 407  (68.5) 189 (31.5) 594 (100) 
Lamivudine 347(53.1) 306 (46.9) 653 (100) 
The calculation above is based on the following formula:  
 Adherence= (pills dispensed /pills prescribed per day) / days between refills) x 100 % 
 
5.4.3 Measuring adherence level via Therapeutic Drug Monitoring (TDM) 
Table 5.17 describes the detected and not detected drugs in the first and second blood 
samples for participants as tested by the LC-SM/SM machine. It also shows the total 
number of participants whose blood was unavailable for testing in both the first and second 
blood samples. Each blood sample contained more than one drug as they were tested for 
multiple drugs. The number of first blood samples for each drug was much more than their 
second blood samples. Blood samples were unavailable for more than 75% of the second 
blood samples for each drug since these patients did not come to provide second blood 
samples the  researcher and his data collectors attempted several times to call the patients to 
participate.The drug which was most detected in the first blood samples was Efavirenz and 
the least detected was Lamivudine. In the second blood samples, Efavirenz was the most 
detected drug followed by Nevirapine and Lamivudine as the least detected.  
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Table 5-17: Blood sample analyzed by LC-MS/MS using Therapeutic Drug            
Monitoring (TDM) method in HIV positive patients on HAART (n=925) 
Drug name Yes (%) No (%) NA (%) 
Efaviranz in 1
st 
blood sample 445 (48.1) 180  (19.5) 300 (32.4) 
Efaviranz in 2
nd
 blood sample 120 (13) 13 (1.4) 792 (85.6) 
Nevirapine in 1
st
 blood sample 394 (42.6) 172 (18.6) 359 (38.8) 
Nevirapine in 2
nd
 blood sample 82 (8.9) 13 (1.4) 850 (89.7) 
Lamivudine in 1
st
 blood sample 299 (32.3) 197 (21.3) 429 (46.4) 
Lamivudine in 2
nd
 blood sample 42 (4.5) 19 (2.1) 864 (93.4) 
    Yes = Drug is detected by the LC-SM/MS machine 
    No = Drug is Not detected by the LC-MS/MS machine 
    NA= Blood is not available for analysis by LC-MS/MS machine 
    N = Number of patients 
 
 
Table 5.18 below shows the test results for three antiretroviral drugs in human plasma using 
the LC-MS/MS machine. The medication was in a combined format. Efavirenz was 
detected in 71.2 % of the participants, Nevirapine in 69.6% of them and Lamivudine in 
60.3% of the participants, at the quantity of 10ng/ml or more( the least value at which the 
drugs were detected. 
 
Table 5-18: Blood sample analyzed by LC-MS/MS using Therapeutic Drug Monitoring 
(TDM) method in HIV positive patients on HAART 
 
Drug name 
TDM level as tested by LC-SM/SM machine  
Total Positive (%) Negative (%) 
Efaviranz 445 (71.2) 180  (28.8) 625 (100) 
Nevirapine 394 (69.6) 172 (30.4) 566 (100) 
Lamivudine  299 (60.3) 197 (39.7) 496 (100) 
Positive= Means drug is detected at 10 ng/ml or more by the LC-MS/MS machine. 
Negative= Means drug was not detected at 10 ng/ml or more 
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5.5 Descriptive results of HIV adherence predictors  
Table 5.19 below shows the results on reasons for missing medication among HIV-positive 
patients as given by the participants in the overall self-reported adherence questionnaire. 
Participants assigned the answer "Yes" if they agreed with the reason given for missing 
medication and assigned a "No" as an answer if they did not agree. The table contains 20 
reasons for missing medication with "Yes" and "No" responses for 925 participants. The 
most frequent reasons for missing medication were: beliefs and preference for traditional 
medicine, ran out of pills, simply forgot and cost of treatment too high. The least frequent 
reasons for missing medication were felt a sleep through dose time, felt sick or ill, felt like 
drug was toxic and poor relationship with health care providers 
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Table 5-19: Reasons for missing medications in HIV positive patients (n =925) 
Reason(s) for missing treatment dose(s) 
 
Yes (%) No (%) 
   
Beliefs and preference for traditional medicine  
 
372 (40.2) 553 (59.8) 
Ran out of pills  
 
351 (37.9) 574 (62.1) 
Simply forgot  
 
317 (34.3) 608 (65.7) 
Cost of treatment too high  
 
297 (32.1) 628 (67.9) 
   
Was busy with other things  
 
292 (31.6) 633 (68.4) 
Distance to hospital too long and costly  
 
269 (29.1) 656 (70.9) 
   
Religious belief  
 
258 (27.9) 667 (72.1) 
Wanted to avoid side effects 
 
255 (27.6) 670 (72.4) 
   
Was away from home as reason for missing medications 
 
253 (27.4) 672 (72.6) 
Felt well 
 
241 (26.1) 684 (73.9) 
Had a change in daily routine  
 
237 (25.6) 688 (74.4) 
Had problem taking pills at specified times  
 
236  (25.5) 689 (74.5) 
Treatment and drug collection time too long  232 (25.1) 693 (74.9) 
Had simply many pills  232 (25.1) 693 (74.9) 
Stigma  
 
230 (24.9) 695 (75.1) 
Felt depressed / overwhelmed  
 
230 (24.9) 695 (75.1) 
Poor relationships with health provider  
 
 228 (24.6) 697 (75.4) 
Felt like drug was toxic  
 
227 (24.5) 698 (75.5) 
Felt sick or ill  
 
218 (23.6) 707 (76.4) 
Felt a sleep through dose time  
 
200 (21.6) 725 (78.4) 
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Table 5.20 below reveals the results of 10 factors which are believed to facilitate the 
adherence to HAART among HIV-positive patients. Participants assigned "Yes" as a 
response if they agreed with the factors as factors facilitating adherence and assigned a 
"No” response if they did not agree. The most common factors facilitating adherence were 
disclosure, belief in the efficacy of pills, afraid of developing resistance to drugs and afraid 
of my health condition getting worse.The least common factors facilitating adherence to 
HAART were the use of alarm/clock, to avoid paying for new drugs and the need to care 
for others. 
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Table 5-20: Factors facilitating adherence to HAART in HIV positive patients (n =925) 
Reasons facilitating adherence Yes (%) No (%) 
 
Disclosure (revealing disease status) 
 
714 (77.2) 211 (22.8) 
 
Belief in the efficacy of pills  
 
 693 (74.9) 232 (25.1) 
 
Afraid of developing resistance to drugs. 
 
672 (72.6) 253 (27.4) 
 
Afraid of my health condition getting worse. 
 
659 (71.2) 266 (28.8) 
 
Acceptance of one’s HIV status. 
 
655 (70.8) 270 (29.2) 
 
Afraid of my health getting worse. 
 
652 (70.5) 273 (29.5) 
 
Self-efficacy to take and adhere to ART. 
 
651 (70.4) 274 (29.6) 
 
The need to care for others. 
 
648 (70.1) 277 (29.9) 
 
To avoid paying for new drugs  
 
524 (56.6) 401 (43.4) 
 
Use of Alarm/ clock  
 
421 (45.5) 504 (54.5) 
ART = Antiretroviral Treatment 
 
 
 
Table 5.21 below shows the results of 6 types of alternative medicine used by HIV-positive 
patients who were on HAART. The most common types of alternative medicine used are 
herbal medicine, mind-body therapies and yoga. The least commonly used types of 
alternative medicine are dietary supplements, religious treatment and acupuncture. 
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Table 5-21: Alternative medicine used for HIV treatment in HIV positive patients on 
HAART 
Alternative medicine Yes (%) No (%) 
Herbal medicine 335 (36.2) 590 (63.2) 
Mind-body therapies 215 (23.2) 710 (76.8) 
Yoga 210 (22.7) 715 (77.3) 
Acupuncture 190 (20.5) 735 (79.5) 
Dietary supplements 190 (20.5) 735 (79.5) 
Religious treatment 190 (20.5) 735 (79.5) 
 
 
Table 5.22 below reveals the results of clinical investigations carried out by HIV-positive 
patients before they started undergoing HAART and 6 months or more after they have 
undergone HAART. This is the same for all 925 participants. Investigations included the 
CD4, CD8 and viral load tests. Six hundred and forty out of 925 participants had pre-
treatment CD4 > 300 cells/ul with and overall mean value of 254.91 for pre-treatment CD4. 
Two hundred seventy eight participants had post-treatment CD4 value of less than 300 cells 
/ul, with overall mean value of 450.21 for post treatment CD4. This result shows that there 
was an increase in the pre-treatment CD4 value after the participants had undergone 
HAART treatment for at least 6 months.  The mean pre-treatment viral load was very high 
(151416.2 copies/ml) while the mean post-treatment viral load value was 117.   The role of 
pre-treatment analysis was to show if there is improvement of the values after patients start 
their medication (post-treatment).  
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Table 5-22: Clinical investigation results in HIV positive patients (n=925) 
             
 Variable 
               Pre-treatment              Post-treatment 
    N (%) Mean Median     N (%) Mean Median 
CD8 cells /ul 
<300 
301--600 
601--900 
901--1200 
1201--1500 
1501--1800 
1801--2100 
>2100 
 Total 
 
  39 (4.2) 
161 (17.4) 
222 (24.0) 
204 (22.1) 
141 (15.2) 
  91 (10.2) 
  48 (5.2) 
  16 (1.7) 
 925 (100) 
 
1119.59 
 
945.00 
 
  38 (4.1) 
177 (19.1) 
262 (28.3) 
233 (25.2) 
116 (12.5) 
     55 (5.9) 
     30 (3.2) 
     14 (1.5) 
 925 (100) 
 
1396.47 
 
 
 
8700 
Viral load copies /ml 
<50 
50-- 1000 
>1000 
Total 
 
381 (41.2) 
153 (16.3) 
391 (42.3) 
 925 (100) 
 
151416.2 
 
 
327.00 
 
797 (86.2) 
  98 (10.6) 
    30 (3.2) 
925 (100) 
 
  117.00 
 
 
Log viral load 
<3 
3--4.5 
>4.5 
Total 
 
 692 (75.0) 
 123 (13.1) 
 110 (11.9) 
  925 (100) 
 
 
 
 
 
846 (91.5) 
    54 (5.8) 
    25 (2.7) 
 925 (100) 
 
 
 
 
 
Pre-treatment = before the start of HAART 
Post-treatment= First investigation done after 6 month or more after the commencement of 
HAART. This same for all participants 
  
 
Table 5.23 below describes the HIV-positive patients’ disease history on the day they were 
interviewed by their doctors in the clinic for the first time. Out of 925 patients, 556 or 
60.1% did not have any other diseases apart from being HIV-positive. One hundred and 
thirty eight (14.9%) had co-existing infectious diseases such as TB or PCP, and 96 or 
10.6% had both liver and renal diseases. Nine patients had both renal and co-existing 
infectious diseases. 
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Table 5-23: Diseases history of HIV positive patients while on HAART (n=925) 
Past medical history  N                           %
No history of any other disease except HIV 556                      60.1 
Co-existing infectious disease such as TB or PCP 138                       14.9
Has both liver and renal disease 96                        10.6 
Associated liver disease only 65                         7.0
Associated renal disease only 35                        3.8
Has both liver disease and co existing infectious disease 26                        2.8
Has both renal disease and co existing infectious disease 9                           1.0
Past medical history = Patients past history on the day they were interviewed by their 
doctor in the clinic for the first time. 
PCP = Pneumocystis pneumonia 
TB= Tuberculosis 
 
Table 5.24 below shows the results of the comparison between biological markers for pre-
treatment and post-treatment status in HIV- positive patients. The mean pre-treatment CD4 
values are significantly different from the mean post-treatment CD4  value at 95% CI of  -
129.623, 82.653 whereas the mean CD8 pre-treatment count shows no significant 
difference with the mean post-treatment CD8 level at 95% CI of -1104.279, 550.521. 
Regarding the viral load and log10 viral load, both show significance difference before and 
after treatment at 95% CI of 109296.03, 188394.52 and 0.211, 0.304 respectively. 
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Table 5-24: Comparison between biological markers for HIV patient pre-treatment and 
post-treatment using paired t test (n=925) 
 
       Variable 
 
N 
 
 Mean Standard 
Deviation 
 
95% Confidence 
Interval 
CD4 Pre-treatment 925    
Post-treatment 925 -195.296 363.952 (-129.623, 82.653) 
CD8 Pre-treatment 925    
Post-treatment 925 -276.879 12822.4 (-1104.279, 550.521) 
Viral load Pre-treatment 925    
Post-treatment 925 148,800 612903 (109296.03, 188394.52) 
Log10  
Viral load 
Pre-treatment 925    
Post-treatment 925 0.257 0.721 (0.211, 0.304) 
 
5.6 Comparing three specific drug levels as detected by TDM using LC-MS/MS 
machine vs. Overall adherence level measured by self-reported questionnaire 
This section is on comparison between the various measures of Therapeutic Drug 
Monitoring (TDM) with the overall adherence level as measured by the self-reported 
questionnaire. Only participants who actually took Efavirenz, Lamivudine and Nevirapine 
had their therapeutic drug level tested. Patients indicated which drug they were on before 
they start answearing the self-reported questionnaire and this was also confirmed from their 
pharmacy records. We compared the drug levels detected in human plasma via TDM using 
the LC-MS/MS machine with the adherence level calculated by the self-reported 
questionnaire.  
 
Table 5.25 below shows the results of overall adherence level that was measured by the 
self-reported questionnaire in comparison with the Efavirenz level as detected by TDM 
using the LC-MS/MS machine. Overall the adherence level as measured by SRA was 0.80, 
0.76 and 0.71 for Efavirenz, Nevirapine and Lamivudine (Table 5.25). This contrasted with 
the overall adherence measured using TDM of 0.71, 0.70 and 0.60 for the same drugs 
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respectively. For the true positive values detected by both the SRA and TDMs were 0.94, 
0.92 and 0.89 for Efavirenz, Nevirapine and Lamivudine. While, the true negative values of 
both the SRA and TDMs were 0.55, 0.62 and 0.56 for the same drugs respectively. 
 
Table 5-25: Adherence levels by SRA and TDM and Sensitivity and specificity of SRA 
versus TDM for each drug tested using TDM as the gold standard 
Drug SRA 
adherence 
(%) 
TDM 
adherence 
(%) 
SRA/TDM 
adherence 
SRA/TDM 
non-
adherence 
Efavirenz 501/625 
(80.2) 
445/625 
(71.2) 
421/445 
(94.6) 
100/180 
(55.6) 
Nevirapine 430/566 
(76.0) 
394/566 
(69.6) 
366/394 
(92.9) 
108/172 
(62.8) 
Lamivudine 352/496 
(71.0) 
299/496 
(60.3) 
267/299 
(89.3) 
112/197 
(56.9) 
 
 
Table 5.26 displays the sensitivity, specificity, positive and negative predictive values for 
the 3 drugs. SRA sensitivity was highest for Efavirenz (0.95; 95% CI 0.92, 0.96) and 
lowest for Lamivudine (0.89; 95% CI 0.85, 0.92). SRA specificity ranged between 0.56 and 
0.63 and was highest for Nevirapine. PPV for SRA ranged between 0.76 (Lamivudine) and 
0.84 (Efavirenz). A similar pattern was seen for NPV. Overall diagnostic accuracy ranged 
between 0.76 (Lamivudine) and 0.84 (Nevirapine). For the diagnostic accuracy, all the the 
three drugs (Efavirenz, Nevirapine and Lamivudine) have an acceptable area of under the 
curve which is above 0.70. 
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Table 5-26: PPV, NPV and diagnostic accuracy of SRA versus TDM for each drug tested 
using TDM as the gold standard  
Drug Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Diagnostic 
accuracy 
(95% CI) 
Efavirenz 0.95  
(0.92, 0.96) 
0.56  
(0.48, 0.63) 
0.84 
(0.81, 0.87) 
0.81 
(0.73, 0.87) 
0.83  
(0.80, 0.86) 
Nevirapine 0.93  
(0.90, 0.95) 
0.63 
(0.55, 0.70) 
0.85 
(0.81, 0.88) 
0.79 
(0.72, 0.85) 
0.84 
(0.80, 0.87) 
Lamivudine 0.89 
(0.85, 0.92) 
0.57 
(0.50, 0.64) 
0.76 
(0.71, 0.80) 
0.78 
(0.70, 0.84) 
0.76 
(0.72, 0.80) 
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5.7 Cross tabulation of overall adherence level as measured self-reported 
questionnaire and selected independent variables 
Bivariate analysis was conducted to determine if there was any statistically significant 
association between the dependent and independent variables. In this part of the analysis, 
we examined the quantifiable relationship between the measured overall self-reported 
adherence levels, which has been dichotomized into those who are adherent to treatment 
with those who are non-adherent to treatment. We defined those who were adherent as 
patients who had adherence level equal to or more than 95% (using the self-reported 
questionnaire), while those who were not-adherent were defined as patients who had 
adherence level less than 95%. We used the 95% cut-off point since it is the WHO 
requirement for adherence to HAART among HIV/AIDS-positive patients. 
 
Table 5.27 provides an insight to the socio-demographic factors and self-reported 
adherence level. Seven demographic factors were examined (gender, religion, ethnicity, 
education, marital status, average monthly income, and age group in years). Out of these 
factors, education level, marital status, average monthly income and age in years were 
statistically significant with the overall adherence level as measured by the self-reported 
questionnaire. Among the married participants, 92.2% were adherent to HAART while 
7.8% of them were not adherent. On the other hand, almost two thirds of the unmarried 
respondents (64.5%) were adherent to their medication compared to 35% of them who were 
not adherent to the HAART. In short, married patients have higher odds ratio of 6.503 
(95% CI 4.469, 9.462) compared to the reference group of the unmarried.  
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Among the income categories, those with an income range of RM 1,501 – 2,500 have the 
highest adherence level; this group had an OR of 7.708 (95% CI 4.148, 14.323) which was 
the highest compared to the rest of the income categories. The patient’s age showed an 
increasing trend with the adherence level of the patient, as the age categories of 31 – 44 and 
44 and above have at least more than 10 times higher adherence level compared to those 
aged 18 – 30, where their odds ratio were 10.877 ( 95% CI 4.944, 23.927) and 21.379 (95 
CI 9.446, 48.386) respectively. Among the patients educational level categories, the 
categories  ‘Secondary level IV’, ‘Secondary level V’ and ‘Degree level’ have at least more 
than 9 times higher adherence level compared to the other education categories as indicated 
by their Odds ratio of 26.924 (95% CI 11.009, 65.848), 9.71 (95% CI 3.618, 26.064) and 
6.574 (95% CI 2.018, 21.42) respectively. Other socio-demographic characteristics such as 
gender, religion and ethnicity were not statistically significant with the adherence level as 
measured by the overall self-reported questionnaire. 
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Table 5-27: Cross-tabulation of socio-demographic characteristics of adherent and non-
adherent HIV positive patients using overall adherence self-reported questionnaire (n=925) 
Variable  Adherent 
(%) 
Not Adherent 
(%) 
 Total 
(%) 
OR (95%CI) 
Gender     
Female  
Male 
Total 
 
171 (78.1) 
585 (82.9) 
756 (81.7) 
 
48 (21.9) 
121 (17.1) 
169 (18.3) 
  
219 (23.7) 
706 (76.3) 
925 (100) 
 
Reference category 
0.736 (0.506, 1.072) 
Religion 
Islam 
Buddhism 
Hinduism 
Christianity 
Taoism 
Others  
Total 
 
215 (83.3) 
368 (82.1) 
40 (75.5) 
82 (84.5) 
39 (70.9) 
12 (85.7) 
756 (81.7) 
 
43 (16.7) 
80 (17.9) 
13 (24.5) 
15 (15.5) 
16 (29.1) 
2 (14.3) 
169 (18.3) 
  
258 (27.9) 
448(48.4) 
53 (5.7) 
97 (10.5) 
55 (5.9) 
14 (1.5) 
925 (100) 
 
Reference category 
0.794 (0.171, 3.692) 
0.270 (0.034, 2.117) 
1.232 (0.234, 6.478) 
0.312 (0.056, 1.725) 
0.794 (0.082, 7.651) 
Ethnicity 
Malay 
Chinese 
Indian 
Others 
Total 
 
209 (83.6) 
474 (81.0) 
57 (79.2) 
16 (88.9) 
756 (81.7) 
 
41 (16.4) 
111 (19.0) 
15 (20.8) 
2 (11.1) 
169 (18.3) 
  
250 (27.0) 
585 (63.2) 
72 (7.8) 
18 (1.9) 
925 (100) 
 
Reference category 
1.154 (0.245, 5.433) 
2.356 (0.304, 18.272) 
7.678 (0.715, 82.402) 
Completed Education level  
No formal schooling 
Primary school 
Secondary school – 3 
Secondary school – 5 
High school (form6 level) 
Diploma 
Degree 
Total 
 
55 (46.6) 
108 (72.5) 
222 (88.4) 
200 (93.0) 
51 (85.0) 
36 (87.8) 
84 (92.3) 
756 (81.7) 
 
63 (53.4) 
41 (27.5) 
29 (11.6) 
15 (7.0) 
9 (15.0) 
5 (12.2) 
7 (7.7) 
169 (18.3) 
  
118 (12.8) 
149 (16.1) 
251 (27.1) 
215 (23.2) 
60 (6.5) 
41 (4.4) 
91 (9.8) 
925 (100) 
 
Reference category* 
8.544 (3.490, 20.914) 
26.924 (11.009, 65.848) 
9.71 (3.618, 26.064) 
4.053 (1.225, 13.41) 
5.454 (1.161, 25.630) 
6.574 (2.018, 21.42) 
Marital status 
Single  
Married 
Total 
 
225 (64.5) 
531 (92.2) 
756 (81.7) 
 
124 (35.5) 
45 (7.8) 
169 (18.3) 
  
349 (37.7) 
576 (62.3) 
925 (100) 
 
Reference category* 
6.503 (4.469, 9.462) 
Average monthly income 
≤RM 1,500 / Month 
   RM 1,501—2,500 
   RM 2,501—10,000 
   Total 
 
228 (62.3) 
227 (93.8) 
301 (95.0) 
756 (81.7) 
 
138 (37.7) 
15 (6.2) 
16 (5.0) 
169 (18.3) 
  
366 (39.5) 
242 (26.2) 
317 (34.3) 
925 (100) 
 
Reference category* 
7.708 (4.148, 14.323) 
2.488 (1.127, 5.490) 
Age group in years 
18—30 
31—44 
45 or more 
Total 
 
210(63.6) 
312 (92.3) 
234 (91.1) 
756 (81.7) 
 
120 (36.4) 
26 (7.7) 
23 (8.9) 
169 (18.3) 
  
330 (35.7) 
338 (36.5) 
257 (27.8) 
925 (100) 
 
Reference category* 
10.877 (4.944, 23.927) 
21.379 (9.446, 48.386) 
Demographic factors examined ─ gender, religion, ethnicity, completed educational, marital status average 
monthly income and age group in years. 
* Statistically significant 
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Table 5.28 shows the cross-tabulation of adverse effects to treatment and the overall 
adherence level as reported by the self-reported adherence questionnaire. The variables 
‘vomiting’, ‘diarrhoea’, ‘loss of appetite’, ‘itching’, ‘tiredness’, ‘rash’ and ‘fever’ were 
found to be statistically significant with the overall adherence level as measured by the self-
reported questionnaire.  The variables ‘diarrhoea’, ‘vomiting’, ‘tiredness’ and ‘loss of 
appetite’ had shown bigger odds ratio among the adverse effect variables, with an odds 
ratio of 0.107 (95% CI 0.074, 0.155), 0.100 (95% CI 0.068, 0.144), 0.296 (95% CI (0.210, 
0.418) and 0.185 (95% CI 0.130, 0.264) respectively.  
 
Patients who had these adverse effects were less likely to be adherent to treatments. The 
variables ‘rash’, ‘itching’ and ‘fever’ had relatively smaller odds ratio among the adverse 
effect variables; these three variables had demonstrated a similar pattern of odds ratio 
which is 0.027 (95% CI 0.017, 0.043), 0.055 (95% CI 0.037, 0.082) and 0.092 (95% CI 0.064, 
0.134) respectively. In general, all of these adverse effects variables had shown an odds 
ratio approximately less than one, which indicates that adverse effects (i.e. side effects) of 
treatment would decrease the adherence level towards HIV medication.  
 
Other variables such as ‘dry mouth’ and ‘headache’ were found to be not statistically 
significant with the overall adherence level according to the overall self-reported 
questionnaire. 
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Table 5-28: Adverse/Side effects of treatment and overall adherence level as measured 
using self-reported questionnaire (n =925) 
VARIABLE Adherent 
(%) 
Not Adherent 
(%) 
Total OR (95%CI) 
Rash    
 Yes 62 (36.7) 107 (63.3) 169 (18.3) 0.027 (0.017, 0.043)* 
 No 694 (91.8) 62 98.2) 756 (81.7) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Itching     
 Yes 83 (41.5) 117 (58.5) 200 (21.6) 0.055 (0.037, 0.082)* 
 No 673 (92.8) 52 (7.2) 725 (78.4)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Loss of Appetite    
 Yes 148 (60.7) 96 (39.3) 244 (26.4) 0.185 (0.130, 0.264)* 
 No 608 (89.3) 73 (10.7) 681 (73.6) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Dry mouth     
 Yes 165 (82.1) 36 (17.9) 201 (21.7) 1.031 (0.687, 1.549) 
 No 591 (81.6) 133 (18.4) 724 (78.3)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Diarrhoea     
 Yes 113 (51.8) 105 (48.20 218 (23.6) 0.107 (0.074, 0.155)* 
 No 643 (90.9) 64 (9.1) 707 (76.4) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Tiredness     
 Yes 184 (67.6) 88 (32.4) 272 (29.4) 0.296 (0.210, 0.418)* 
 No 572 (87.6) 81 (12.4) 653 (70.6)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Vomiting     
 Yes 99 (49.3) 102 (50.7) 201 (21.7) 0.100 (0.068, 0.144)* 
 No 657 (90.7) 67 (9.3) 724 (78.3)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Fever     
 Yes 104 (49.3) 107 (50.7) 211 (22.8) 0.092 (0.064, 0.134)* 
 No 652 (91.3)  62 (8.7) 714 (77.2)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Headache     
 Yes 110 (81.5) 25 (18.5) 135 (14.6) 0.980 (0.613, 1.570) 
 No 646 (81.8) 144 (18.2) 693 (85.4)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Adverse effects of treatment analysed -rash, itching, loss of appetite, dry mouth, diarrhoea, vomiting,   
fever and headache. Reference category is No 
* Statistically significant 
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Table 5.29 below shows the cross-tabulation of alternative medication used and overall 
adherence level as measured by the self-reported adherence questionnaire. The following 
alternative medication variables were found to be statistically significant with the overall 
adherence level as measured by the self-reported questionnaire: ‘use of herbal medicine’, 
‘use of body mind therapy’, ‘use of dietary supplements’, ‘use of religious treatment’ and 
‘use of acupuncture’. 
 
The variables ‘use of religious treatment’, ‘use of dietary supplements’, and ‘use of 
acupuncture’ had relatively small odds ratio compared to the other alternative medication 
variables; their odds ratio were 0.071 (95% CI 0.049, 0 .105), 0.072 (95% CI 0.049, 0.107) 
and 0.073 (95% CI 0.050, 0.108) respectively. Conversely, variables such as ‘use of body 
mind therapy’ and ‘use of herbal medicine’ had bigger odds ratio compared to the other 
variables; the odds ratio of these variables were 0.093 (95% CI 0.064, 0.135) and 0.302 
(95% CI  0.214, 0.426) respectively. In general, all of these alternative medication variables 
had shown approximately an odd ratio of less than one, which indicates that, the use of 
alternative medication causes patients not to adhere to their HIV medication. Only the 
variable ‘use of Yoga’ was found as not having a statistically significant effect to the 
overall adherence level based on the self-reported questionnaire.  
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Table 5-29: Alternative medicine used by HIV positive patients and overall adherence 
level calculated by self-reported questionnaire (n=925) 
Variables Adherent 
(%) 
Non-Adherent 
(%) 
Total 
(%) 
OR (95%CI) 
Use of dietary supplements    
 Yes 83 (43.7) 107 (56.3) 190 (20.5) 0.071 (0.049, 0.105)* 
 No 673 (91.6) 62 (8.4) 735 (79.5) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Use of Religious treatment     
 Yes 84 (43.7) 107 (56.3) 190 (20.5) 0.072 (0.049, 0.107)* 
 No 672 (91.6) 62 (8.4) 735 (79.5) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Use of Yoga    
 Yes 100 (85.5) 17 (14.5) 117 (12.6) 1.363 (0.791, 1.347) 
 No 656 (81.2) 152 (18.8) 808 (87.4) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Use of Acupuncture    
 Yes 85 (43.7) 107 (56.3) 190 (20.5) 0.073 (0.050, 0.108)* 
 No 671 (91.6) 62 (8.4) 735 (79.5) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Use of body mind therapy    
 Yes 107 (49.8) 108 (50.2) 215 (23.2) 0.093 (0.064, 0.135)* 
 No 649 (91.4) 61 (8.6) 710 (76.8)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Use of Herbal Medicine     
 Yes 234 (69.9) 101 (30.1) 335 (36.2) 0.302 (0.214, 0.426)* 
 No 522 (88.5) 68 (11.5) 590 (63.8)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Alternative medication examined - use of herbal medicine, use of alcohol, use of religious treatment, use of 
body mind therapy, use of dietary supplements, use of yoga & use of acupuncture. Reference category is No 
* Statistically significant values 
 
Table 5.30 below shows the cross-tabulation of reasons facilitating adherence to HAART 
and the overall adherence level as measured using the self-reported adherence 
questionnaire. The following variables were found to be statistically significant with the 
overall adherence level according to the self-reported questionnaire:  ‘Use of alarm/ clock’, 
‘Acceptance of HIV status’, ‘Belief in efficacy of the pills’, ‘Self-efficacy to take & adhere 
to medication’, ‘Afraid of my health getting worse’, ‘Afraid of developing drug resistance’, 
and ‘Disclosure about HIV status’. 
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The variables ‘Use of alarm/clock’, ‘Acceptance of HIV status’, ‘Afraid of my health 
getting worse’ and ‘Afraid of developing drug resistance’ had relatively small odds ratio 
compared to the other variables for factors of facilitating adherence; their odds ratio were 
7.057 (95% CI 4.445, 11.205), 5.686 (95% CI 3.989, 8.106), 6.782 (95% CI 4.729, 9.728), 
and 7.210 (95% CI 5.025, 10.348) respectively. On the other hand, variables such as ‘Belief 
in efficacy of the pills’, ‘Self-efficacy to take medication’ and ‘Disclosure about HIV 
status’ had bigger odds ratio compared to the other reasons facilitating adherence; the odds 
ratio of these variables were 8.711 (95% CI 6.036, 12.575), 12.527 ( 95% CI 8.459, 
18.551), and 10.819 (95% CI 7.435, 15.744) respectively.  
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Table 5-30: Reasons facilitating adherence to HAART and their overall adherence level as 
measured using self-reported questionnaire (n=925) 
Variable Adherent 
(%) 
Not Adherent 
(%) 
Total 
(%) 
OR (95% CI) 
Use of Alarm/ clock    
 Yes 398 (94.5) 23 (5.5) 421 (45.5) 8.234 (5.108, 11.205)* 
 No 358 (71.0) 146 (29.0) 504 (54.5) 
 
 Total 756 (81.7) 169 918.3) 925 (100)  
Acceptance of HIV status    
 Yes 590 (90.1) 65 (9.9) 655 (70.8) 5.686 (3.989, 8.106)* 
 No 166 (61.5) 104 (38.5) 270 (29.2)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
To avoid paying for new drugs    
 Yes 461 (82.6) 97 (17.4) 558 (60.3) 1.159 (0.827, 1.627) 
 No 295 (80.4) 72 (19.6) 367 (39.7)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Belief in the efficacy of pills    
 Yes 631 (91.1) 62 (8.9) 693 (74.9) 8.711 (6.036, 12.575)* 
 No 125 (53.9) 107 (46.1) 232 (25.1)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Self-efficacy to take & 
adhere to medication 
   
 Yes 609 (93.5) 42 (6.5) 651 (70.4) 12.527(8.459, 18.551)* 
 No 147 (53.6) 127 (46.4) 274 (29.6) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Afraid of  health  
getting worse 
   
 Yes 593 (91.0) 59 (9.0) 652 (70.5) 6.5230 (4.729, 9.617)* 
 No 163 (59.7) 110 (40.3) 273 (29.5) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Afraid of developing drug  
resistance 
   
 Yes 610 (90.8) 62 (9.2) 672 (72.6) 7.210 (5.025, 10.348)* 
 No 146 (57.7) 107 (42.3) 253 (27.4) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Disclosure of HIV     
 Yes 652 (91.3) 62 (8.7) 714 (77.2) 10.819 (7.435, 15.744)* 
 No 104 (49.3) 107 (50.7) 211 (22.8) 
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
The need to care for  
dependents 
   
 Yes 516 (83.1) 97 (17.4) 613 (66.3) 1.298 (0.927, 1.853) 
 No 295 (80.4) 72 (19.6) 367 (33.7)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Reasons facilitating adherence examined - use of Alarm/ clock, acceptance of HIV status, to avoid paying for 
new drugs, belief in the efficacy of pills, the need to care for others, afraid of my health getting worse, afraid 
of developing drug resistance, disclosure and self-efficiency to take & adhere to medication. Reference 
category is No 
*statistically significant 
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Table 5.31 shows the cross-tabulation of reasons for missing medication and the overall 
adherence level as reported by the self-reported adherence questionnaire. The following 
variables of reasons for missing medication were found to be statistically significant with 
the overall adherence level measured by the self-reported questionnaire: ‘Simply forgot’, 
‘Cost of treatment too high’, ‘Distance to hospital too long and costly’, ‘Ran out of pills’ 
and ‘Away from home’  The variables  ‘Simply forgot’, ‘Cost of treatment too high’ and 
‘Away from home’ had relatively small odds ratio compared to the other variables of 
reasons of missing medication; their odds ratio were 0.160 (95% CI 0.111, 0.230), 0.171 
(95% CI 0.119, 0.244) and 0.097 (95% CI 0.199, 0.199) respectively.  
 
Variables such as ‘Distance to hospital too long and costly’ and ‘Ran out of pills’ had 
relatively bigger odds ratio compared to the other reasons for missing medication; the odds 
ratio of these variables were 0.240 (95% CI 0.170, 0.340) and 0.449 (95% CI 0.321, 0.630) 
respectively. In general, the odds ratio for the above reasons of missing medication was less 
than one, which indicates that these reasons were negatively associated with the overall 
adherence level. In other words, these factors would decrease the level of adherenc to 
HAART. Only the variable ‘Busy with other things’ was found to be insignificantly 
associated with the overall adherence to HAART. 
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Table 5-31: Reasons for missing medications and overall adherence level using self-
reported questionnaire (n=925) 
Variable Adherent  
(%) 
Not Adherent 
(%) 
Total 
(%) 
OR (95%CI) 
Simply forget     
 Yes 200 (63.1) 117 (36.9) 317 (34.3) 0.160 (0.111, 0.230)*
 
 No 556 (91.4) 52 (8.6) 608 (65.7)   
 Total 756 (81.7) 169 (18.3) 925 (1000  
Cost of treatment too high     
 Yes 186 (62.6) 111 (37.4) 297 (32.1) 0.171 (0.119, 0.244)*
 
 No 570 (90.8) 58 (9.2) 628 (67.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Distance to hospital too  
long and costly 
   
 Yes 175 (65.1) 94 (34.9) 269 (29.1) 0.240 (0.170, 0.340)*
 
 No 581 (88.6) 75 (11.4) 656 (70.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Busy with other things     
 Yes 176 (83.0) 36 (17.0) 212 (22.9) 1.121 (0.748, 1.681) 
 No 580 (81.3) 133 (18.7) 713 (77.1)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Run out of pills     
 Yes 260 (74.1) 91 (25.9) 351 (38.0) 0.449 (0.321, 0.630)* 
 No 496 (86.4) 78 (13.6) 574 (62.0)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Away from home    
 Yes 146 (57.7) 107 (42.3) 253 (27.4) 0.097 (0.199, 0.199)*
 
 No 610 (90.8) 62 (9.2) 672 (72.6)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
 Reasons for missing medications examined- simply forget, cost of treatment too high, distance to hospital too 
long and costly, busy with other things, run out of pills, away from home and wanted to avoid side effects.  
The reference category is No.    
* statistically significant 
 
 
Table 5.32 below presents the cross-tabulation of another group of reasons for missing 
medications and the overall adherence level as measured using the self-reported adherence 
questionnaire. The following variables were found to be statistically significant with the 
overall adherence level as measured by the self-reported questionnaire: ‘Had simply many 
pills’, ‘Fell asleep during dose time’, ‘Did not want others to notice taking medication’ 
‘Had a change in daily routine’ and ‘Wanted to avoid side effects’. 
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The variables ‘Fell asleep during dose time’ and ‘Did not want others to notice taking 
medication’ have relatively small odds ratio compared to the other factors of missing 
medication; their odds ratio were 0.084 (95% CI 0.058, 0.123) and 0.073 (95% CI 0.050, 
0.108) respectively. On the other hand, variables such as ‘Had simply many pills’, ‘Had a 
change in daily routine’ and ‘Wanted to avoid side effects’ have bigger odds ratio 
compared to the other factors of missing medication; the odds ratio of these variables were 
0.115 (95% CI 0.080, 0.166), 0.353 (95% CI 0.249, 0.501) and 0.121  (95% CI 0.084, 
0.174) respectively. This indicates that these reasons
2
 were negatively associated with the 
overall adherence level and thus may result in patients being less adherent to their 
medication. Other reasons for missing medication were found to be not significantly 
associated with the overall adherence to HAART as calculated by the self-reported 
adherence questionnaire. These reasons include ‘Felt like drug was toxic’, ‘Felt sick or ill’, 
‘Had problems taking medicine at specific times’ and ‘Religious belief’. 
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Table 5-32: Reasons for missing medications and overall adherence level using self-
reported questionnaire (n=925) 
Variable Adherent 
(%) 
Not-Adherent 
(%) 
Total 
(%) 
OR (95%CI) 
Had simply many pills    
 Yes 125 (53.9) 107 (46.1) 232 (25.1) 0.115 (0.080, 0.166)*
 
 No 631 (91.1) 62 (8.9) 693 (74.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Fell asleep during dose 
time 
    
 Yes 94 (7.0) 106 (53.0) 200 (21.6) 0.084 (0.058, 0.123)*
 
 No 663 (91.3) 63(8.7) 725 (78.4)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Did not wanted others to  
notice taking medicine 
   
 Yes 83 (43.9) 106 (56.1) 189 (20.4) 0.073 (0.050, 0.108)*
 
 No 673 (91.4) 63 (8.6) 736 (79.6)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Had a change in daily  
routine 
   
 Yes 163 (68.8) 74 (31.2) 237 (25.6) 0.353 (0.249, 0.501)*
 
 No 593 (86.2) 95 (13.8) 688 (74.4)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Felt like drug was toxic    
 Yes 83 (85.6) 14 (14.4) 97 (10.5) 1.365 (0.755, 2.470) 
 No 673 (81.3) 155 (18.7) 828 (89.5)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Wanted to avoid side 
effects 
    
 Yes 125 (54.3) 105 (45.7) 230 (24.9) 0.121 (0.084, 0.174)*
 
 No 631 (90.8) 64(9.2) 695 (75.1)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Felt sick or ill     
 Yes 69 (82.1) 15 (17.9) 84 (9.1) 1.031 (0.574, 1.851) 
 No 687 (86.7) 154 (18.3) 841 (90.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
 
Table 5.33 below presents the cross-tabulation of the third group of reasons for missing 
medication and the overall adherence level as measured using the self-reported adherence 
questionnaire. The variables ‘Felt depressed’, ‘Felt well’, ‘Treatment and drug collection 
time too long’ and ‘Poor relationship with health provider’ were found to be statistically 
significant with the overall adherence level based on the self-reported questionnaire.   
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The variable ‘Poor relationship with health provider’ has relatively bigger odds ratio 
compared to the other reasons of missing medication; it has an odds ratio of 0.323 (95% CI 
0.230, 0.453). On the other hand, the variables ‘Felt depressed’, ‘Felt well’, and ‘Treatment 
and drug collection time too long’ have relatively small odds ratio compared to the ‘Poor 
relationship with health provider’ as reasons for missing medications. Their odds ratio were 
0.117 (95% CI 0.081, 0.168), 0.106 (95% CI 0.074, 0.152) and 0.136 (95% CI 0.095, 0.196) 
respectively. In general, the odds ratio for the above reasons for missing medication was less 
than one, which indicates that these reasons were negatively associated with the overall 
adherence level. In other words, these factors would decrease the level of adherence to 
HAART. The variables ‘Had problems taking medicine at specific time’, ‘Religious belief’ 
and ‘Beliefs & preference for traditional medicine’ were found to be insignificantly 
associated with the overall adherence to HAART according to the self-reported adherence. 
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Table 5-33: Reasons for missing medications and overall adherence level using self-
reported questionnaire (n=925) 
Variable Adherent 
(%) 
Not-Adherent 
(%) 
Total 
(%) 
OR (95%CI) 
Felt depressed    
 Yes 124 (53.9) 106 (46.1) 230 (24.9) 0.117 (0.081, 0.168)*
 
 No 632 (90.9) 63 (9.1) 695 (75.1)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Felt well     
 Yes 124 (51.5) 117 (48.5) 241 (26.1) 0.106 (0.074, 0.152)*
 
 No 632 (92.4) 52 (7.6) 684 (73.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Had problems taking 
medicine at specific time    
 
 Yes 93 (84.5) 17 (15.5) 110 (11.9) 1.254 (0.726, 2.166) 
 No 663 (81.3) 152 (18.7) 815 (88.1)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Religious belief     
 Yes 71 (82.6) 15 (17.4) 86 (9.3) 1.064 (0.594, 1.908) 
 No 685 (81.6) 154 (18.4) 839 (90.7)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Treatment and drug collection  
time too long 
   
 Yes 130 (56.0) 102 (44.0) 232 (25.1) 0.136 (0.095, 0.196)*
 
 No 626 (90.3) 67 (9.7) 693 (74.9)  
 Total 756 (81.7) 169 (18.3) 925 (100)  
Poor relationships with  
health provider 
   
 No 262 (70.4) 110 (29.6) 372 (40.2)  
 Yes 494 (89.3) 59 (10.7) 553 (59.8) 0.323 (0.230, 0.453)*
 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Beliefs and preference for  
traditional medicine 
   
 Yes 52 (81.2) 12 (18.8) 64 (6.9)  
 No 704 (81.8) 157 (18.2) 861 (93.1) 0.702 (0.442, 1.114) 
 Total 756 (81.7) 169 (18.3) 925 (100)  
Reasons for missing medications examined - had simply many pills, fell asleep during dose time, felt 
depressed, felt well, treatment and drug collection time too long, poor relationships with health provider, 
beliefs and preference for traditional medicine. Reference category is No 
*statistically significant 
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5.8 Cross-tabulations of HIV adherent predictors vs. three specific drug levels as 
measured by TDM using LC-MS/MS machine 
This section is on the cross-tabulation of three specific drug levels as detected by TDM 
versus adherence determinants (adverse effects of treatment, alternative medication, 
reasons facilitating adherence to HAART and reasons for missing medication). Table 5.34 
shows the results of cross tabulation analysis of the adverse effects of treatment and TDM 
method for detecting Efavirenz, Nevirapine and Lamivudine level using the LC-MS/MS 
machine. The variables ‘Rash’, ‘Itching’, ‘Diarrhoea’, ‘Vomiting’ and ‘Fever’ were found 
to be statistically significant with the TDM level of all the three drugs mentioned above.  
 
These variables had shown similar odds ratios across all three drugs, with the exception of 
variables ‘Rash’ and ‘Itching’ which had shown relatively small odds ratios compared to 
the other factors of adverse effects to treatment. The odds ratios of these variables (rash and 
itching) were 0.204 (95% CI 0.133, 0.312) and 0.235 (95% CI 0.158, 0.350) for Efavirenz; 
0.212 (95% CI 0.138, 0.324) and 0.207 (95% CI 0.138, 0.310) for Nevirapine; 0.263(95% 
CI 0.171, 0.404) and 0.266 (95% CI 0.177, 0.401) for Lamivudine. Likewise, the variables 
‘Vomiting’ and ‘Fever’ in TDM for Nevirapine had shown smaller odds ratios of 0.239 
(95% CI 0.159, 0.360) and 0.281 (95% CI 0.189, 0.419) respectively.  
 
The variables ‘Dry mouth’ and ‘Headache’ were found to be insignificant in all three TDM 
drugs. Variables ‘Loss of appetite’ and ‘Tiredness’ were found insignificant in Lamivudine 
and Nevirapine data, respectively. The rest of the variables (diarrhoea, vomiting and fever) 
of almost all three TDM drugs had shown an odds ratio between 0.281 and 0.399. In other 
words, patients suffering from the above side effects are more likely to be non-adherent to 
their medication compared to patients who did not suffer from them. 
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Table 5-34: Comparing the TDM level of three specific antiretroviral medications with their adverse effects. (n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Rash 
       Yes 
       No 
48 (41.7) 
397(77.8) 
67 (58.3) 
113 (22.2) 
0.204 
(0.133, 0.312) 
50 (41.7) 
344 (77.1) 
70 (58.3) 
102 (22.9) 
0.212  
(0.138, 0.324) 
44 (36.1) 
255 (68.2) 
78 (63.9) 
119 (31.8) 
0.263 
(0.171, 0.404) 
Itching  
       Yes 
       No 
64 (46.0) 
381 (78.4) 
75 (54.0) 
105 (21.6) 
0.235 
(0.158, 0.350) 
60 (42.9) 
334 (78.4) 
80 (57.1) 
92 (21.6) 
0.207 
(0.138, 0.310) 
52 (37.4) 
247 (69.2) 
87 (62.6) 
110 (30.8) 
0266  
(0.177, 0.401) 
Appetite 
       Yes 
       No 
110 (62.5) 
335 (74.6) 
66 (37.5) 
114(25.4) 
0.567 
(0.391, 0.823) 
77 (51.3) 
317 (76.2) 
73 (48.7) 
99 (23.8) 
0.329 
(0.223, 0.487) 
93 (58.9) 
206 (60.9) 
65 (41.1) 
132 (39.1) 
0.917  
(0.624, 1.347) 
Dry Mouth  
       Yes 
       No 
82 (68.3) 
363 (71.9) 
38 (31.7) 
142 (28.1) 
0.844 
(0.549, 1.299) 
109 (74.7) 
285 (67.9) 
37 (25.3) 
135 (32.1) 
1.395 
(0.912, 2.135) 
73 (63.5) 
226 (59.3) 
42 (36.5) 
155 (40.7) 
1.192 
(0.775, 1.835) 
Diarrhoea 
       Yes 
       No  
72 (50.7) 
373 (77.2) 
70 (49.3) 
110 (22.8) 
0.303  
(0.205, 0.449) 
75 (50.7) 
319 (76.3) 
73 (49.3) 
99 (23.7) 
0.319 
(0.215, 0.472) 
62 (43.7) 
237 (66.9) 
80 (56.3) 
117 (33.1) 
0.383  
(0.257, 0.570) 
Tiredness  
       Yes 
       No 
118 (62.4) 
327 (75.0) 
71 (37.6) 
109 (25.0) 
0.553  
(0.384, 0.798) 
113 (65.7) 
281 (71.3) 
59 (34.3) 
113 (28.7) 
0.770  
(0.525, 1.130) 
79 (51.0) 
220 (64.5) 
76 (49.0) 
121 (35.5) 
0.571  
(0.389, 0.840) 
Vomiting         
       Yes 
       No 
71 (50.7) 
374 (77.1) 
69 (49.3) 
111 (22.9) 
0.305 
(0.206, 0.453) 
59 (44.7) 
 335 (77.2 
73 (55.3) 
 99 (22.8) 
0.239  
(0.159, 0.360) 
52 (39.4) 
247 (67.9) 
80 (60.6) 
117 (32.1) 
0.308  
(0.204, 0.465) 
Fever  
       Yes 
       No 
76 (51.4) 
369 (77.4) 
72 (48.6) 
108 (22.6) 
0.309  
(0.210, 0.455) 
69 (48.3) 
325 (76.8) 
74 (51.7) 
98 (23.2) 
0.281 
(0.189, 0.419) 
63 (44.4) 
236 (66.7) 
79 (55.6) 
118 (33.3) 
0.399  
(0.268, 0.594) 
Headache  
       Yes 
       No 
56 (62.9) 
389 (72.6) 
33 (37.1) 
147 (27.4) 
0.641 
(0.401, 1.026) 
62 (69.7) 
332 (69.6) 
27 (30.3) 
145 (30.4) 
1.003 
(0.613, 1.641) 
44 (62.0) 
255 (60.0) 
27 (38.0) 
170 (40.0) 
1.086 
(0.648, 1.822) 
Adverse effects analysed included, rash, itching, dry mouth, Diarrhoea, Tiredness, Vomiting, Fever and Headache. 
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Table 5.35 shows the results of cross tabulation between the alternative use of medication 
and TDM method for detecting Efavirenz, Nevirapine and Lamivudine level using the LC-
MS/MS machine. The following variables of alternative medication were found to be 
statistically significant with all three TDM levels as measured by the LC-MS/MS machine: 
‘Use of dietary supplements’, ‘Use of Religious Treatment, ‘Use of Acupuncture, ‘Use of 
Body Mind Therapy’ and ‘Use of Herbal Medicine’. 
 
The variables ‘Use of Dietary Supplement’, ‘Use of Religious Treatment’, as well as ‘Use 
of Acupuncture’ had relatively smaller and similar odds ratios between 0.210 and 0.310. On 
the other hand, the variable ‘Use of Herbal medicine’ had a relatively bigger odds ratio 
compared to the other alternative medication variables; the odds ratio of this variable is 
0.602 (95% CI 0.421, 0.862) for Efavirenz, 0.585 (95% CI 0.406, 0.841) for Nevirapine 
and 0.570 (95% CI 0.395, 0.824) for Lamivudine. The variable ‘Use of Body Mind 
Therapy’ had shown significance only in TDM Efavirenz with an odds ratio of 0.310 (95% 
CI 0.210, 0.458). In general, all of the significant alternative to medication variables had 
shown approximately an odds ratio of less than one, which indicates that the use of 
alternative to medication causes patients not to adhere to their HIV medication. Only ‘Use 
of Yoga’ variable was found to not have a statistically significant effect to all three TDM 
levels as measured by the LC-MS/MS machine. 
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Table 5-35: Alternative medicine used by HIV positive patients and TDM status for three specific drugs as detected by LC-MS/MS machine 
(n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Use of Dietary 
supplement      
      Yes 
       No 
59 (44.7) 
386 (78.3) 
73 (55.3) 
 107 (21.7) 
0.224 
(0.150, 0.336) 
59 (44.7) 
335 (77.2) 
73 (55.3) 
99 (22.8) 
0.239 
(0.159, 0.360) 
50 (38.5) 
249 (68.0) 
80 (61.5) 
117 (32.0) 
0.294 
(0.194, 0.445) 
Use of Religious 
treatment 
       Yes 
       No 
60 (45.8) 
385 (77.9) 
71 (54.2) 
109 (22.1) 
0.239 
(0.160, 0.358) 
59 (44.7) 
335 (77.2) 
73 (55.3) 
99 (22.8) 
0.239 
(0.159, 0.360) 
49 (38.0) 
250 (68.1) 
80 (62.0) 
117 (31.9) 
0.287 
(0.189, 0.435) 
Use of Yoga 
       Yes 
       No 
49 (70.0) 
396 (71.4) 
21 (30.0) 
159 (28.6) 
0.937 
(0.544, 1.613) 
62 (71.3) 
332 (69.3) 
25 (28.7) 
147 (30.7) 
1.098 
(0.664, 1.816) 
46 (66.7) 
253 (59.3) 
23 (33.3) 
174 (40.7) 
1.275 
(0.804, 2.352) 
Use of 
Acupuncture 
       Yes 
       No 
64 (47.8) 
381 (77.6) 
70 (52.2) 
110 (22.4) 
0.264 
(0.177, 0.394) 
54 (42.2) 
340 (77.6) 
74 (57.8) 
98 (22.4) 
0.210 
(0.139, 0.319) 
49 (38.3) 
250 (67.9) 
79 (61.7) 
118 (32.1) 
0.293 
(0.193, 0.445) 
Use of body mind 
therapy  
       Yes 
       No 
75 (50.7) 
370 (77.6) 
73 (49.3) 
107 (22.4) 
0.310 
(0.210, 0.458) 
84 (63.2) 
310 (71.6) 
49 (36.8) 
123 (28.4) 
0.674 
(0.447, 1.015) 
82 (42.8) 
217 (67.5) 
70 (57.2) 
125 (32.5) 
0.675 
(0.458, 0.994) 
Use of Herbal 
Medicine  
       Yes 
       No 
136 (64.2) 
309 (74.8) 
76 (35.8) 
104 (25.2) 
0.602 
(0.421, 0.862 
139 (62.6) 
255 (74.1) 
83 (37.4) 
89 (25.9) 
0.585 
(0.406, 0.841) 
101 (52.1) 
198 (65.6) 
93 (47.9) 
104 (34.4) 
0.570 
(0.395, 0.824) 
Adverse effects analysed included, rash, itching, dry mouth, Diarrhoea, Tiredness, Vomiting, Fever and Headache. 
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Table 5.36 shows the results of cross tabulation between reasons facilitating adherence to 
HAART and TDM method for detecting Efavirenz, Nevirapine and Lamivudine level using 
the LC-MS/MS machine. The following reasons facilitating adherence to HAART were 
found to be statistically significant with the all the three TDM levels as measured by LC-
MS/MS machine: ‘Afraid of my health getting worse’, ‘Use of alarm/clock’, ‘Belief in the 
efficacy of pills’, and ‘Self-efficacy to take & adhere to medication’. 
 
These significant variables had shown similar pattern of odds ratios across all of the three 
drugs, with the exception of the ‘Use of alarm/clock’ variable which had shown relatively 
bigger odd ratios – in two out of the three TDM models – compared to the other facilitating 
factors; the odds ratios of this variable were 4.929 (95% CI 3.173, 7.659) for Nevirapine 
and 4.622 (95% CI 3.060, 6.983) for Lamivudine. The variables ‘Afraid of my health 
getting worse’, ‘Acceptance of HIV status’, ‘Belief in the efficacy of pills’, ‘Self-efficacy 
to take & adhere to medication’, ‘Afraid of developing drug resistance’, and ‘Disclosure’ 
had smaller and similar odds ratios which are in between 0.25 and 0.36.  
 
The variable ‘Acceptance of HIV status’ was found insignificant in Efavirenz and 
Lamivudine data, while the variables ‘Afraid of developing drug resistance’ and 
‘Disclosure or revealing of one’s HIV status’ were found insignificant in the models of 
Nevirapine and Lamivudine respectively. The variables ‘To avoid paying for new drugs’ 
and ‘The need to care for others’ were found to be insignificant in all three TDM levels as 
measured by the LC-MS/MS machine. In general, the odds ratio for the above reasons 
facilitating adherence was greater than one, which indicates that these reasons were 
positively associated with the overall adherence level. In other words, these factors would 
increase the level of adherence to HAART. 
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Table 5-36: Reasons facilitating adherence to HAART and TDM status for three specific drugs as detected by LC-MS/MS machine (n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Afraid of my health  
getting worse      
      Yes 
       No 
 
347 (77.3) 
98 (55.7) 
 
102 (22.7) 
78 (44.3) 
2.708 
(1.870, 3.921) 
 
291 (78.4) 
103 (52.8) 
 
80 (21.6) 
92 (47.2) 
3.249 
(2.234, 4.725) 
 
224 (68.7) 
75 (44.1) 
 
102 (31.3) 
95 (55.9) 
2.782 
(1.897, 4.079) 
Use of Alarm/ clock 
       Yes 
       No  
250 (83.3) 
195 (60.0) 
50 (16.7) 
130 (40.0) 
3.333 
(2.288, 4.855) 
201 (87.0) 
193 (57.6) 
30 (13.0) 
142 (42.4) 
4.929 
(3.173, 7.659) 
164 (80.0) 
135 (46.4) 
41 (20.0) 
156 (53.6) 
4.622 
(3.060, 6.983) 
Acceptance of HIV  
status 
       Yes 
       No 
 
313 (76.9) 
132 (58.3) 
 
120 (23.1) 
60 (41.7) 
1.186 
(0.818, 1.718) 
 
307 (77.7) 
87 (50.9) 
 
88 (22.3) 
84 (49.1) 
3.368 
(2.298, 4.936) 
200 (63.1) 
99 (55.3) 
117 (36.9) 
80 (44.7) 
1.381 
(0.952, 2.005) 
To avoid paying for  
new drugs 
       Yes 
       No 
260 (69.9) 
185 (73.1) 
112 (30.1) 
68 (26.9) 
0.853 
(0.598, 1.217) 
238 (68.8) 
156 (70.9) 
108 (31.2) 
64 (29.1) 
0.904 
(0.625, 1.308) 
179 (60.1) 
120 (60.6) 
119 (39.9) 
78 (39.4) 
0.978 
(0.677, 1.412) 
Belief in the efficacy  
of pills 
       Yes 
       No 
 
365 (78.2) 
80 (50.6) 
 
102 (21.8) 
78 (49.4) 
3.489 
(2.383, 5.109) 
313 (76.3) 
81 (51.9) 
97 (23.7) 
75 (48.1) 
2.988 
(2.027, 4.404) 
232 (67.1) 
67 (44.7) 
114 (32.9) 
83 (55.3) 
2.521 
(1.703, 3.732) 
Self-efficiency to 
take & adhere to 
medication  
       Yes 
       No 
 
 
339 (79.2) 
106 (53.8) 
 
 
89 (20.8) 
91 (46.2) 
 
 
3.270 
(2.271, 4.709) 
 
 
297(79.0) 
97 (51.1) 
 
 
79 (21.0) 
93 (48.9) 
 
 
3.604 
(2.471, 5.257) 
 
 
220 (68.8) 
79 (44.9) 
 
 
100 (31.2) 
97 (55.1) 
 
 
2.701 
(1.848, 3.948) 
Afraid of developing 
drug resistance  
       Yes 
 
342 (77.6) 
 
99 (22.4) 
2.717 
(1.882, 3.922) 
 
267 (77.3) 
 
100 (22.7) 
1.443 
(0.996, 2.090) 
 
229 (67.4) 
 
111 (32.6) 
2.535 
(1.719, 3.738) 
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       No 103 (56.0) 81 (44.0) 127 (51.5) 70 (48.5) 70 (44.9) 86 (55.1) 
Disclosure  
       Yes 
       No  
 
371 (77.9) 
74 (49.7) 
 
105 (22.1) 
75 (50.3) 
3.581 
(2.431, 5.275) 
 
323 (76.7) 
71 (49.0) 
 
98 (23.3) 
74 (51.0) 
3.435 
(2.311, 5.106) 
 
215 (67.6) 
84 (41.3) 
 
126 (32.4) 
71 (58.7) 
1.442 
(0.981, 2.119) 
The Need to care for  
others  
       Yes 
       No 
304 (71.4) 
141 (70.9) 
122 (28.6) 
58 (29.1) 
1.025 
(0.707, 1.485) 
267 (71.8) 
127 (65.5) 
105 (28.2) 
67 (34.5) 
1.342 
(0.925, 1.946) 
203 (62.5) 
96 (56.1) 
122 (37.5) 
75 (43.9) 
0.982 
(0.683, 1.413) 
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Table 5.37 shows the results of cross tabulation of reasons for missing HIV medication and 
TDM method for detecting Efavirenz, Nevirapine and Lamivudine level using the LC-
MS/MS machine. The variables ‘Simply forgot’, ‘Cost of treatment too high’, ‘Away from 
home’, ‘Had simply many pills’, ‘Distance to hospital too long and costly’, ‘Ran out of 
pills’, and ‘Busy with other things’ were found to be statistically significant with the TDM 
level of the three TDM drugs (Efavirenz, Nevirapine and Lamivudine).  
 
The variables ‘Simply forgot’, ‘Cost of treatment too high’, ‘Away from home’ and ‘Had 
simply many pills’ significantly contributed to all of the thee TDM drugs (Efavirenz, 
Nevirapine and Lamivudine), while  other variables were found partially significant in 
some of the TDM drugs. For example, ‘Distance to hospital too long & costly’ and ‘Ran 
out of pills’ were not statistically significant in Nevirapine and Lamivudine data, and ‘Busy 
with other things’ was not statistically significant in Efavirenz data. We can also see that 
the odds ratio in Nevirapine model was approximately 0.35, while the odds ratio of 
Lamivudine model was slightly bigger, with an odds of approximately 0.4.  
 
Odds ratios of less than one were shown for the Efavirenz model, as follows: 0.319 ( 95% 
CI 0.223, 0.458) for the variable ‘Simply forgot’; 0.349( 95% CI 0.243, 0.500) for ‘Cost of 
treatment too high’; 0.499 (95% CI  0.346, 0.720) for ‘Distance to hospital too long and 
costly’; 0.431 (95% CI 0.298, 0.624) for ‘Ran out of pills’; 0.397 (95% CI  0.274, 0.574) 
for ‘Away from home’; and 0.353 (95% CI  0.242, 0.515) for the variable ‘Had simply 
many pills’. In general, all of the significant reasons for missing HIV medication had 
shown odds ratios of approximately less than one, which indicates that the presence of 
these reasons causes patients not to adhere to their HIV medication. 
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Table 5-37: Reasons for missing medications and TDM status for three specific drugs as detected by LC-MS/MS machine (n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Simply forget      
      Yes 
       No 
125 (55.8) 
320 (79.8) 
99 (44.2) 
81 (20.2) 
0.319 
(0.223, 0.458) 
117 (55.7) 
277 (77.8) 
93 (44.3) 
79 (22.2) 
0.359 
(0.248, 0.519) 
97 (49.0) 
202 (67.8) 
101 (51.0) 
96 (32.2) 
 
0.452 
(0.312, 0.654) 
Cost of treatment too 
high 
       Yes 
       No  
115 (56.1) 
330 (78.6) 
90 (43.9) 
90 (21.4) 
0.349 
(0.243, 0.500) 
107 (56.3) 
287 (76.3) 
83 (43.7) 
89 (23.7) 
0.340 
(0.275, 0.580) 
81 (46.3) 
218 (67.9) 
94 (53.7) 
103 (32.1) 
0.407 
(0.279, 0.594) 
 Distance to hospital    
  too long and costly 
       Yes 
       No 
113 (60.8) 
332 (75.6) 
73 (39.2) 
107 (24.4) 
0.499 
(0.346, 0.720) 
112 (63.3) 
282 (72.5) 
65 (36.7) 
107 (27.5) 
0.654 
(0.448, 0.954) 
82 (52.6) 
217 (63.8) 
74 (47.4) 
123 (36.2) 
0.628 
(0.428, 0.922) 
 
Busy with other 
things 
       Yes 
       No 
93 (66.4) 
352 (72.6) 
47 (33.6) 
133 (27.4) 
0.748  
(0.499, 1.119) 
105 (70.5) 
289 (69.3) 
44 (29.5) 
128 (30.7) 
0.010 
(0.008, 0.014) 
83 (64.3) 
216 (58.9) 
46 (35.7) 
151 (41.1) 
1.261 
(0.832, 1.912)  
Run out of pills 
       Yes 
       No 
103 (58.2) 
342 (76.3) 
74 (41.8) 
106 (23.7) 
0.431 
(0.298, 0.624) 
200 (71.2) 
194 (68.1) 
81 (28.8) 
91 (31.9) 
1.158 
(0.809, 1.658) 
112 (54.9) 
187 (64.0) 
92 (45.1) 
105 (36.0) 
0.684 
(0.475, 0.985) 
Away from home 
       Yes 
       No 
100 (56.8) 
345 (76.8) 
76 (43.2) 
104 (23.2) 
0.397 
(0.274, 0.574) 
89 (53.3) 
305 (76.4) 
78 (46.7) 
94 (23.6) 
0.352 
(0.240, 0.515) 
70 (45.2) 
229 (67.2) 
85 (54.8) 
112 (32.8) 
0.403 
(0.273,  0.594) 
Had simply many 
pills  
       Yes 
       No 
 
88 (54.3) 
357 (77.1) 
 
74 (45.7) 
106 (22.9) 
 
0.353 
(0.242, 0.515) 
 
75 (49.3) 
319 (77.1) 
 
77 (50.7) 
95 (22.9) 
 
0.290 
(0.196, 0.429) 
 
65 (43.6) 
234 (67.4) 
 
84 (56.4) 
113 (32.6) 
 
0.374 
(0.252, 0.554) 
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Table 5.38 shows the results of cross tabulation of reasons for missing HIV medication and 
TDM method for detecting Efavirenz, Nevirapine and Lamivudine level using the LC-
MS/MS machine. Variables ‘Fell asleep during dose time’, ‘Did not want others to notice 
taking medicine’, ‘Had a change in daily routine’, ‘Wanted to avoid side effects’, and ‘Felt 
depressed’ were found to be statistically significant with the TDM level of the three TDM 
drugs (Efavirenz, Nevirapine and Lamivudine). Variables ‘Felt like drug was toxic’ and 
‘Felt sick or ill’ were found to not have a statistically significant effect to all the three TDM 
levels as measured by LC-MS/MS machine. The variables ‘Had a change in daily routine’ 
and ‘Wanted to avoid side effects’ were not statistically significant in analysis of 
Nevirapine, & Lamivudine data. 
 
Lamivudine model has the most number of non-significant variables (four). Nevirapine, 
with three non-significant variables, is at the second spot while Efavirenz has the smallest 
number of non-significant variables (two). The variables ‘Fell asleep during dose time’ and 
‘Did not want others to notice taking medicine’ had shown relatively smaller and similar 
odds ratios of around 0.2 to 0.3. On the other hand, the variable ‘Felt depressed’ had a 
slightly bigger odds ratio compared to the other reasons for missing medication; the odds 
ratio of this variable was 0.320 (95% CI 0.219, 0.468) for Efavirenz, 0.268 (95% CI 0.181, 
0.397) for Nevirapine and 0.331 (95% CI 0.222, 0.493) for Lamivudine.  
 
In general, all significant reasons for missing HIV medication had shown approximately 
odds ratios of less than one, which indicates that these reasons were negatively associated 
with the overall adherence level. In other words, these factors would decrease the level of 
adherence to HAART. 
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Table 5-38: Reasons for missing medications and TDM status for three specific drugs as detected by LC-MS/MS machine (n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Fell asleep during 
dose time  
       Yes 
       No  
61 (42.4) 
384 (79.8) 
83 (57.6) 
97 (20.2) 
0.186 
(0.125, 0.277) 
64 (45.7) 
330 (77.5) 
76 (54.3) 
96 (22.5) 
0.245 
(0.164, 0.366) 
51 (38.9) 
248 (67.9) 
80 (61.1) 
117 (32.1) 
0.301 
(0.199, 0.455) 
Did not wanted 
others to notice 
taking medicine  
       Yes 
       No 
61 (45.9) 
384 (78.0) 
72 (54.1) 
108 (22.0) 
0.238 
(0.159, 0.356) 
58 (43.6) 
336 (77.6) 
75 (56.4) 
97 (22.4) 
0.223 
(0.148, 0.337) 
49 (38.3) 
250 (67.9) 
79 (61.7) 
118 (32.1) 
0.293 
(0.193, 0.445) 
 Had a change in 
daily routine 
       Yes 
       No 
87 (60.8) 
358 (74.3) 
56 (39.2) 
124 (25.7) 
0.538 
(0.363, 0.797) 
107 (65.2) 
287 (71.4) 
57 (34.8) 
115 (28.6) 
0.752 
(0.511, 1.108) 
73 (54.1) 
226 (62.6) 
62 (45.9) 
135 (37.4) 
0.703 
(0.471, 1.049) 
Felt like drug was 
toxic 
       Yes 
       No 
42 (68.9) 
403 (71.5) 
19 (31.1) 
161 (28.5) 
0.883 
(0.498, 1.565) 
47 (67.1) 
347 (70.0) 
23 (32.9) 
149 (30.0) 
0.877 
(0.514, 1.497) 
36 (60.0) 
263 (60.3) 
24 (40.0) 
173 (39.7) 
0.987 
(0.569, 1.712) 
Wanted to avoid side 
effects 
       Yes 
       No 
96 (56.5) 
349 (76.7) 
74 (43.5) 
106 (23.3) 
0.394 
(0.271, 0.572) 
96 (59.3) 
298 (73.8) 
66 (40.7) 
106 (26.2) 
0.528 
(0.360, 0.772) 
90 (57.3) 
209 (61.7) 
67 (42.7) 
130 (38.3) 
0.836 
(0.569, 1.227) 
Felt sick or ill 
       Yes 
       No 
39 (68.4) 
406 (71.5) 
18 (31.6) 
162 (28.5) 
0.864 
(0.480, 1.556) 
37 (68.5) 
357 (69.7) 
17 (31.5) 
155 (30.3) 
0.945 
(0.516, 1.729) 
32 (65.3) 
267 (59.7) 
17 (34.7) 
180 (40.3) 
1.269 
(0.684, 2.354) 
Felt depressed  
       Yes 
       No 
85 (53.5) 
360 (77.3) 
74 (46.5) 
106 (22.7) 
0.320 
(0.219, 0.468) 
73 (48.0) 
321 (77.5) 
79 (52.0) 
93 (22.5) 
0.268 
(0.181, 0.397) 
61 (41.5) 
238 (68.2) 
86 (58.5) 
111 (31.8) 
0.331 
(0.222, 0.493) 
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Table 5.39 shows other results of cross tabulation of reasons for missing HIV medication 
and TDM method for detecting Efavirenz, Nevirapine and Lamivudine level using the LC-
MS/MS machine. The variables ‘Felt well’ and ‘Treatment & drug collection time too long’ 
were found to be statistically significant with the TDM level of the three TDM drugs 
(Efavirenz, Nevirapine and Lamivudine). The variable ‘Beliefs and preference for 
traditional medicine’ was found as not statistically significant in all three TDM levels based 
on the LC-MS/MS machine. Variables ‘Had problems taking medicine at specific time’, 
‘Poor relationship with health provider’ and ‘Religious belief’ were reported as not 
statistically significant in Nevirapine & Lamivudine. 
 
Lamivudine and Nevirapine models have the highest number of non-significant variables 
(four), while Efavirenz has the smallest number of non-significant variables. The variable 
‘Treatment & drug collection time too long’ had relatively bigger odds ratio compared to 
other reasons for missing medication; the odds ratio of this variable was 0.410 (95% CI  
0.281, 0.597) for Efavirenz, 0.345 (95% CI 0.234, 0.508) for Nevirapine and 0.382 (95% 
CI 0.257, 0.566) for Lamivudine. In general, all significant reasons for missing HIV 
medication in this table had shown approximately odds ratios of less than one, which 
indicates that these reasons were negatively associated with the overall adherence level. In 
a nutshell, these factors would decrease the level of adherence to HAART. 
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Table 5-39: Reasons for missing medications and TDM status for three specific drugs as detected by LC-MS/MS machine (n =925) 
  TDM status of Efavirenz TDM status of Nevirapine TDM status of Lamivudine 
Factor Positive Negative 
OR (95% CI) 
(Efaviranz) Positive Negative 
OR (95% CI) 
(Nevirapine) Positive Negative 
OR (95% CI) 
(Lamivudine) 
Felt well  
       Yes 
       No  
87 (52.4) 
358 (78.0) 
79 (47.6) 
101 (22.0) 
0.311 
(0.213, 0.453) 
81 (48.5) 
313 (78.4) 
86 (51.5) 
86 (21.6) 
0.259 
(0.176, 0.381) 
64 (40.8) 
235 (69.3) 
93 (59.2) 
104 (30.7) 
0.486 
(0.307, 0.769) 
Had problems taking 
medicine at specific 
time  
       Yes 
       No 
43 (66.2) 
402 (71.8) 
22 (33.8) 
158 (28.2) 
0.768 
(0.445, 0.278) 
55 (68.8) 
339 (69.8) 
25 (31.2) 
147 (30.2) 
0.954 
(0.572, 1.590) 
39 (56.5) 
260 (60.9) 
30 (43.5) 
167 (39.1) 
0.835 
(0.499, 1.396) 
 Religious belief 
       Yes 
       No 
33 (55.0) 
412 (72.9) 
27 (45.0) 
153 (27.1) 
0.264 
(0.264, 0.780) 
38 (65.5) 
356 (70.1) 
20 (34.5) 
152 (29.9) 
0.811 
(0.457, 1.440) 
29 (56.9) 
270 (60.7) 
22 (43.1) 
175 (39.3) 
0.854 
(0.476, 1.535) 
Treatment and drug 
   collection time too  
   long 
       Yes 
       No 
92 (56.8) 
353 (76.2) 
70 (43.2) 
110 (23.8) 
0.410 
(0.281, 0.597) 
83 (52.5) 
311 (76.2) 
75 (47.5) 
97 (23.8) 
0.345 
(0.234, 0.508) 
65 (43.9) 
234 (67.2) 
83 (56.1) 
114 (32.8) 
0.382 
(0.257, 0.566) 
Poor relationships 
  with health provider 
       Yes 
       No 
133 (67.9) 
272 (73.2) 
112 (32.1) 
68  (26.8) 
0.297 
(0.206, 0.428) 
129 (71.9) 
265 (67.8) 
102 (28.1) 
70 (32.2) 
0.334 
(0.231, 0.484) 
136 (62.4) 
163 (58.6) 
82 (37.6) 
115 (41.4) 
1.170 
(0.814, 1.683) 
Beliefs and preference 
for traditional 
medicine 
       Yes 
       No 
25 (62.5) 
420 (71.8) 
15 (37.5) 
165 (28.2) 
0.655 
(0.337, 1.273) 
30 (65.2) 
364 (70.0) 
16 (34.8) 
156 (30.0) 
0.8036 
(0.426, 1.516) 
21 (58.3) 
278 (60.4) 
15 (41.7) 
182 (39.6) 
0.917 
(0.460, 1.824) 
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Table 5.40 below presents the summary of the results of cross-tabulations for four methods 
of assessing the level of adherence to HAART (HIV adherence predictors): 1) adherence 
level measured by overall self-reported questionnaire; 2) adherence level measured by 
TDM level for Efavirenz; 3) adherence level measured by TDM level for Nevirapine; and 
4) adherence level measured by TDM level of Lamivudine.  
 
The side effect variables - ‘Rash’, ‘Itching’, ‘Diarrhoea’, ‘Vomiting’ and ‘Fever’ - are 
significant predictors for adherence to HAART based on all four models. The variables 
‘Loss of appetite’ and ‘Tiredness’ were found to be insignificant in TDM for Lamivudine 
method and TDM for Nevirapine method respectively. Variables ‘Dry mouth’ and 
‘Headache’ were found to be insignificant according to all four methods of assessing the 
adherence level of HIV medication (HAART). Regarding  the use of alternative medication 
by patients, variables ‘Use of dietary supplement’, ‘Use of religious treatment’, ‘Use of 
acupuncture’ and ‘Use of herbal medicine’ were found to be significant predictors for 
adherence to HAART based on all four methods. On the other hand, the variable ‘Use of 
body mind therapy’ was found to be significant only in the self-reported questionnaire and 
insignificant in the other three TDM methods. Only the variable ‘Use of Yoga’ as an 
alternative medication to HAART was found as insignificant in all four methods of 
assessing the adherence level to HIV medication (HAART). 
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 The cross-tabulation results of the reasons facilitating adherence to HAART using the four 
methods of assessing adherence level mentioned previously are as follows: the variables 
‘Use of alarm clock’, ‘Belief in the efficacy of pills’, and ‘Self-efficacy to adhere to 
medication’ were found to be significant predictors to all four methods of assessing the 
adherence level to HIV medication. The variable ‘Acceptance of HIV status’ was found to 
be insignificant in TDM for Efavirenz and TDM for Lamivudine, while the variables 
‘Afraid of drug resistance’ and ‘Disclosure about HIV status’ were found to be insignificant 
in TDM Nevirapine and TDM Lamivudine respectively. The variables ‘Avoid paying for 
new drugs’ and ‘The need to care for others’ were found to be insignificant in all of the 4 
methods of assessing adherence level of HAART. 
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         Table 5-40: Factors affecting adherence to HAART (adherence predictors) using four different methods (n =925) 
Categories Factor OSRAQ 
TDM 
Efaviranz 
TDM 
Nevirapine 
TDM 
Lamivudine 
Sign. 
Level 
Adverse effect of treatment Rash Yes Yes Yes Yes 4 
Adverse effect of treatment Itching Yes Yes Yes Yes 4 
Adverse effect of treatment Appetite Yes Yes Yes No 3 
Adverse effect of treatment Dry Mouth No No No No 0 
Adverse effect of treatment Diarrhoea Yes Yes Yes Yes 4 
Adverse effect of treatment Tiredness Yes Yes No Yes 3 
Adverse effect of treatment Vomiting Yes Yes Yes Yes 4 
Adverse effect of treatment Fever Yes Yes Yes Yes 4 
Adverse effect of treatment Headache No No No No 0 
Use of Alternative Medication  Use of Dietary supplement Yes Yes Yes Yes 4 
Use of Alternative Medication  Use of Religious treatment Yes Yes Yes Yes 4 
Use of Alternative Medication  Use of Yoga No No No No 0 
Use of Alternative Medication  Use of Acupuncture Yes Yes Yes Yes 4 
Use of Alternative Medication  Use of body mind therapy Yes No No No 1 
Use of Alternative Medication  Use of Herbal Medicine Yes Yes Yes Yes 4 
Reasons Facilitating Adherence Use of Alarm/ clock Yes Yes Yes Yes 4 
Reasons Facilitating Adherence Acceptance of HIV status Yes No Yes No 2 
Reasons Facilitating Adherence To avoid paying for new drugs No No No No 0 
Reasons Facilitating Adherence Belief in the efficacy of pills Yes Yes Yes Yes 4 
Reasons Facilitating Adherence Self-efficiency Yes Yes Yes Yes 4 
Reasons Facilitating Adherence Afraid of drug resistance Yes Yes No Yes 3 
Reasons Facilitating Adherence Disclosure Yes Yes Yes No 3 
Reasons Facilitating Adherence The need to care for others No No No No 0 
         Total ‘Yes:                                                                                                 18                 16                15                   14 
            OSRAQ = Overall Self-Reported Adherence questionnaire, TDM for Efavirenz  =Therapeutic Drug Monitoring for Efavirenz, Adverse effect = Adverse effect to HAART 
            TDM for Nevirapine = Therapeutic Drug Monitoring for Nevirapine, TDM for Lamivudine =Therapeutic Drug Monitoring for Lamivudine 
            4 = Variable is predictor of adherence level to HAART by all the four methods above, 3 = variable is predictor of adherence to HAART by 3 methods 
            2 = Variable is predictor of adherence level to HAART by two methods, 1 = variable is predictor of adherence to HAART by one method only. 0 = variable is not predictor of  
            adherence 
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Table 5.41 below shows the cross tabulation results of the reasons for missing medication 
and also four methods to assess the level of adherence to HAART. The variables ‘Simply 
forgot’, ‘Cost of treatment too high’, ‘Away from home’, ‘Had many pills’, ‘Fell asleep 
during dose time’, ‘Stigma’, ‘Felt depressed’, ‘Felt well’, and ‘Drug collection time too long’ 
were found to be significant predictors of all the four methods of assessing the level of 
adherence to HAART. The variables ‘Wanted to avoid side effects’ and ‘Poor relationship 
with health care provider’ are significant in only the following three methods: overall self-
reported questionnaire, TDM for Efavirenz and TDM for Nevirapine.  
 
The variables ‘Distance to hospital too long’, ‘Ran out of pills’, and ‘Had a change in daily 
routine’ are found to be insignificant in two models – TDM for Nevirapine and TDM for 
Lamivudine methods. The variables ‘Had problems at specific time’, and ‘Religious belief’ 
are not significant in the following three methods: overall self-reported questionnaire, TDM 
for Nevirapine and TDM for Lamivudine data. The variables ‘Busy with other things’, ‘Felt 
like drug was toxic’, ‘Felt sick or ill’, and ‘Beliefs of traditional medicine’ were found to be 
insignificant in all four methods of assessing the adherence level to HIV medication. 
 
The result of the cross-tabulation of 43 factors with four different methods of measuring 
adherence to HAART shows the following: Twenty-three factors were strong predictors of 
adherence as measured by all four methods of measuring adherence to HAART; four factors 
were predictors of adherence according to three methods; four other factors were predictors 
of adherence as confirmed by two methods  and other eight factors were shown not to be 
predictors of adherence to HAART as they were found insignificant by all four methods of 
measuring adherence.  
  175 
 
 
           Table 5-41: Factors affecting adherence to HAART (adherence predictors) using four different methods (n =925) 
Categories Factor OSRAQ  
TDM 
Efaviranz 
TDM 
Nevirapine 
TDM 
Lamivudine 
Sign. 
Level 
Reasons for missing medic. Simply forget  Yes Yes Yes Yes 4 
Reasons for missing medic. Cost of treatment too high Yes Yes Yes Yes 4 
Reasons for missing medic. Distance to hospital too long Yes Yes No No 2 
Reasons for missing medic. Busy with other things No No No No 0 
Reasons for missing medic. Run out of pills Yes Yes No No 2 
Reasons for missing medic. Away from home Yes Yes Yes Yes 4 
Reasons for missing medic. Had simply many pills Yes Yes Yes Yes 4 
Reasons for missing medic. Fell asleep during dose time Yes Yes Yes Yes 4 
Reasons for missing medic. Stigma Yes Yes Yes Yes 4 
Reasons for missing medic. Had a change in daily routine Yes Yes No No 2 
Reasons for missing medic. Felt like drug was toxic No No No No 0 
Reasons for missing medic. Wanted to avoid side effects Yes Yes Yes No 3 
Reasons for missing medic. Felt sick or ill No No No No 0 
Reasons for missing medic. Felt depressed Yes Yes Yes Yes 4 
Reasons for missing medic. Felt well Yes Yes Yes Yes 4 
Reasons for missing medic. Had problems at specific time No Yes No No 1 
Reasons for missing medic. Religious belief No Yes No No 1 
Reasons for missing medic. Drug collection time too long Yes Yes Yes Yes 4 
Reasons for missing medic. Poor relationships with provider Yes Yes Yes No 3 
Reasons for missing medic. Beliefs of traditional medicine No No No No 0 
                 Total Yes                                                    14                 16               11                   9 
 
               OSRAQ = Overall Self-Reported Adherence questionnaire, TDM for Efavirenz  =Therapeutic Drug Monitoring for Efavirenz,  
               TDM for Nevirapine = Therapeutic Drug Monitoring for Nevirapine, TDM for Lamivudine =Therapeutic Drug Monitoring for Lamivudine 
Reasons for missing medic = Reasons for missing HIV medications. 4 = Variable is predictor of adherence level to HAART by all  the four methods above, 3 = variable is                        
predictor of adherence to HAART by 3 methods.  2 = Variable is predictor of adherence level to HAART by two methods, 1 = variable is predictor of adherence to 
                  HAART by one method only. 0 = variable is not predictor of adherence 
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5.9 Multiple logistic regressions models 
This section is about the interpretation & reporting of four logistic regression models. 
These models assessed the factors that affect adherence towards HIV medication using 
the following dependent variables: overall self-reported adherence questionnaire, TDM 
level for Efavirenz, TDM level for Nevirapine and TDM level for Lamivudine. The 
independent variables used were: socio-demographic characteristics, reasons for missing 
medication, factors facilitating adherence, use of alternative medication and adverse 
effects of HIV treatment. Table 5.42 below shows the model building stages of the first 
model; this model was the best-fit model that could be used to explain the dependent 
variable ‘Adherence of HIV medication as measured by the overall self-reported 
adherence questionnaire’. This table uses the forward variable selection technique, which 
sequentially selects variables with the smallest log likelihood ratio and an acceptable 
Hosmer –Lemshow statistic. 
 
Table 5-42: Forward Adding Model building stages for adherence / non-adherence as 
measured by overall self-reported questionnaire (n =925)  
Variable 2 Log likelihood Difference 
Hosmer-Lemshow 
Chi-Square Sig. 
Diarrhoea 731.417   
  Vomiting 659.369 72.048 1.535 0.464 
Use of religious treatment 540.612 118.757 5.126 0.275 
Use of herbal medicine 467.124 73.488 8.53 0.129 
Use of Alarm/ Clock 422.917 44.207 14.088 0.051 
Acceptance of HIV status 386.465 36.452 3.747 0.808 
Self-efficiency  370.433 16.032 5.88 0.661 
Simply forgot 321.734 48.699 14.734 0.065 
Distance to hospital too long & costly 300.392 21.342 7.266 0.508 
Educational level 273.285 27.107 1.889 0.984 
Age 250.914 22.371 2.903 0.94 
Income 224.971 25.943 7.59 0.474 
Self-efficacy = Self-efficiency to take & adhere to medication 
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Table 5.43 below goes into the heart of the results. After evaluating the forward adding 
variable, the best and most parsimonious model of the overall adherence/non-adherence 
to HIV medication as measured using the overall self-reported adherence questionnaire is 
summarized in table 5.43. In the beginning, we evaluated 48 variables in our modeling. 
Then, after making adjustments based on the Hosmer-Lemshow approach, we obtained 
twelve variables that actually had effect and improved the fitness of the model. The 
twelve variables in the table are the final multivariate variables that can explain the 
overall adherence / non-adherence of HIV medication as measured by the self-reported 
adherence questionnaire. The variables were ‘Diarrhoea’, ‘Vomiting’, ‘Use of religious 
treatment’, ‘Use of herbal medicine’, ‘Use of alarm /clock’, ‘Acceptance of HIV status’, 
‘Self-efficacy to take & adhere to medication’, ‘Simply forgot’, ‘Distance to hospital too 
long and costly’, ‘Education’, ‘Age of the patient in categories’ and ‘Income status’.  
 
Based on our findings, patients who experienced side effects such as diarrhoea and 
vomiting  which resulted from antiretroviral treatment were  less likely to be adherent to 
HIV medication with an OR of 0.081, (95% CI 0.034, 0.192) and OR of 0.131, (95% CI 
0.058, 0.294) respectively. Also, patients using alternative medication such as religious 
treatment and herbal medicine were less likely to be adherent to the antiretroviral drugs 
with an OR of 0.067 (95% CI 0.027, 0.165) and OR of 0.227 (95% CI 0.103, 0.501) 
respectively.  Reasons facilitating adherence to treatment such as ‘Use of alarm /clock’, 
‘Self-efficacy to adhere’ and ‘Acceptance of HIV status’  all had a positive relationship 
with adherence to antiretroviral  medication with OR values as follows: 6.712 (95% CI 
2.747, 16.397), 4.711 (95% CI 2.062, 10.76), and 4.727 (95% CI 1.96, 11.403) 
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respectively. This positive relationship means that these facilitating factors increase 
patients’ level of adherence to HAART. 
 
The variables ‘Simply forgot’ and ‘Distance to hospital too long and costly’ were 
significant reasons for missing medication; these variables had a negative relationship 
with the adherence towards HIV antiretroviral drugs with an OR of 0.08 (95% CI 0.033, 
0.197) and 0.264 (95% CI 0.111, 0.632) respectively. The negative relationship means 
that these two reasons will decrease the level of adherence to HAART in patients who 
consider them as reasons for missing medication.  
 
Among the demographic variables, educational level , patients who belong to the 31 – 44 
years of age and patients whose income are in the 1,500 – 2,500 and 2,501 – 10,000 
categories were  more likely to be adherent with  OR of 1.43 (95% CI 1.108, 1.844), 
5.119 (95% CI 2.159, 12.14), 6.139 (95% CI 2.289, 16.465) and 9.993 (95% CI 3.175, 
31.454) respectively. This implies that the above-mentioned factors increase the level of 
adherence to HAART. Besides the twelve variables, there are 36 other factors which are 
found to be significant in the univariate analysis but not significant in the multivariate 
analysis. These variables were reported in the cross-tabulation section earlier (Section 
5.7).   
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The researcher had checked all possible two-way interactions one at a time, and found no 
significant interaction effect in the above model. Thus, the variables in Table 5.42 or 
Table 5.43 best explain the dependent variable ‘Adherence of HIV medication as 
measured by the overall self-reported questionnaire’. Interpretation of the independent 
variables was based on the right most columns in Table 5.38, labelled "Exp (B)". More 
information about the interpretation and discussion are presented in Chapter 6 
(discussion). 
Table 5-43: Model I overall adherence/non-adherence measured by self-reported 
questionnaire (n =925) 
Variables (Yes versus No) Crude odd ratio Adjusted Odds ratio 
(95% CI) 
Diarrhoea (Yes versus No) 0.107 (0.074, 0.155) 0.081 (0.034, 0.192) 
Vomiting (Yes versus No)  0.099 (0.068, 0.144) 0.131 (0.058, 0.294) 
Use of religious treatment (Yes versus No) 0.071 (0.049, 0.105) 0.067 (0.027, 0.165) 
Use of herbal medicine (Yes versus No) 0.302 (0.214, 0.426) 0.227 (0.103, 0.501) 
Use of Alarm /Clock (Yes versus No) 7.057 (4.445, 11.205) 6.712 (2.747, 16.397) 
Self efficacy to adhere (Yes versus No) 12.527 (8.459, 18.551) 4.711 (2.062, 10.761) 
 Acceptance of HIV status (Yes versus No) 5.687 (3.989, 8.106) 4.727 (1.960, 11.403) 
Simply forget (Yes versus No) 0.160 (0.111, 0.230) 0.080 (0.033, 0.197) 
Distance to travel too long (Yes versus No) 0.240 (0.170, 0.340) 0.264 (0.111, 0.632) 
Education level (Yes versus No) 0.986 (0.898, 1.084) 1.430 (1.108, 1.844) 
Age 18 – 30  Reference Group Reference Group 
Age 31 – 44  5.765 (3.554, 9.352) 5.119 (2.159, 12.14) 
Age 45 or more 0.880 (0.492, 1.575) 1.077 (0.388, 2.990) 
Income  ≤ RM 1,500 / month Reference Group  Reference Group 
Income  RM 1,501 – 2,500 3.109 (1.620, 5.192) 6.139 (2.289, 16.465) 
Income  RM 2,501 – 10,000 4.088 (2.151, 7.152) 9.993 (3.175, 31.454) 
Constant  3.673 
Self-efficacy to adhere = Self-efficacy to take & adhere to medication 
Distance to travel too long = Distance to hospital too long and costly 
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Figure 5.5 shows the ROC curve of the logistic regression model using the Overall Self-
Reported Questionnaire results; it offers an excellent visual comparison of the models' 
performances. As we can observe, the curve is above the diagonal line, which indicates 
that the model performs well. The area under the curve (AUC) of this model was 
approximately 0.92 (95% CI 0.895, 0.941). This means that the model can predict 92% of 
the outcomes correctly. In other words, the predicted logistic regression model reports 
more adherence level compared to the threshold of self-reported questionnaire reports. 
The ROC curve tells us how well the model predicts adherence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5 Receiver Operating Characteristic curve of the logistic regression for 
comparing the models' performance of overall self-reported adherence questionnaire 
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Table 5.44 below shows the model building stages of the second model; it uses the 
forward adding variable technique which sequentially selects the variables with the 
smallest log likelihood ratio and an acceptable Hosmer –Lemshow statistic. This model is 
the best-fit model to explain the dependent variable ‘Adherence to HIV medication as 
measured by TDM for Efavirenz using the LC-MS/MS machine’. The table provides the 
following information: description of the variables, -2 log likelihood ratio, deviance, and 
Hosmer-Lemshow statistics (chi-square value and its corresponding significance level). 
 
Table 5-44: Forward Adding Model building stages of Adherence / non-adherence as 
measured by TDM for Efaviranz (n = 791) 
Variable 2 Log likelihood Difference 
Hosmer-Lemshow 
Chi-Square Sig. 
Diarrhoea 715.119 
   Vomiting 701.389 13.73 0.151 0.927 
Use of Religious treatment 675.384 26.005 1.511 0.68 
Use of Dietary supplement 658.649 16.735 5.961 0.202 
Use of Alarm / Clock 644.373 14.276 7.218 0.301 
Belief in efficiency  625.489 18.884 5.921 0.549 
Simply forget 604.729 20.760 9.529 0.300 
Felt sleep during dose time 583.994 20.735 12.864 0.117 
Age 557.429 26.565 7.832 0.45 
      RFA –Belief = Belief in the efficacy of pills,  
 
After the evaluation of the forward adding variable of model II, the best and the most 
parsimonious model of the adherence/non-adherence of HIV medication as measured by 
TDM level of Efavirenz was summarized in Table 5.44. In the beginning, we evaluated 
48 variables in the modeling, but after making adjustments based on Hosmer-Lemshow 
approach, we obtained nine variables that have effects on the model. These nine variables 
presented in the table are the final multivariate variables that can explain the adherence/ 
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non-adherence of HIV medication as measured by TDM level of Efavirenz. The variables 
are ‘Diarrhoea’, ‘Vomiting’, ‘Use of religious treatment as alternative treatment for HIV’, 
‘Use of dietary supplements as alternative treatment’, ‘Use of alarm/clock’, ‘Belief in the 
efficacy of pills’, ‘Simply forgot’, ‘Felt asleep during dose time’ and ‘Age of the patient 
in categories’.  
 
It was found that when patients have considered diarrhoea and vomiting as adverse 
effects of antiretroviral drugs, they were less likely to be adherent to HIV medication 
with an OR of 0.667 (95% CI 0.393, 1.134) and 0.613 (95% CI 0.36, 1.046) respectively. 
Also, Patients using alternative medication such as religious treatment and dietary 
supplements as an alternative treatment are less likely to be adherent to their 
antiretroviral drugs with an OR of 0.547 (95% CI 0.321, 0.934) and 0.812 (95% CI 0.458, 
1.34) respectively. Reasons facilitating adherence such as ‘Use of alarm/clock’ and 
‘Belief in the efficacy of pills’ have a positive relationship with adherence to the HIV 
antiretroviral drugs with an OR of 2.107 (95% CI 1.336, 3.323) and 2.169 (95% CI 1.357, 
3.468) respectively. This implies that these reasons increase patient’s adherence level to 
their antiretroviral treatment. 
 
The variables ‘Simply forgot’ and ‘Felt asleep during dose time’ were shown to be 
significant reasons for missing medication; these variables have a negative relationship 
with the adherence towards HIV antiretroviral drugs with an OR of 0.501 (95% CI of 
0.319, 0.787) and 0.323 (95% CI of 0.198, 0.526) respectively. This negative relationship 
means that these reasons will decrease patients’ level of adherence to HAART. Among 
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the demographic variables, patients who belonged to the categories of 18 – 30 and 31 – 
44 years significantly contributed towards the adherence to HIV medication. Patients 
aged 31 – 44 were more likely to be more adherent with an OR of 2.457 (95% CI 1.451, 
4.159) compared to the base age group, 18 – 30 years. Age group III (45 years and above) 
did not significantly contribute towards the adherence to HIV medication. There were 39 
factors which were significant in the univariate analysis but not significant among the 
nine significant factors in the multivariate analysis. These variables were also reported in 
the above cross-tabulation, Section 5.7. 
 
Table 5-45: Forward Adding Model (III) building stages of Adherence / non-adherence 
as measured by TDM level for Efaviranz (n =791) 
Variables (Yes versus No) Crude Odds ratio 
(95% CI) 
Adjusted Odds ratio 
(95% CI) 
Diarrhoea (Yes versus No) 0.303 (0.205, 0.449) 0.667 (0.393, 1.134) 
Vomiting  (Yes versus No) 0.305 (0.206, 0.453) 0.613 (0.360, 1.046) 
Religious treatment (Yes versus No) 0.239 (0.160, 0.358) 0.547 (0.321, 0.934) 
Dietary supplement (Yes versus No) 0.224 (0.15, .336) 0.812 (0.458, 1.340) 
RFA-Use of Alarm / Clock (Yes versus No) 3.333 (2.288, 4.855 2.107 (1.336, 3.323) 
RFA-Belief in efficiency (Yes versus No) 3.489 (2.383, 5.109) 2.169 (1.357, 3.468) 
RMM-Simply forgot (Yes versus No) 0.320 (0.223, 0.458) 0.501 (0.319, 0.787) 
RMM-Slept during dose time (Yes versus No) 0.186 (0.125, 0.277) 0.323 (0.198, 0.526) 
Age 18 – 30  Reference Group Reference Group 
Age 31 – 44  2.286 (1.510, 3.460) 2.457 (1.451, 4.159) 
Age 45 or more 0.622 (0.389, 0.994) 1.109 (0.671, 1.832) 
Constant  2.139 
RFA – Belief = Belief in the efficacy of pills,  
RMM –Slept= Felt asleep during dose time. 
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Figure 5.6 shows the ROC curve of the logistic regression model using the results of 
TDM level for Efavirenz model. It offers an excellent visual comparison of the models' 
performances. As we can observe, the curve is above the diagonal line, which indicates 
that the model performs well. This means that 79% of the patients would have a higher 
chance of adhering to their HIV medication (as indicated by the predicted model of the 
overall self-reported questionnaire) than not adhering to it.  The area under the curve 
(AUC) of this model is approximately 0.79 (95% CI of 0.773, 0.852). This means the 
model is able to predict 79% of outcomes accurately.  
 
 
 
Figure 5-6 Receiver Operating Characteristic curve of the logistic regression for 
comparing the models' performance of TDM level for Efaviranz (n =791) 
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Table 5.46 below shows the model building stages of the third model; it uses the forward 
adding variable technique which sequentially selects the variables with the smallest log 
likelihood ratio and an acceptable Hosmer –Lemshow statistic. This model is the best-fit 
model to explain the dependent variable of ‘Adherence of HIV medication as measured 
by TDM level for Nevirapine’. The table provides the following information: description 
of the variables, -2 log likelihood ratio, deviance, and Hosmer-Lemshow statistics (chi-
square value & its corresponding p-value). 
 
Table 5-46: Forward Adding Model (III) building stages of Adherence / non-adherence 
as measured by TDM level for Nevirapine ( n=653) 
Variables 2 Log_likelihood Difference 
Hosmer-Lemshow 
Chi-Square Sig. 
Diarrhoea 662.781   
  Vomiting 638.69 24.091 0.263 0.877 
Use of Religious treatment  613.804 24.886 1.017 0.907 
Use of Dietary supplement 602.158 11.646 5.285 0.259 
Use of Alarm / Clock 585.590 16.568 5.976 0.309 
Afraid of my health getting worse  563.119 22.471 8.577 0.284 
RMM_ Felt asleep during dose time 540.625 22.494 4.928 0.669 
Income 501.660 38.965 11.835 0.159 
Marital status 479.637 22.023 7.920 0.246 
Acceptance of HIV = Acceptance of HIV status, 
RMM – Slept = Felt asleep during dose time. 
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After an evaluation of the forward adding variable of model III, the best and the most 
parsimonious model of the adherence /non-adherence to HIV medication as measured by 
TDM level of Nevirapine was summarized in Table 5.46. In the beginning, we evaluated 
48 variables in the modeling, but after making adjustments based on the Hosmer-
Lemshow approach, we obtained nine variables that have effects on the model. These 
nine variables are the final multivariate variables that can explain the adherence/non-
adherence to HIV medication as measured by TDM level of Nevirapine. The variables 
are ‘Diarrhoea’, ‘Vomiting’, ‘Use of religious treatment as alternative treatment for HIV’, 
‘Use of dietary supplements as alternative treatment’, ‘Use of alarm/clock’, ‘Acceptance 
of HIV status’, ‘Fell asleep during dose time’, ‘Income’ and ‘Marital status’. 
 
Based on our findings, when patients considered diarrhoea and vomiting as side effects of 
antiretroviral drugs, they were less likely to be adherent to HIV medication with an OR of 
0.590 (95% CI 0.346, 1.006) and 0.454( 95% CI 0.261, 0.788) respectively. This means 
that diarrhoea and vomiting decrease patients’ adherence to their antiretroviral treatment. 
Patients using alternative medication such as religious treatment and dietary supplements 
as an alternative treatment are less likely to be adherent to the antiretroviral drugs with an 
OR of 0.389 (95% CI 0.224, 0.676) and 0.729 (95% CI 0.413, 1.087) respectively. This 
implies that the use of these types of alternative medication decreases the level of 
adherence to HAART. Reasons facilitating adherence such as ‘Use of alarm/clock’ and 
‘Afraid of my health getting worse’ have a positive relationship with the adherence to 
HIV antiretroviral drugs with an OR of 2.612 (95% CI 1.607, 4.244) and 3.996 (95% CI 
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2.367, 6.747) respectively. This positive relationship means that the above-mentioned 
facilitating reasons increase patients’ adherence level to their medication. 
 
The variable ‘Fell asleep during dose time’ is the only significant reason for missing 
medication in Model (III) of adherence/non-adherence as measured by TDM level for 
Nevirapine. This variable had a negative relationship with the adherence level of 
antiretroviral drugs with an OR of 0.223 (95% CI 0.133, 0.374).  It implies that this 
reason decreases the level of adherence to HAART.  
 
Among the demographic variables, a patient’s marital status and income significantly 
contributed towards the adherence to HIV medication. Patients who belonged to the 
income categories II and III  (RM 1,500 – RM 2,500 and RM 2,501 – RM 10,000 
respectively) were more likely to be adherent to the HIV medication with an OR of 0.220 
(95% CI 0.126, 0.385) and 0.216 (95% CI 0.111, 0.419) compared to the base income 
group (less than RM 1,500). As for the marital status, married patients were more likely 
to adhere to their HIV medication as shown by an OR of 2.931 (95% CI 1.307, 3.814). 
Other 39 factors were significant in the univariate analysis but not significant in the 
multivariate analysis. These variables are also reported in the above cross-tabulation 
(Section 5.7). 
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Table 5-47: Forward Adding Model (III) building stages of Adherence / non-adherence 
as measured by TDM level for Nevirapine ( n = 653) 
Variables (Yes versus No) Crude Odds ratio 
(95% CI) 
Adjusted Odds ratio  
(95% CI) 
Diarrhoea (Yes versus No) 0.319 (0.215, 0.472) 0.590 (0.346, 1.006) 
Vomiting (Yes versus No) 0.239 (0.159, 0.360) 0.454 (0.261, 0.788) 
Religious treatment  (Yes versus No) 0.239 (0.159, 0.360) 0.389 (0.224, 0.676) 
Dietary supplement (Yes versus No) 0.239 (0.159, 0.360) 0.729 (0.413, 1.087) 
Use of Alarm / Clock (Yes versus No) 4.930 (3.173, 7.659) 2.612 (1.607, 4.244) 
RFA_ Afraid of health (Yes versus No) 3.249 (2.234, 4.725) 3.996 (2.367, 6.747) 
RMM_ asleep (Yes versus No) 0.245 (0.164, 0.366) 0.223 (0.133, 0.374) 
Income  ≤ RM 1,500 / month Reference Group Reference Group 
Income  RM 1,501 – 2,500 1.472 (0.964, 2.247) 0.220 (0.126, 0.385) 
Income  RM 2,501 – 10,000 1.405 (0.855, 2.308) 0.216 (0.111, 0.419) 
Marital status (Yes versus No) 0.784 (0.548, 1.123) 2.931 (1.307, 3.814) 
Constant    4.836 
RFA Afraid = Afraid of my health getting worse,  
RMM asleep = Felt asleep during dose time 
 
In addition, the researcher checked all possible two-way interactions one at a time and 
found no significant interaction effect in the above model. Thus, the variables in Table 
5.46 and 5.47 best explain the dependent variable of ‘Adherence of HIV medication as 
measured by TDM for nevirapine’. The interpretation of the independent variables is 
based on the right most columns in Table 5.47, labelled "Adjusted odd ratio". More 
information about the interpretation and discussion are presented in Chapter 6 
(discussion). 
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Figure 5.7 shows the ROC curve of the logistic regression model using the results of the 
TDM level for Nevirapine model; it offers an excellent visual comparison of the models' 
performances. As we can observe, the curve is above the diagonal line, which indicates 
that the model performs well. The area under the curve (AUC) of this model is 
approximately 0.77(95% CI of 0.725, 0.817). This means the model can predict 77% of 
the outcomes accurately.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7 Forward Adding Model (III) building stages of Adherence / non-adherence as 
measured by TDM level for Nevirapine (n =653) 
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Table 5.48 below shows the model building stages of the fourth model; it uses the 
forward adding variable technique which sequentially selects the variables with the 
smallest log likelihood ratio and an acceptable Hosmer –Lemshow statistic. This model is 
the best-fit model to explain the dependent variable of ‘Adherence to HIV medication as 
measured by TDM for Lamivudine using the LC-MS/MS machine’. The variables 
selected in this model had the smallest Log likelihood ration and a good Hosmer –
Lemshow statistic. The table provides the following information: description of the 
variables, -2 log likelihood ratio, deviance, and lastly Hosmer-Lemshow statistics. 
 
Table 5-48: Forward Adding Model building stages of Adherence / non-adherence as 
measured by TDM level for Lamivudine (n= 594) 
Variable 2 Log likelihood Difference 
Hosmer-Lemshow 
Chi-Square Sig. 
Diarrhoea 643.819   Chi-Square Sig. 
Vomiting 627.697 16.122 0.894 0.640 
Use of Acupuncture 605.317 22.38 2.307 0.511 
RFA -Acceptance 592.802 12.515 6.938 0.327 
RMM_ Asleep 578.055 14.747 7.46 0.280 
Busy with other things 560.834 17.221 3.024 0.883 
Marital status 542.834 18.000 14.531 0.069 
    RFA –Acceptance = Acceptance of HIV status  
    RMM-Asleep = Felt asleep during dose time,  
 
After the evaluation of the forward adding variable of model IV, the best and the most 
parsimonious model of the adherence/non-adherence to HIV medication as measured by 
TDM level of Lamivudine was summarized in Table 5.49. In the beginning, we evaluated 
48 variables in the modelling, but after making adjustments based on the Hosmer-
Lemshow approach, we obtained seven variables that have effects on the model. These 
seven variables shown in the table were the final multivariate variables that can explain 
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the adherence/non-adherence of HIV medication as measured by TDM level of 
Lamivudine. The variables were ‘Diarrhoea’, ‘Vomiting’, ‘Use of acupuncture as 
alternative medication’, ‘Acceptance of HIV status’, ‘Fell asleep during dose time’, 
‘Busy with other things’, ‘Distance to hospital too long and costly’ and ‘Marital status’. 
 
It was found that patients who had diarrhoea and vomiting as adverse effects of 
antiretroviral drug were less likely to be adherent to HIV medication with an OR of 
1.55(95% CI 0.964, 2.513) and OR of 1.889, (95% CI 1.155, 3.091) respectively. The use 
of acupuncture as an alternative treatment was the only alternative medicine that was 
significant in Lamivudine model. It indicates that patients using acupuncture as an 
alternative treatment were less likely to be adherent to the antiretroviral drugs with an OR 
of 2.491 (95% CI 1.552, 3.997).  The variable ‘Acceptance of HIV status’ was the only 
reason that facilitated adherence to antiretroviral drugs. In other words, ‘Acceptance of 
HIV status’ had a positive relationship with adherence to HIV antiretroviral drugs with an 
OR of 0.52 (95% CI 0.339, 0.797).  
 
The variables ‘Fell asleep during dose time’ and ‘Busy with other things’ were the 
common and significant reasons for missing medication. These variables had a negative 
relationship with the adherence to the HIV antiretroviral drugs with an OR of 2.227, 
(95% CI 1.402, 3.539) and 2.227 (95% CI 1.402, 3.539) respectively. This means that the 
variables may decrease the adherence level to antiretroviral treatment. Among the 
demographic variables, only marital status significantly contributed towards the 
adherence to HIV medication with an OR of 0.774 (95% CI 0.511, 1.173). There were 
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41other factors which were significant in the univariate analysis but not significant in the 
multivariate analysis. These variables are also reported in the above cross-tabulation, 
Section 5.7. 
 
 
Table 5-49: Model IV of Adherent versas not adherent as measured by TDM level for 
Lamivudine (n = 594) 
Variables (Yes versus No) Crude Odds ratio 
(95% CI) 
Adjusted Odds ratio  
(95% CI) 
Diarrhoea (Yes versus No) 0.383 (0.257, 0.570) 1.556 (0.964, 2.513) 
Vomiting (Yes versus No)  0.308 (0.204, 0.465) 1.889 (1.155, 3.091) 
Use of Acupuncture (Yes versus No) 0.293 (0.193, 0.445) 2.491 (1.552, 3.997) 
RFA_Acceptence (Yes versus No) 2.512 (1.712, 3.686) 0.520 (0.339, 0.797) 
RMM_asleep (Yes versus No) 0.301 (0.199, 0.455) 2.227 (1.402, 3.539) 
Busy with other things (Yes versus No) 0.344 (0.232, 0.509) 1.791 (1.167, 2.749) 
Marital status (Yes versus No) 0.836 (0.583, 1.198) 0.774 (0.511, 1.173) 
Constant  0.197 
RFA-Acceptance = Acceptance of HIV status  
RMM- asleep = Felt asleep during dose time 
 
As done in the above modelling, after checking all possible two-way interactions, the 
researcher found no significant interaction effect in the above model. Thus, the variables 
in Table 5.48 and 5.49 best explain the dependent variable of ‘Adherence of HIV 
medication as measured by TDM for lamivudine’. More information about the 
interpretation and discussion are presented in Chapter 6 (discussion). 
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Figure 5.8 shows the ROC curve of the logistic regression model using the results of 
TDM level for Lamivudine model; it offers an excellent visual comparison of the models' 
performances. As we can observe, the curve is above the diagonal line, which indicates 
that the model performs well. The area under the curve (AUC) of this model is 
approximately 0.75 (95% CI of 0.708, 0.796). This means that the model accurately 
predicts 75% of the outcomes correctly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8 Receiver Operating Characteristic curve of the logistic regression for 
comparing the models' performance of TDM level for Lamivudine (n =594) 
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Table 5.50  below presents the summary of four logistic regression models of adherence 
level to HIV medication (HIV adherence predictors) as measured by the overall self-
reported questionnaire and TDM for three
3
 Highly Active Antiretroviral Treatment 
(HAART). As the table shows, model one of the ‘Overall adherence measured by self-
reported questionnaire’ had the most significant variables compared to the other three 
models
4
, it had 12 significant adherence predictors that can predict the level of adherence 
to HAART and 7 non-significant predictors.  
 
Model two of adherence level as measured by TDM level for Efavirenz had the second 
highest number of significant variables with 10 significant predictors and 9 non-
significant predictors. While model three of adherence level measured by TDM level for 
Nevirapine had the third highest number of significant variables that can predict the level 
of adherence to HAART, with 8 significant factors and 11 non-significant factors. 
Finally, model four of adherence level measured by TDM level for Lamivudine had the 
least number of significant variables that can predict the level of adherence to HAART; it 
contained 7 significant factors and 12 non-significant factors.  
 
The variables of ‘Diarrhoea’ and ‘Vomiting’ (adverse effects to treatment) were 
significant predictors for adherence to HAART based on all four models. The variables 
‘Use of religious treatment as alternative medication’ and ‘Use of alarm/clock as reason 
facilitating adherence’ were significant in three models (Model 1, 2 and 3). ‘Fell asleep 
during dose time’ as a reason for missing medication was significant in Model 2, 3, and 
                                               
3 Three TDM drugs 1) Efavirenz, 2) Nevirapine and 3) Lamivudine) 
4 Adherence measured by TDM Efavirenz method, TDM Nevirapine method and TDM Lamivudine 
method. 
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4. The following variables had a significant effect on two models: ‘Use of dietary 
supplements as alternative treatment’ had effect on Model 2 and Model 3, ‘Acceptance of 
HIV status’ as a facilitating factor had an effect on Model 1 and Model 4, while the 
variable of ‘Simply forgot’ as a reason for missing medication had an effect on Model 1 
and Model 2. Finally, among the demographic variables, age, income and marital status 
of the patient had a significant effect on two models: age in Model 1 and 2; income in 
Model 1 & 3; and marital status in Model 3 & 4. 
 
The variables ‘Use of herbal medicine’, ‘Self-efficacy to take & adhere to medication’, 
‘Distance to hospital too long and costly’ and ‘Education level’ were found as significant 
only in Model 1 of the overall self-reported adherence questionnaire. The following 
variables were found to be not significant in Model 1 of the overall adherence level 
measured by the self-reported questionnaire: ‘Use of dietary supplements’, ‘Use of 
acupuncture’, ‘Belief in the efficacy of pills’, ‘Afraid of my health getting worse’, and 
‘Fell asleep during dose time’. 
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Table 5-50: Comparing the results of four different multivariate regression models for adherence to HAART  ( n =925 ) 
                                                                                                           Total Yes                   12              10                 8                     7       
SAR: Multivariate regression model for overall adherence using self-reported adherence questionnaire. 
TDM_Efv: Multivariate regression model for Therapeutic Drug Monitoring (TDM) of Efaviranz level using LC-MS/MS machine 
TDM_Nev: Multivariate regression model for Therapeutic Drug Monitoring (TDM) of Nevirapine level using LC-MS/MS machine 
TDM_Lam: Multivariate regression model for Therapeutic Drug Monitoring (TDM) of Lamivudine level using LC-MS/MS machine 
 Yes = The variable is significant, No = The variable is not significant 
# Categories Variable SRA TDM_Efv TDM_Nev TDM_Lam 
1 Adverse effect to HAART Diarrhoea Yes  Yes  Yes  Yes  
2 Adverse effect to HAART Vomiting Yes  Yes  Yes  Yes  
3 Use of alternative medication  Use of religious treatment as alt treatment for HIV Yes  Yes  Yes  No 
4 Use of alternative medication Usage of Herbal medicine Yes  No No No 
5 Use of alternative medication Use of dietary supplements as alternative treatment  No Yes  Yes  No 
6 Use of alternative medication Use  of Acupuncture as alternative treatment No No No Yes  
7 Reasons facilitating adherence Use of Alam/ clock Yes  Yes  Yes  No 
8 Reasons facilitating adherence Acceptance of HIV status Yes  No No Yes 
9 Reasons facilitating adherence Self-efficacy to take & adhere to medication  Yes  No No No 
10 Reasons facilitating adherence Belief in the efficacy of pills No Yes  No No 
11 Reasons facilitating adherence Afraid of my health getting worse No Yes  No No 
12 Reasons for missing medication Simply forget Yes  Yes  No No 
13 Reasons for missing medication Distance to hospital too long and costly Yes  No No No 
14 Reasons for missing medication Felt asleep during dose time No Yes  Yes  Yes  
15 Reasons for missing medication Was busy with other things  No   No No Yes 
16 Socio-demographic variables Education Yes  No No No 
17 Socio-demographic variables Age of patient Yes  Yes  No No 
18 Socio-demographic variables Income of patient Yes  No Yes  No 
19 Socio-demographic variables Marital  status of patient No No Yes Yes 
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CHAPTER 6 Discussion 
6.1 Study methods and Sampling information 
This study assesses the adherence level towards the Highly Active Antiretroviral 
Therapy (HAART) using a variety of measures and methods; using combination 
methods of analysis is more reliable than using individual method. In this respect, this 
study is deemed to be a study with multiple methods ascompared to most of the earlier 
studies with limited methods. The study sample was drawn from a cross-section of 
HIV/AIDS patients in Sungai Buloh Hospital. The sampling method applied in the 
study was simple convenience sampling in order to ensure no preference in the selection 
process which may introduce selectivity bias. Each patient in our sample had an equal 
probability of being selected from a list of all population units (Kothari, 2003). The 
sample size formula used in the study was sufficiently adequate (n=925) as most of the 
other similar studies used samples which were comparatively less in size; in general, the 
greater the sample size, the more precise the estimates are.  In terms of the power of the 
test, the study had used 80% of power at the 0.05 level of significance (two sided), and 
other similar studies had used same power test. This is rather significant since the 
greater the power of the test, the higher the probability of not committing Type II error.  
  
6.2 Descriptive statistics of socio- demographic variables 
Findings of socio-demographic variables (age, gender, race, educational, religion and 
income) in the adherence towards antiretroviral treatment is inconsistent. Some 
researchers find association between socio-demographic variables of the patient and the 
adherence level of antiretroviral treatment, while others find no association between the 
two. In this section, we discuss the effects of the following socio-demographic factors 
on the adherence level of antiretroviral treatment: age, gender, race, educational, 
religion and income level. 
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The majority of respondents in this study were male; this is probably due to the fact that 
females were not willing to participate in the study. This difference may also contribute 
to the fact that the prevalence of HIV infection is more predominant among men in 
South East Asian countries (UNAIDS, 2002). In Malaysia, men represent the majority 
(92%) of HIV cases while women and girls account for less than 10% of this total 
(Taylor, Nadchatram, & Faisal, 2007). This contradicts the findings of Nyambura 
(2003) that – in his study of factors that influence non-adherence to antiretroviral 
therapy among HIV and AIDS patients in Kenya – found more female respondents 
compared to the males. In terms of the respondents’ age, the majority of patients belong 
to the younger age group, as younger people are always more vulnerable to the HIV 
epidemic than older people,  and this result is similar to other studies that were 
conducted.  
 
As shown by the results of the study, the majority of HIV-positive patients in this study 
were Chinese, followed by Malays, and the least were Indians. This could be due to bias 
since the questionnaire is self-administered. Perhaps this inconsistency can  also be 
explained by the fact that the majority of people living near the study site are Chinese 
This result is contrary to previous similar studies and reports, which show that the 
Malay ethnic group makes up the majority of HIV-positive patients in Malaysia.. 
Correspondingly, in terms of religion, Buddhists made up the majority of the 
respondents, followed by Muslims and Hindus. This pattern can also be given a similar 
explanation as in the case with the ethnic group. Regarding marital status, there was not 
a big difference in number between the married and singles in our study findings. In 
some other studies, HIV/AIDS is more likely to be prevalent among the unmarried 
compared to the married ones (unfpa, 2012).  
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Patients who received less than primary education were the majority respondents in this 
study. The more educated and skilled people are, the more likely they tend to protect 
themselves and the less prone they would be to engage in risky sexual behaviour. 
Similarly, patients with a monthly income level of less than RM 3,500 made up more 
than half of the respondents; this may indicate that prevalence of HIV/ AIDS is higher 
among people with low income. According to (Bartelmus, 2005; Grainger, Webb, & 
Elliott, 2001) HIV affects mainly those who are usually less economically active in jobs 
& vocations; hence, HIV is more prevalent among the less skilled and less educated 
patients (UNAIDS, UNFPA, & UNIFEM;, 2012). Domestically and internationally, it 
was proven that HIV/AIDS is more prevalent among patients with lower levels of 
socioeconomic status (Siti et. al., 2007). 
 
Lastly, we found that the heterosexual route was the most common route of 
transmission with (48.8%) of the participants acquiring their infection through this 
route. This may indicate that there is a huge shift in the mode of infection which used to 
be through the injecting drug use in the past 15 years (Siti N. Z et al., 2007). The 
prominence of heterosexual transmission in this study may be due to the dominance of 
Chinese respondents (63.24%) in our study. Siti et. al., (2007) had reported that 
heterosexual transmission of HIV is more common among Chinese Malaysians, in 
contrast to Malay and Indian Malaysians  for whom the IDU transmission predominates 
by far (Siti N. Z et al., 2007).  
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The second route of infection according to our results findings was injecting drug use 
(30.1%). This used to be the highest route of infection and the reduction in number of 
people who get infected through this route could be due to the successful harm 
reduction program implemented in the country in the past 10 years.  Based on the 
Malaysian HIV epidemic report, injecting drug use is the predominant mode of HIV 
transmission (72.7%), followed by heterosexual intercourse (15.3%) and homosexual 
(1.7%) (Taylor et al., 2007).  
 
According to Munoz-Moreno et. al., (2007), a study done on 11 Spanish hospitals found 
that intravenous drug use was the most prevalent route of HIV/AIDS transmission 
(33%), heterosexual intercourse came second with 32%, followed by blood product 
transfusion of HIV/AIDS with a 5% score. In Canada, injection drug use exposure 
accounted for 17.7% of cumulative adult HIV case reports in the year 2008 (Public 
Health Agency of Canada, 2010). Heterosexual sex was estimated to account for one-
third of total new diagnoses in Alabama 2006 (Sawires, Szekeres, & Cooates, 2007).  
 
Usually, homosexual sex has a higher risk in the transmission of HIV/AIDS than the 
heterosexual route in most parts of the western world. Similar results were found in this 
study as it was shown that heterosexual route is the main contributor of HIV AIDS, 
which account for 48.8% cases compared to the homosexual route of transmission 
which comprises 15.1%. Homosexuality is not acceptable to the majority of the 
Malaysian society as they are restricted by religious and cultural values. However, it has 
shown an increasing trend in the recent years compared to the past few years. In 
summary, our findings in terms of age, sex, marital status, education level, race and 
religion were similar with some studies and not similar with others which were 
conducted in the developed world, as shown above.  
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6.3 Measuring Adherence Level 
Measuring the adherence level of high antiretroviral treatment is very important in 
determining the outcome of a patient’s treatment. In this study, we measured the 
adherence level using three different methods to ensure that we would obtain an 
accurate and reliable measure. Three methods were also used due to the fact that there is 
no gold standard in measuring the adherence level and it has been suggested in many 
studies to use more than one method to measure adherence level (Paterson, Potoski, & 
Capitano, 2002; J. Wagner et al., 2001). First, the researcher used the overall self-
reported adherence level to determine the adherence level as reported by the HIV-
positive patients on HAART. This was based on the number of doses missed and the 
time interval. Secondly, the researcher calculated the adherence level based on the 
online pharmacy records for HAART collected by the patients. Thirdly, we measured 
the adherence level based on the tested drug level in patients’ blood using the LC-
MS/MS machine, which is the most accurate machine to detect medication level. 
 
6.3.1 Measuring Adherence level using over all self-reported Adherence 
Questionnaire 
In this section, adherence level was measured using the overall self-reported adherence 
questionnaire. The calculation of the adherence level was based on the number of 
missed doses in the last 2 weeks, 4 weeks and 6 weeks. This interval was used to 
determine whether there is significant difference in the adherence level measured in a 
long and short time basis.  It was noticed that the adherence level in the last two weeks 
was greater than the adherence level in the last 4 weeks. This could be due to the fact 
that participants filling in the questionnaire in the last 2 weeks tended to remember the 
number of doses they missed within the 2 weeks more than in the last 4 weeks.  
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Participants also missed more medication doses in the last 6 weeks compared to the last 
4 and 2 weeks. Many studies have shown that recall bias tends to underestimate the 
level of adherence to HAART and thus the adherence level measured by self-reported 
questionnaires is mostly reduced as patients may not remember the date he had taken his 
medication, leading to low adherence level as in Ethiopia (Balcha, Jeppsson, & Bekele, 
2011; Sreeranga, 2010). The overall adherence level calculated in our study was 81.7% 
which was less than the adherence level calculated in other developing countries. The 
adherence level calculated in South Eastern Nigeria by Ukwe and team members was 
86.1% (Ukwe, Ekwunife, Udeogaranya, & Iwuamadi, 2011), and the one calculated in 
South Africa using the self-reported questionnaire was 88% (J. Nachega et al., 2004). 
However, the overall adherence level calculated in this study is considered to be high 
(81.7%) compared with other developing countries (I. Escobar, M. Campo, J. Martín et 
al., 2003). 
 
 Adherence level measured via self-reported questionnaire in some developed countries 
such as France was found to be 78.1% (Moatti et al., 2000), which is less than the 
adherence level measured in Malaysia. Haug et al. In United States found the adherence 
level as reported by the self-reported questionnaire to be 76.7% which is also less than 
the level obtained in our study (Malta, Strathdee, Magnanini, & Bastos, 2008). The self-
reported adherence level obtained in USA by Hinkin and team members was 80.7% 
(Hinkin et al., 2004) and this figure is almost equal to the level calculated in this study. 
Based on the few examples mentioned above, adherence level measured by the self-
reported questionnaire may not depend on whether a country is developed or 
developing, even though it makes more sense for the level to be higher in developed 
countries than developing countries.  
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Developed countries usually have excellent infrastructure, very good transportation 
system, as well as more treatment centres compared to developing countries. More 
importantly, hospital waiting time for patients receiving HAART in those countries is 
less than in developing countries, and nutritional and financial status of the patients are 
also much better. All of the above-mentioned reasons will definitely make the level of 
adherence to HAART much better in developed countries compared to developing 
countries.  
 
In Section 6.3, the adherence level was found to be high among educated patients with 
high income. This could be due to the fact that educated patients may know and 
understand the HIV/AIDS and the level of adherence to HAART more than the patients 
with less education or the non-educated. High income contributed positively towards 
adherence level as patients have money to spend on treatment, nutrition, better housing; 
all this helps patients with high income to be more adherent to treatment than patients 
with lower income. Adherence level of 81.7% is considered to be a good level even 
though it is less than the 95% level requested by the World Health Organization 
(WHO). In our study, the adherence level is either similar to or slightly higher than the 
level obtained by some studies conducted in other developed parts of the world. The 
overall adherence level measured by the self-reported questionnaire was 81.7%. This is 
less than the 95% adherence required by WHO to prevent the development of 
resistance, cross resistance and treatment failure (Bartlett, 2002).  
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6.3.2 Measuring adherence level using pharmacy records 
Participants in this study were included if they were on a combination of antiretroviral 
treatment. Only patients on Efavirenz, Nevirapine and Lamivudine were included in this 
study since these were the most commonly prescribed HIV medication by their 
physicians and the most commonly used drugs by the patients receiving treatment in the 
hospital.  
 
The patients’ pattern of medication collection behavior over the preceding six months 
showed a decreasing trend as illustrated in Chapter 6 (Figure 5.3). This means that 
patients collected more medication in the first month than in the second or third month, 
and the quantity collected decreased with time. Consequently, it definitely decreased 
their adherence level as times goes on; this could be either because they were becoming 
tired of collecting their medication, or they were unhappy with their medication or both. 
Patients can become reluctant to collect their medication due to severe adverse effects, 
depression and long distance to hospital (Ammassari et al., 2001; Carlucci et al., 2008; 
Starace et al., 2002). 
 
The adherence level measured by pharmacy refill records revealed that Efavirenz had 
the highest adherence level (73.2% with 95% CI of 69.3 to 0.76.1 of adherence) among 
the three drugs. This could be due to the fact that the drug is given once daily at 
bedtime, which is also a very convenient time to take the medication since patients will 
be at home. In addition, Efavirenz is also prescribed as a single drug, not in a 
combination form as the other two (Nevirapine and Lamivudine). Adverse effects are 
much less in single drugs than in combined forms (Vanni et al., 2007); thus, patients 
may prefer Efavirenz to the other two drugs. 
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Nevirapine, on the other hand, had an adherence level of 68.5%, which was a little less 
than Efavirenz. This could be due to the fact that the drug is given in a combined form 
with other antiretroviral drugs and it is associated with many adverse effects due to its 
combination with other medication as reported by several studies (Carr & Cooper, 2000; 
Harding, Molloy, Easterbrook, Frame, & Higginson, 2006). Nevirapine could also be 
prescribed twice daily at the time during which patients are most likely to be at work or 
busy with other things. Taking Nevirapine during working time could result in patients 
forgetting their medication at home.  
 
Patients on Lamivudine had the lowest adherence level (53.1%) as calculated by the 
pharmacy refill method. This reduction in adherence level could also be due to the 
adverse effects associated with the medication prescribed in combined forms (Qurishi et 
al., 2003).  Compared to Efavirenz, this drug is taken twice daily and without food 
restrictions, which could result in other adverse effects. 
 
In general, adherence level for the above three drugs (Efavirenz, Nevirapine and 
Lamivudine) as measured by the pharmacy refill method was much less than the overall 
adherence level measured using the self-reported adherence questionnaire for the above  
three medications which was found to be 81.7%. This could be due to the fact that self-
reported adherence using a questionnaire is over estimated as shown in other similar 
studies (Adams, Soumerai, Lomas, & Ross-Degnan, 1999; Fong et al., 2003; Miller et 
al., 2002). 
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6.3.3 Measuring adherence level using TDM 
First and second blood samples collected from HIV-positive patients were analyzed 
with the LC-MS/MS machine to detect three antiretroviral drugs: Efavirenz, Nevirapine 
and Lamivudine in both samples. Table 5.17 (in the results chapter) shows that 
participants on Efavirenz were more adherent (71.2% adherent) compared to those on 
Nevirapine (69.6% adherent) and Lamivudine (60.3% adherent). These findings are 
affected by the dose frequency, dose time, adverse effects of each drug and the 
availability of each medication (in single or combined form) as discussed earlier in this 
section. It is important to acknowledge other factors that can reduce the amount of 
medication detected by the LC-MS/MS machine such as drugs metabolism and drug 
interactions with other substances in the body. Abnormal metabolism due to any disease 
or any of the above factors will lead to the reduction of level of adherence to HAART. 
The adherence level would be low when the amount of drug detected by the machine is 
low. If there is an abnormality in the renal system for example, much of the drug may 
be excreted, thus resulting in a low level of HAART in the blood and consequently low 
adherence level.  
 
This method of measuring adherence level is objective and is the most accurate method 
since drug levels are detected in the patients’ blood using a very sensitive machine. 
Before the blood samples were collected, patients with other diseases except HIV had 
been excluded; patients with abnormal liver and renal tests had also been excluded from 
this study. There were no published studies on measuring the level of adherence to 
HAART in Malaysia and South East Asia using the LC-MS/MS machine, and therefore 
the findings from this study could be used as a reference for similar future studies. 
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6.4 Comparing the three specific drug levels as detected by TDM using LC-MS  
machine vs. Overall adherence level measured by self-reported questionnaire 
This is the first ever reported study in South East Asia to validate a locally and 
culturally adapted self-reported adherence (SRA) questionnaire with detected levels of 
three anti-retroviral medications in human plasma using LC-MS/MS. As expected, SRA 
adherence levels were slightly higher than those obtained by TDM. Social desirability 
bias could probably account for some for this difference but it was less than we 
expected. The levels of sensitivity and PPV of SRA in Malaysia are comparable to 
levels obtained elsewhere (Godin, Gagné, & Naccache, 2003). We have also determined 
that SRA is surprisingly sensitive but not very specific and this has been shown by other 
researchers (Biadgilign, Deribew, Amberbir, Deribe, & Berhane, 2010). This is to be 
expected given that high sensitivity is often accompanied by low specificity.  The high 
PPV levels are not actually that surprising given that the actual adherence to medication 
is high, naturally giving rise to high PPV. The fairly high diagnostic accuracy is 
probably a result of fairly high discriminative ability of the SRA instrument to decide 
who has adhered or not adhered to medication. This is backed up with the fairly high 
AUC values of SRA, which has been shown elsewhere by other researchers (Duong et 
al., 2001).  
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TDM is expensive and requires complex machinery and trained personnel to perform 
(Rakhmanina, Van Den Anker, & Soldin, 2004). These factors make it rather unsuitable 
for use in resource-poor environments. With this kind of profile, this begs the question 
whether SRA could therefore be trusted enough to replace TDM in measuring 
adherence and the answer is in the affirmative. When high sensitivity and PPV are 
required, SRA can be relied upon to check adherence. We hope that this piece of 
research will help answer the question whether SRA could reliably be used to measure 
adherence in HAART patients in a resource-poor environment.  
 
Limitations of this study include recall bias and social desirability bias (Shi et al., 2010). 
Recall bias was minimized by ensuring proper definition and articulation of the research 
question and improving the quality of the questionnaire.  Social desirability bias was 
minimized by engaging a research assistant who was not directly involved in the HIV 
clinic to collect the data. In summary, SRA is a surprisingly accurate instrument for 
measuring HAART adherence compared to TDM and can be reliably used in practice in 
a resource-poor setting. 
 
6.5 Cross tabulation of the HIV adherence predictors (independent variables) with 
overall self-reported adherence questionnaire 
This section discusses the findings of cross tabulation of factors affecting adherence to 
Highly Active Antiretroviral Therapy (HAART) and the adherence level as measured 
by the overall self-reported adherence questionnaire. This cross tabulation analysis 
helps us to understand the adherence behaviour and factors that affect people's 
adherence to antiretroviral drugs. Table 5.27 (in the results chapter) shows the cross 
tabulation of seven
5
 socio-demographic factors and the overall self-reported adherence 
                                               
5 Gender, religion, ethnicity, education, marital status, income and age 
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level. Based on our results, four out of the seven socio-demographic variables (patient’s 
level of education, marital status, average monthly income and age group in years) 
significantly influenced the level of adherence to HAART. 
 
The study results did not show whether an increase or decrease in the pattern of 
educational level corresponds with an increase or decrease in the adherence level. 
However, level three of secondary school had the biggest odds ratio compared to the 
other levels of education; this signifies that patients with level three of secondary school 
are more likely to adhere to ARV medication. Other studies had found significant 
relationship between high education level and correspondingly high adherence level 
(Talam et. al.,2008). In the case of this study, education and adherence did not show a 
pattern; it is not clear why those with level 3 of secondary school had higher odds ratio 
compared to patients with diploma and degree. This setting is totally different from the 
findings of other similar studies. This difference may be possibly due to the fact that 
those with formal education are more aware of the side effects of antiretroviral 
treatment and the fact that there is no cure for HIV/AIDS; thus, they may decide to 
rationalize this point and therefore are less likely to adhere to ARV medications 
(Uzochukwu et al., 2009). According to other studies on chronic diseases, patient’s 
education is the most important tool that can contribute to adherence towards 
medication of chronic diseases such as hypertension, diabetes, cardiovascular diseases 
etc., and thereby reduces the morbidity and mortality rates of these conditions (Shiri, 
2007). 
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Similarly, the relationship between income categories and adherence level did not show 
a pattern. Patients with an income Level II (RM 1,501 – RM 2,500) had the biggest 
odds ratio compared to Levels I and III (≤RM 1,500 and RM 2,501 – 10,000 
respectively). Similar studies show that there is positive association between adherence 
level and the income level; Kleeberfer et. al., (2001) had mentioned that low income is 
indirectly associated with low adherence to antiretroviral drugs. In this study, the reason 
behind the lack of pattern between adherence level and patient’s income level cannot be 
explained. Thus, based on the income status of respondents, income is not a good 
predictor of adherence to antiretroviral treatment. On the other hand, results of the study 
show that married patients were more likely to adhere to their antiretroviral medications 
compared to the unmarried ones. This can be justified by the fact that married 
individuals may help to remind their spouses to take their medication or even put 
pressure on their spouses to take their medication in order to live longer. This type of 
relationship is also supported by other studies: (Gallant & Block, 1998; Uzochukwu et 
al., 2009). 
 
For the age variable, the study findings show that older patients were more adherent to 
their medication compared to their younger counterparts; for instance, patients aged 45 
years and above had the biggest odds ratio compared to patients aged below 45 years 
who had smaller odds ratio. This can best be explained by the fact that older patients are 
most likely married and have children, and therefore would want to live longer to care 
for them. Older people are also usually wiser than the young and may accept their HIV 
status more easily as well as take their HIV medications in order to stay alive. Many 
studies have also found association between adherence level and older age, and are thus 
consistent with our study findings (Montessori et al., 2000; Salami et. al.,2010; Wenger 
et al., 1999). For those under the age of 30 years, their non-adherence could be as a 
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result of the fact that they are most likely unmarried and unemployed or with low 
income (Uzochukwu et al., 2009). Similar results were found in multivariate logistic 
analysis developed in Section 6.8. 
 
The above cross tabulation reveals no differences between HIV medication adherence 
level measured by the overall self-reported questionnaire and other socio-demographic 
characteristics such as religion, gender and ethnicity. As mentioned earlier, the study 
had used sufficient sample size (precision) and power. Other similar studies have shown 
that socio-demographic variables are inconsistent in influencing adherence and the 
scholars agreed that many of the demographic factors are not good predictors of 
adherence to antiretroviral treatment (Williams & Friedland, 1997). 
 
6.5.1 Adherence and Side Effect 
A side effect is usually regarded as an undesirable secondary effect which occurs in 
addition to the desired therapeutic effect of a drug or medication. In this study, 
participants were provided a list of 9 side effects associated with HAART, and asked to 
check those that applied to them using a binary scale of “yes” and “no”. Table 5.28 in 
the results chapter shows the cross tabulation results of nine side effect variables (rash, 
itching, loss of appetite, dry mouth, diarrhoea, tiredness, vomiting, fever and headache) 
with overall level of adherence to antiretroviral drugs as measured by the self-reported 
questionnaire. Adverse effects including vomiting, diarrhoea, tiredness and loss of 
appetite were the most common side effects in our study. According to the odds ratio, 
these side effect variables decreased by at least 10% of the level of adherence to 
antiretroviral drugs. Among these, variables ‘dry mouth’ and ‘headache’ were found as 
not significant in the adherence to antiretroviral drugs.  
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The variables ‘rash’ and ‘itching’ were reported to have smaller odd ratios compared to 
the above-mentioned side effects; according to their odds ratio, these variables decrease 
the adherence level by 3% and 6% respectively. In contrast to this finding, the literature 
reports that the most common side effects of antiretroviral drugs are ‘rash’ and ‘itching’. 
Studies that found significant association between adherence and side effects include: 
Ammassari et al., (2001), Harzke et al., (2004), Giacomet et al., (2003), Moahmmed et 
al., (2004), Nachega et al., (2004), Van Oosterhout et al., (2005) and many others. 
  
In many studies, it was reported that medication side effects were the most common 
reason for non-adherence (Duran et. al., 2001 and Chesney et. al., 2000). These studies 
have shown that there is inverse relationship between medication side effects and 
adherence. In other words, when patients experience side effects, they tend to stop 
undergoing treatment or take it irregularly (S. Duran, M. Savès et al., 2001). Chesney et 
al., (2000) found that 24% of patients reported that wanting to avoid side effects was a 
reason for their failure to take medication as prescribed.  
 
6.5.2 Factors facilitating adherence to antiretroviral treatment 
Factors facilitating adherence help patients to take their antiretroviral medications 
regularly and are also referred to as adherence motivators. Usually when these factors 
exist, patients are more likely to adhere to the HAART regimen than those who lack 
these factors. This implies that there is direct relation between factors facilitating 
adherence and patients’ level of adherence to treatment. Table 5.30 provides nine 
factors that facilitate adherence to antiretroviral drugs. Among these, seven variables 
were significantly related to the adherence to antiretroviral drugs, whereas the 
remaining two factors were found to be insignificant. The discussion in this section only 
revolves around the variables that were found to be significant.  
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Acceptance of HIV status enhances patients’ level of adherence to antiretroviral drugs, 
extant literature indicate that the lack of acceptance of HIV status and the disease 
implications would lead to poor level of adherence to antiretroviral drugs (Johnson et 
al., 2003). This study found that patients who accept their HIV status would have higher 
adherence level compared to patients who do not accept it. Non-acceptance of the 
disease may also exacerbate symptoms and lead to poorer overall mental and physical 
health. Belief in antiretroviral treatment is an essential component of good adherence, as 
shown in Table 5.30 (in the results chapter), patients who believe in the efficacy of 
HAART and have faith in the treatment have a greater likelihood to adhere to the ARV 
medications compared to those who do not believe in them.  
 
Adherence to medication has also been shown to be determined by self-efficacy to take 
and adhere to the medication. Self-efficacy is a person’s belief or confidence in their 
ability to carry out a target behaviour successfully; it enhances a person’s confidence in 
their ability to overcome barriers and succeed in change. This study found that the 
presence of self-efficacy would increase the patient’s level of adherence level to ARV 
by a factor of 12.52 with a 95% CI of (8.459, 18.551). The fear of their health getting 
worse and the development of drug resistance have shown to be prevalent among 
HIV/AIDS patients (Meng et al., 2008). The study results had shown that the fear of 
health deterioration and drug resistance had a positive significant relationship with the 
behaviour of adherence to HAART. Patients who feared health deterioration and drug 
resistance have more chances of adhering to HIV medication compared to those who do 
not. The results of this study are consistent with the literature and logic. Some studies 
reported that awareness of the role of medication in avoiding severe illness and drug 
resistance  would considerably contribute to high adherence (Colber et. al., 2006). Thus, 
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awareness programmes would provide practical and effective help in improving the rate 
of adherence to antiretroviral drugs. 
 
Disclosure of HIV status to family members and friends was seen as essential to 
successful adherence. Even though it is difficult, literature and experience revealed that 
disclosure is very important and thus HIV patients should disclose their condition to 
relatives and family members. Disclosure encourages support to be given to the patients 
and it plays a vital role in encouraging good adherence. Our study results, for instance, 
showed that patients who disclosed their HIV status to family members or friends had 
bigger odds in adhering to their medication compared to patients who did not disclose 
their status.  
 
On the other hand, the use of alarm or clock also has an important role in promoting 
good adherence to ART. The study results showed significant differences in the level of 
adherence to HAART among patients who used alarm clock and those who do not use 
it. The use of alarm clock would increase the adherence level of a patient on ARV by a 
factor of 7.06 with a 95% CI of (4.445, 11.205). In summary, the results of factors 
facilitating HAART in this study are consistent with other studies, as most respondents 
indicated that the above-mentioned facilitating factors were a major contributing cause 
that increased their level of adherence to medication. 
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6.5.3 Reasons for missing medications 
In Tables 5.31 to 5.33 the researcher provided twenty reasons for missing antiretroviral 
drugs. They include forgetfulness, high cost of treatment, ran out of pills, had simply 
many pills, did not want others to notice them taking medicine, had a change in daily 
routine, depression, and poor relationship with the provider, among others. Out of the 
twenty reasons for missing medication, only six variables are non-significant in 
influencing the level of adherence to antiretroviral drugs. The results showed that each 
reason for missing medication had an odds ratio of less than one; thus, they were 
expected to have a negative relationship with the level of adherence. In general, reasons 
for missing medication would make patients less adherent to their medication regimens.  
 
This study found that forgetfulness as a reason for missing antiretroviral medication is a 
main cause of poor adherence to HAART; it decreased the patients’ level of adherence 
to antiretroviral drugs by 16% compared to patients who did not forget their medication. 
This could be due to many reasons such as the complications of HIV/AIDS affecting the 
enter brain or the memory centre, and short -term memory loss is one of the symptoms 
of HIV/ AIDS. Another possible reason is participants’ low level of intelligence, since 
most of the participants were non-educated or had low levels of education. Side effects 
of some HAART medications may also cause severe headache. Patients who forget to 
take their medication may find it difficult to maintain a schedule, keep track of time, eat 
and drink on a regular basis, and do other daily life routines; therefore, their adherence 
to HAART during drug use is irregular. Forgetfulness does not always occur in 
isolation; other factors can also contribute to it, including memory deficits, emotional 
stress, oversleeping, etc.  
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Similarly, it was reported in other studies that forgetfulness was the principal reason 
reported for skipping doses, and the following papers had found that forgetfulness is the 
main reason for missing ARV medications: Tiyou et. al., (2010); Ostrop et. Al., (1998); 
Barfod et. Al., (2006); Molassiotis et. al., (2002) and several others. 
 
This study had found ‘stigma’ to be one of the reasons that caused individuals to not 
take their medication on time. In the context of this study, stigma refers to the condition 
where patients do not want others to notice them taking their HIV/AIDS medication, 
which makes it as a contributor to non-adherence. Taking HAART is an indication of 
being HIV-positive, and many HIV positive patients prefer not to take such medications 
in order to avoid being identified by friends and relatives as an HIV /AIDS-positive 
patient.  
 
As shown in Table 5.32, stigma may reduce the adherence level of antiretroviral drugs 
by 7.3%. When patients have this fear of stigma, they are more likely to have frequent 
treatment interruptions since the tablets must be hidden and eventually not taken at all in 
the presence of others for fear of being stigmatized (Uzochukwu et al., 2009). Not 
taking medications in front of other people - especially if it is during dosing time - may 
result in patients missing their medications. When medication is missed or its 
consumption is interrupted, it may reduce the adherence to HAART and can even result 
in non-adherence. Studies that had found stigma as significant and a prominent factor in 
decreasing adherence are plenty, and the following are some which are worth 
mentioning: Chongo (2011); Peretti, et. al. (2006); Canadian aboriginal AIDS network 
(2004); and Rintamaki et. al. (2006). 
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Depression, as a reason for missing HIV medication, significantly affected the level of 
adherence to antiretroviral drugs among HIV/AIDS-positive patients. The results in 
Table 5.33 illustrates that depression could reduce the adherence level of antiretroviral 
drugs by 11.7%. Although depression is not medically certified, depressive symptoms 
were self-reported by patients living with HIV; several studies indicated that depressive 
symptoms are associated with disease progression and death (Chongo, 2011). 
Depression is negatively associated with adherence level of antiretroviral drugs. This 
means that when patients are depressed they do not properly adhere to their 
medications, which promotes disease progression and increased mortality rate (Simpson 
et al., 2006). Several studies had found that depression is negatively associated with 
adherence, these studies include: Barfod et al., (2005); Farinpout et al., (2003); Cupsa et 
al., (2000); Catz et al., (2000); and (Chongo, 2011), among many others. 
 
Some participants in this study also complained about the high cost of treatment as a 
reason for missing HIV medications. According to the study results, this particular 
reason for missing medication may reduce the level of adherence to antiretroviral drugs 
by 17.1% as opposed to patients who did not consider such as a reason as a factor for 
missing HIV medications. Although the first line of antiretroviral drugs is free in 
Malaysia, the cost of transportation to obtain antiretroviral drugs might be a reason 
given for non-adherence, as the majority of the study respondents had an average 
monthly income of less than RM 1500 (US $480). Complaints about the cost of 
transportation by respondents indicates that the patients came from far to collect their 
medications, hence it is necessary to reallocate the location of the centres that currently 
provide antiretroviral drugs to the highly prominent HIV locations.  
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Malaysian government provides free drugs for the first line of Highly Active 
Antiretroviral Treatment (HAART), but the second-line treatment is very costly and has 
to be paid by the patients themselves (Vicknasingam et al.,2010). The result on the cost 
of treatment being a barrier to the adherence towards antiretroviral drugs has also been 
reported in other studies (Yu et al., 2007). Daniel et al., (2004). The inability to afford 
medication has been one of the most frequently reported reasons for non-adherence. It 
has also been noted that in poor countries in Africa and other developing countries, the 
cost of antiretroviral treatment is one of the major causes of non-adherence. 
(Uzochukwu et al., 2009). 
 
Poor relationship with health care providers such (i.e. doctors or nurses) is a big 
obstacle and decreases the adherence level of HIV-positive patients to their 
antiretroviral treatment. Respondents in this study supported the fact that poor 
relationship with health care providers is a barrier to the adherence towards HAART. 
Conceptually, it was expected that poor relationship with health care providers has a 
negative relationship with patients’ level of adherence to antiretroviral treatment. The 
study found that patients who had poor relationship with their health care providers may 
have 32% chances of reduced level of adherence to antiretroviral drugs. Several studies 
had reported that non-adherence was caused by lack of confidence and trust between the 
health care provider and the patient (Van Servellen et al.,2002). The findings of this 
study had also been reported in other studies including: Witteveen et al., (2002); 
Malcolm et al., (2003); Powell-Cope et. al., (2003); Remien et al., (2003) and others. 
 
The results showed that it is hard for the patients to take their HIV medications when 
their usual daily routine had changed or was disturbed. Chaotic schedules or disruption 
of daily routine is thought to be a barrier to adherence and it may result in missed doses. 
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Weekends and holidays represent a change in routine from the more structured activity 
on weekdays. Traveling from place to place in searching for support may cause 
difficulty for the patients to attend their monthly reviews and drug collections. 
According to this study, patients who complained about changes in their daily routine 
could have 35% less adherence rate compared to the patients who did not complain 
about them. Conceptually, a change in daily routine is negatively related with the level 
of adherence to antiretroviral drugs. Adamian et. al., (2004) and Graney et. al., (2003) 
found that having a fixed routine would contribute to the adherence level of HIV-
positive patients on ARV medication. On the other hand, it was also reported that 
having many pills was also a contributor to non-adherence.  
 
The study results in Table 5.33 show that patients who complained about having many 
pills may have 11% less adherence rate compared to those who do not complain about 
it. Theoretically, having many pills is negatively associated with the level of adherence 
to antiretroviral drugs. Patients are often concerned that taking medication may 
accidentally reveal their HIV status to their friends; therefore, single daily dosing is an 
important issue in improving adherence rate (Uzochukwu et al., 2009). Based on our 
study, the average number of pills per day was between three to six pills. For those on 
single medication, they would have less than 4 pills per day which is not a large amount 
and not an issue of concern. 
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Running out of antiretroviral pills was one of the reasons for missing medication 
according to this study. The study shows that running out of antiretroviral pills reduced 
the adherence level by 45% among HIV-positive patients on antiretroviral treatment. 
Running out of antiretroviral drugs is associated with poor level of adherence to 
antiretroviral drugs; thus, this would promote the development of resistance to drugs, 
cross resistance, worsening of patients’ health status,  treatment failure and also 
increases the risk of transmission of other opportunistic infections (Uzochukwu et al., 
2009). The findings of this study are consistent with those found by Iliyasu et. al., 
(2005) and Mukhtar-Yola (2006).  
 
As previously mentioned, this study found that six out of twenty reasons of missing 
medication were insignificant in affecting the level of adherence among HIV patients 
who are on antiretroviral drugs. These reasons were: busy with other things, felt like 
drug was toxic, felt sick or ill, had problems taking medicine at specific times, religious 
beliefs, and beliefs & preference for traditional medicine. The results of these variables 
are inconsistent with some of the earlier studies that found these reasons to produce 
significant results in missing medications. This could be due to the fact that participants 
in our study were not affected by these reasons for missing medications and therefore 
did not consider them as being significant. Participants in the other studies might have 
considered other elements, for example religious treatment and preference to traditional 
medicine (if they are religious and have a strong belief in traditional medicine), contrary 
to those in our study and vice versa.  
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For example, studies by Mohammed et al., (2004); and Murphy et al., (2003) found that 
the variable ‘drug was toxic/harmful’ was a significant reason for missing medication, 
whereas the variable ‘busy with other things’ was reported as a major reason for missing 
medication by Catz et al., (2000); Ferguson et al., (2002); Stout et al., (2004) and many 
other studies. Other similar studies reported feeling sick or worse as an important reason 
for missing medication. However, on the contrary, we found that all six of the above-
stated reasons to be insignificant based on our findings in Chapter 6. The studies of Catz 
et al., (2000) and Byakika-Tusiime et al., (2005)  found feeling sick as a significant 
reason for missing HIV medication. 
 
In summary, most of the reasons for missing medication presented in this study are 
consistent with the findings of other similar studies. Almost all of the reasons for 
missing HIV medication reported in this study had an odds ratio of less than one, which 
indicates that it is negatively related to Highly Active Antiretroviral Treatment 
(HAART) adherence levels in HIV-positive patients.  
 
6.6 Comparison of HIV adherent predictors vr three specific drug levels as 
measured by TDM using LC-MS/MS machine And Overall adherence as measured 
by self-reported questionnaire 
Since adherence is a complex behaviour and difficult to evaluate; we used different 
techniques to measure the level of adherence to antiretroviral drugs. As mentioned 
earlier, Therapeutic Drug Monitoring (TDM) was one of the methods used to determine 
the level of adherence to antiretroviral treatment, and the overall self-reported adherence 
questionnaire to calculate the adherence level. Thus, in this section we discuss the 
comparisons of three specific drug levels as detected by TDM versus factors affecting 
adherence (adherence predictors) to Highly Active Antiretroviral Therapy (HAART).  
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6.6.1 Side Effects variables 
Table 5.34 shows results of the cross tabulation of adverse effects of treatment and 
TDM method for detecting Efavirenz, Nevirapine and Lamivudine levels. The following 
side effects were found to be statistically significant with the TDM level for all three 
drugs (Efavirenz, Nevirapine and Lamivudine): ‘Rash’, ‘Itching’, ‘Diarrhoea’, 
‘Vomiting’ and ‘Fever’. This finding indicates that patients who experience the above 
side effects would most likely be non-adherent to the specific medication associated 
with that particular adverse effect. These side effects are the most common and most 
serious adverse effects associated with antiretroviral medications used to treat HIV 
infection (Hawkins, 2010; Remien et al., 2003). Moreover, these side effects were 
reported to be significant based on the measurement by the overall self-reported 
adherence questionnaire.  
 
Although dry mouth and headache were found as insignificant in all three TDMs 
(Efavirenz, Nevirapine and Lamivudine), it was reported as significant by other similar 
studies, stating that these side effects are common adverse effects among patients. 
Similarly, we found that these two side effects were insignificant in the overall self-
reported questionnaire adherence level. Other adverse effects such as loss of appetite 
and tiredness were less common among patients who used the three drugs above. In this 
study, almost all adverse effects of antiretroviral treatment were found to be negatively 
associated with the level of adherence to treatment.  
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This negative relationship means that patients who suffered these adverse effects would 
be uncomfortable and reluctant to take any medications associated with such symptoms. 
Thus, adverse effects reduce patients’ level of adherence to antiretroviral treatment. 
This reduction in adherence level or even non-adherence to antiretroviral medication 
may result in the development of drug resistance, cross resistance and treatment failure. 
It would be vital for health care providers, physicians or pharmacists to identify the 
adverse effects to HAART in order to help patients by either changing the medication or 
provide treatment for such side effects.  
 
6.6.2 Alternative Medication and self-reported adherence level 
Table 5.35 displays the results of cross tabulation between the use of alternative 
medication and TDM method for detecting Efavirenz, Nevirapine and Lamivudine level 
using the LC-MS/MS machine. The table shows that using alternative medication such 
as dietary supplements, religious treatment, acupuncture and herbal medicine were 
found to be statistically significant with all three TDM levels as measured by the LC-
MS/MS machine. Many patients with HIV status use alternative medication as a 
treatment for HIV/AIDS. The broad realm of alternative medication comprises herbal 
remedies, spiritual practices/prayers, traditional medicines, acupuncture, mind body 
therapy and numerous others. The reasons for using alternative medicine include stress 
reduction, relief of side-effects and symptoms (i.e. dermatological disorders, nausea, 
depression, insomnia, weakness etc) and pain relief (Tamuno, 2011).  
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According to other studies, the use of acupuncture and herbal medications has become 
one of the most commonly used alternative therapies for AIDS (Peltzer et. al., 2010). 
Likewise, this study shows that the use of acupuncture and herbal medicine was 
significant in all four methods of measuring adherence level for Efavirenz, Nevirapine 
Lamivudine using the LC-MS/MS machine as well as the overall adherence level based 
on the self-reported adherence questionnaire. The use of acupuncture and herbal 
medications decreased the adherence to antiretroviral drugs, and this may be due to the 
usually “powerful” status and beliefs attributed to traditional medicine. The above 
alternative medications used were found to decrease adherence level according to both 
the self-reported questionnaire and TDM monitoring for the three above-mentioned 
drugs. A possible explanation to this is when patients get tired from undergoing 
HAART or feel that the drugs do not have an effect on them, they may decide to go for 
herbal medicine or religious treatment. The use of dietary supplement was insignificant 
in all four methods of measuring adherence level (based on Efavirenz, Nevirapine 
Lamivudine and Self-reported Questionnaire). According to a UNICEF report (2010), 
the use of dietary supplement is very important for people living with HIV/AIDS 
because the body has to fight the virus and opportunistic infections (UNICEF, 2010). 
Insufficient nutrition can increase vulnerability to HIV infections and also promote the 
progression from infection to illness (Chongo, 2011). This study had shown that the use 
of dietary supplement reduced the adherence level as indicated by its small odds ratio 
(less than one). 
 
 
 
 
  225 
Theoretically, the use of complementary and alternative medicines decrease adherence 
to HAART among HIV-positive patients; this may be due to the usually “supreme” 
status and beliefs attributed to traditional medicine used in a multi-cultural society like 
Malaysia. This strong belief in alternative or complimentary medicine may cause some 
patients to be careless with their antiretroviral treatments (Tamuno, 2011). As reported 
by Owen Smith et. al.(2007), patients using complementary and alternative medicines, 
relative to non-alternative medicine users, were 1.69 times more likely to report missing 
HAART doses in the last 30 days (CI: 1.02-2.80; P=.041) even after adjusting for age, 
education, race, religion and income.   
 
Table 5.36 displays the results of cross tabulation between reasons facilitating 
adherence to HAART and TDM method for detecting Efavirenz, Nevirapine and 
Lamivudine levels using the LC-MS/MS machine as well as self-reported adherence as 
measured by the questionnaire. The table shows that the following reasons of 
facilitating adherence to HAART were found significant in all three TDM levels as 
measured by the LC-MS/MS machine: ‘afraid of my health getting worse’, ‘use of 
alarm/clock’, ‘belief in the efficacy of pills’, and ‘self-efficacy to take & adhere to 
medication’. Many studies have shown that these facilitating factors play a variety of 
important roles in influencing adherence to HAART. There are evidences that self-
efficacy in taking medication and the use of alarm clock as a reminder to patients to take 
their medications would improve medicines adherence (Müller, 2009).  
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Murphy et al. (2003) and Witteveen et al. (2002) found significant relationship between 
patients’ adherence level and the use of reminder tool and self-efficacy to take 
medication as facilitating factors. The use of alarm clock and belief in efficacy of the 
pills were also found to be significant according to the self-reported questionnaire. This 
was indicated by the participants who believed that these two facilitating reasons helped 
them to adhere to their antiretroviral medications. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
It is believed that the variables ‘fear of health deterioration’ and ‘belief in the efficacy 
of antiretroviral treatment’ have positive relationship with adherence to antiretroviral 
treatments; many qualitative studies have reported this type of relationship (Fassinou et 
al., 2004) and Powell-Cope et. al., (2003). On the other hand, the variable ‘needs to care 
for others’ is the only variable that was found to be insignificant in all three TDMs 
(Efavirenz, Nevirapine and Lamivudine). Likewise, it was found insignificant in the 
overall self-reported adherence level using the questionnaire, as discussed earlier. Thus, 
the ‘need to care for others’ is not a good predictor of adherence as it is not significant 
in all of the four methods of measuring adherence (Efavirenz, Nevirapine Lamivudine 
and self-reported questionnaire).    
 
Tables 5.37 through 5.39 provide the results of cross tabulation between reasons 
missing HARRT medications and TDM method for detecting Efavirenz, Nevirapine and 
Lamivudine level using the LC-MS/MS machine. Reasons for missing medication were 
negatively associated with patients’ level of adherence to antiretroviral drugs. These 
tables analyze 20 reasons for missing medications, and among these, 11 of them were 
significantly related with adherence of HAART. These significant variables are: ‘simply 
forgot’, ‘cost of treatment too high’, ‘away from home’, ‘had many pills’, ‘fell asleep 
during dose time’, ‘stigma’, ‘felt depressed’, ‘felt well’, and ‘drug collection time too 
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long’. They were found to be significant predictors by all four methods of assessing the 
level of adherence to HAART. These findings are consistent with the results of other 
studies like the following: Adamian et. al., (2004);  Graney et. al., (2003); (Uzochukwu 
et al., 2009); Iliyasu et. al., (2005); and Mukhtar-Yola (2006).  
 
The following reasons for missing medications were found to be insignificant in all four 
methods of measuring the level of adherence to antiretroviral drugs (Efavirenz, 
Nevirapine Lamivudine and Self-reported Questionnaire): ‘felt like drug was toxic’, 
‘felt sick or ill’ ‘busy with other things’ and ‘beliefs for traditional medicine’. 
According to the respondents, these reasons were not significant in influencing their 
adherence to HAART. These results are inconsistent with the findings of similar earlier 
studies in this field including: Mohammed et al., (2004); Murphy et al., (2003); Catz et 
al., (2000); Ferguson et al., (2002); Stout et al., (2004); Byakika-Tusiime et al., (2005). 
 
The variables ‘distance to hospital too long’, ‘ran out of pills’, and ‘had a change in 
daily routine’ were found to be insignificant based on two models – TDM for 
Nevirapine and TDM for Lamivudine methods  – but they are significant based on the 
overall self-reported questionnaire and TDM for Efavirenz. The long distance to 
hospital may discourage patients to come and obtain their medication as it might 
exhaust them. It may also cause patients to postpone their visit to the hospital, which 
will eventually result in the patients defaulting from treatment. This was particularly 
true in the case of patients who lived further away and had no other choice but to walk, 
but often these patients were unable to find the time and energy to make a trip to the 
hospital. This discussion may be true in our study as most of our respondents had low 
income. To address this problem, intervention designers or ARV distribution system 
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would allow patients to pick up drugs from any health facility in order to help those 
patients who are complaining from distance to hospital (Skoval et. al.,2006).  
 
While the variable ‘ran out of pills’ was a significant barrier to adherence, this variable 
is significant based on the overall self-reported adherence and TDM of Efavirenz. The 
problem of running out of antiretroviral drugs would result in resistance to drugs, cross 
resistance, worsening of the health status of the patients, leading to treatment failure and  
increases the risk of transmission of other opportunistic infections (Uzochukwu et al., 
2009). The findings of this study are consistent with those found by Iliyasu et. al., 
(2005) and Mukhtar-Yola (2006).  
 
The following two reasons for missing medications were not significant according to the 
overall self-reported questionnaire, TDM for Nevirapine and TDM for Lamivudine: 
‘Had problems at specific times’, and ‘religious belief’. Other reasons for missing HIV 
medications such as ‘busy with other things’, ‘felt like drug was toxic’, ‘felt sick or ill’, 
and ‘beliefs of traditional medicine’ were found to be insignificant in all four methods 
of assessing the level of adherence to HIV medication (HAART). Reasons that were 
insignificant in this section are negatively associated with the level of adherence to 
HAART and thus decrease the level of adherence to treatment. 
 
In summary, the comparison of 43 adherence predictors of HIV using four different 
methods of measuring adherence to HAART had shown the following: Twenty-three 
factors are strong predictors of adherence based on all four methods of measuring 
adherence to HAART. These 23 factors were significant by all four methods used in this 
study and as such can be regarded as factors that affect patients’ adherence to 
antiretroviral treatment. Four other factors are predictors of adherence according to 
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three methods, and another four are predictors of adherence as confirmed by two 
methods for measuring the level of adherence to HAART. The remaining eight factors 
were shown not to be predictors of adherence to HAART as they were not significant by 
all of the four methods of measuring adherence level. 
 
6.7 Multiple logistic regressions models  
A logistic regression model was constructed for each of the following four methods of 
measuring adherence as reported in Chapter Five: Overall self-reported adherence 
questionnaire, TDM level for Efavirenz, TDM level for Nevirapine and TDM level for 
Lamivudine. These logistic regression models were intended to identify factors 
associated with adherence to Highly Active Antiretroviral Treatment (HAART). The 
variables assessed in these four models were categorized into five groups: side effect 
variables, alternative medication variables, facilitating factors, missing medication 
factors and lastly demographic factors. 
 
6.7.1 Logistic regression model one: Self-reported questionnaire 
In regression model one of the overall adherence/non-adherence as measured by the 
self-reported questionnaire, diarrhoea and vomiting were side effects identified to be 
negatively associated with the adherence to antiretroviral treatment. Generally, 
antiretroviral drugs may cause undesirable side effects that would complicate the 
maintenance of good adherence to medication. As reported by Sherman and Fish 
(2000), diarrhoea is prevalent in 30 -70% of HIV-infected patients at some point during 
their illness. Similarly, according to other studies, vomiting is a troubling side effect 
experienced by many patients on antiretroviral treatment which causes discontinuity of 
antiretroviral therapy. Thus, these side effects contribute to non-adherence of the 
medication and consequently may cause resistance towards HIV medications, resulting 
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in treatment failures, opportunistic infections, loss of financial resources and many other 
problems (Ruiz-Pérez et al., 2006). Many similar studies have shown that these side 
effects were consistently associated with decreased adherence level.  
 
Among the alternative medication variables, this study found that the use of religious 
treatment and herbal medicine were significant in the logistic regression model with a 
decreasing effect of adherence to antiretroviral treatments. According to results of other 
studies, the role that religion plays in adherence to medical treatment is a complex and 
varied one; some researchers found that alternative medications such as religious 
treatment and herbal medicine have a positive influence on health behaviours and health 
outcomes (Parspns et. al., 2006; and Walis, 1996), while others indicated that the use of 
herbal medicine has  a negative influence on health behaviours (Pargament et. al., 1998 
and Pargament et. al., 2003). 
 
The facilitating factors such as the use of alarm clock, acceptance of HIV status, and 
self-efficacy were identified to be significantly associated with the improvement of 
adherence to ART. Similar to other studies, these facilitating factors were found to 
increase the adherence to antiretroviral treatments. In our sample, the use of alarm clock 
was the primary factor that facilitated adherence; according to Yao et. al., (2010), 69.4% 
of the study respondents stated that using a watch and/or an alarm clock would help 
them to remember the time of drug intake.  
 
The second significant facilitating factor found in the logistic regression was self 
efficacy. Self-efficacy  refers  to  patients'  beliefs  about  their  capabilities  and  their  
ability  to exercise  personal  control. The following studies have indicated the 
significance of self-efficacy in adherence to antiretroviral drugs: Kgatlwane et. al., 
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(2006); Adam et. al., (2003); and Laws et. al., (2000) among many others. Lastly, in the 
logistic regression model of the overall self-reported questionnaire, we found that the 
acceptance of HIV status was significant with an improving effect on adherence to 
antiretroviral treatment. Many similar studies have agreed that patients’ acceptance of 
HIV status is necessary for both adherence to medication and good health outcomes of 
HIV-positive patients (Abel & Painter, 2003; Kgatlwane et al., 2006; Remien et al., 
2003; Witteveen & van Ameijden, 2002). 
 
 Reasons for missing medications that include forgetfulness and long travel distance 
were found to be significantly related with non-adherence in the logistic regression 
model one of the self-reported adherence questionnaire; these reasons have a decreasing 
effect on the adherence to antiretroviral treatments. According to similar studies, the 
most common reason for missing medication is forgetfulness; the following studies 
have reported forgetfulness as a reason for missing medication: (Harzke et al., 2004; 
Kgatlwane et al., 2006; Marhefka et al., 2004; Mohammed et al., 2004; Molassiotis et 
al., 2002). Kgatlwane, et. al., (2006) reported in their study that 2 out of every 10 
patients missed taking their medication because of forgetfulness.  Distance to travel was 
found to be significant with an odds ratio of less than one; this indicates that long travel 
distances may discourage patients to adhere to antiretroviral treatments as some of them 
might feel tired of traveling to the hospital, postponing it and eventually forgetting to 
collect them. As reported by many studies, patients on antiretroviral drugs are burdened 
by the cost of transportation even though their governments are providing ARVs for 
free.  
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Among the demographic variables, level of education, age and income level of the 
patient showed a significant association with the adherence to antiretroviral treatments. 
Educated patients have more chances of adhering to their antiretroviral treatments 
compared to patients with lower level of education. The association of education on the 
adherence to antiretroviral treatments is inconsistent, some researchers found 
association between patients’ education and level of adherence to antiretroviral 
treatment, while others found no association between the two (Kgatlwane et al., 2006; 
Uzochukwu et al., 2009).  
 
On the other hand, the study results show an increasing trend in the patients’ income 
level was associated with an increase in adherence level; this suggests that patients with 
higher income are more likely to adhere to treatment. This type of relationship is also 
supported by Gallant & Block, 1998 and Uzochukwu, et al., 2009. Similarly, the study 
also shows an increasing  trend or dose-response relationship between a patient’s age 
and adherence rate. The effect of age on the adherence is also controversial as some 
researchers found a positive association between adherence rate and age of the patient, 
while others found either a negative association or no association at all (Kgatlwane et 
al., 2006). In general, the results of this logistic regression model of the overall 
adherence level as measured by the self-reported questionnaire supports the previous 
empirical evidence on factors affecting adherence level of antiretroviral treatments. 
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6.7.2 Logistic regression model two: TDM for Efaviranz 
In regression model two of adherence/non-adherence as measured by TDM for 
Efavirenz, diarrhoea and vomiting were side effects that were identified to be negatively 
associated with the adherence to antiretroviral treatment. According to model two of 
adherence/non-adherence as measured by TDM for Efavirenz, two alternative 
medication variables were found to be significant in this logistic regression model - ‘use 
of religious treatment’ and ‘use of dietary supplement’. These two variables have a 
decreasing effect on adherence to antiretroviral treatments. According to results of other 
studies, the role that religion plays in adherence to medical treatment is a complex and 
varied one; some researchers have found that alternative medications (such as religious 
treatment and herbal medicine) have a positive influence on health behaviours and 
health outcomes (Parspns et. al., 2006; and Walis, 1996) while others have indicated 
that the use of dietary supplement have a negative influence on health behaviours 
(UNICEF, 2010 and (Chongo, 2011). 
 
 
The second significant facilitating factor found in the logistic regression was belief in 
the efficacy of the medications. The study results indicate that patients who believed in 
their antiretroviral treatment (i.e. that it will cure the illness or help to control the 
progression of the disease) have more chances of adhering to their antiretroviral 
treatments. The following studies have indicated the importance of belief in the efficacy 
of the medications in adherence to antiretroviral drugs: Powell-Cope et. al., (2003); 
Kgatlwane et. al., (2006); Abel and Painter (2003); (Witteveen & van Ameijden, 2002); 
and (Remien et al., 2003), among others. 
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Among the reasons for missing medication, forgetfulness and falling asleep during dose 
time were found to be significantly related with non-adherence in the logistic regression 
model two of adherence/non-adherence as measured by TDM for Efavirenz. These 
reasons have a decreasing effect on the adherence to antiretroviral treatments.  
 
In addition to that, falling asleep during dose time was also found to have negative 
association in the adherence to antiretroviral treatment. According to the logistic 
regression results of Model II, sleeping through dose time was a major cause of non-
adherence to antiretroviral treatment.  Other similar studies have reported falling asleep 
as a barrier to the adherence towards antiretroviral treatments. Studies that established 
this relationship include: (Mohammed et al., 2004); (Monreal, Cunha, & Trinca, 2002); 
(Stout et al., 2004) and several others. 
 
From the list of demographic variables, only the patient’s age showed a significant 
association with the adherence to antiretroviral treatments. The effect of age on the 
adherence to antiretroviral treatments is inconsistent; some researchers found an 
association between the patient’s age and level of adherence to antiretroviral treatment, 
while others have found no association between the two. As regression model II of 
TDM for Efavirenz shows, middle aged patients (31-44 years) reported higher 
adherence compared to the younger (≤ 30 years) and older (≥ 45 years) patients. 
Although it is not very clear why middle aged patients were more adherent than the 
other age groups, this may be due to the fact that middle aged patients desire to improve 
their health because of the sense of obligation towards their family as a majority of this 
age group (31-44 years) had children under the age of 18. Watt et. al., (2009) stated that 
these patients are always more concerned about their children and elderly parents.  
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6.7.3 Logistic regression model three: TDM for Nevirapine  
In regression model three of adherence/non-adherence as measured by TDM for 
Nevirapine, diarrhoea and vomiting were identified to be side effects that were 
negatively associated with the adherence to antiretroviral treatment. Generally, 
antiretroviral drugs may cause undesirable side effects that set hurdles in maintaining 
good adherence to antiretroviral medication.  
 
According to model three of adherence/non-adherence as measured by TDM for 
Nevirapine, two alternative medication variables were found significant in this logistic 
regression model - ‘Use of religious treatment’ and ‘Use of dietary supplement’. These 
two variables had a decreasing effect on adherence to antiretroviral treatments. 
According to results of other studies, the role that religion plays in adherence to medical 
treatment is an intricate and varied one; some researchers found that alternative 
medications (such as religious treatment and herbal medicine) have a positive influence 
on health behaviours and health outcomes (Parspns et. al., 2006; and Walis, 1996) while 
others indicated that the use of dietary supplement have a negative influence on health 
behaviours (UNICEF, 2010 and (Chongo, 2011). 
 
Factors facilitating adherence to HAART such as the use of alarm and acceptance of 
HIV status were identified as being significantly associated with improving adherence 
to ART. Similar to other studies, these facilitating factors increase the adherence to 
antiretroviral treatments. The use of alarm clock was the primary factor that facilitated 
adherence in our sample. According to Yao et. al., (2010), 69.4% of the study 
respondents stated that using a watch and/or an alarm clock would help them to 
remember the time of drug intake.  
 
  236 
The second significant facilitating factor found in the logistic regression was the fear of 
health deterioration; this variable had a positive relationship with adherence to 
antiretroviral treatments. In other words, the fear of their health getting worse would 
encourage patients to be more adherent to the antiretroviral treatments in order to 
improve their health and prolong their lives. The studies of Powell-Cope et. al., (2003) 
and (Fassinou et al., 2004) found that the fear of health deterioration is a significant 
facilitator in adherence to antiretroviral drugs.  
 
Among the reasons of missing medication, only falling asleep during dose time was 
found to have an impact on adherence to antiretroviral treatment. According to the 
logistic regression results of model II, sleeping through dose time is a major cause of 
non-adherence to antiretroviral treatment; thus, patients’ level of adherence to treatment 
would be reduced.  Other similar studies reported falling asleep as a barrier to the 
adherence towards antiretroviral treatment. Among the studies that found this 
relationship are: (Mohammed et al., 2004); (Monreal et al., 2002); and (Stout et al., 
2004). When patients undergoing HAART fall asleep, they tend to miss their dosing 
time and thus will have low adherence level compared to patients who do not fall 
asleep.  
 
As for the demographic variables, the age and income level of a patient showed a 
significant association with the adherence to antiretroviral treatments. Patients with 
higher income status have more chances of adhering to their antiretroviral treatments 
compared to patients with lower level of income. The effect of income on the adherence 
to antiretroviral treatments is disputed; some researchers found the association between 
the income status of a patient and level of adherence to antiretroviral treatment (Gallant 
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& Block, 1998; Uzochukwu, et al., 2009) whereas others found no association between 
the two (Kgatlwane et al., 2006; Uzochukwu et al., 2009).  
 
Finally, marital status of the patient was found to singly contribute to the level of 
adherence to antiretroviral treatment. As the regression model three of TDM for 
Nevirapine shows, married patients were almost 3 times more adherent to their 
antiretroviral treatment than the unmarried ones. A possible explanation is that married 
patients may have children and therefore desire to stay alive longer to care for their 
children. Another possibility is that married patients may help to remind each other to 
take their prescribed medications, support each other morally (Uzochukwu et al., 2009). 
 
6.7.4 Logistic regression model four: TDM for Lamivudine  
In regression model three of adherence/non-adherence as measured by TDM for 
Nevirapine, diarrhoea and vomiting were identified to be side effects that were 
negatively associated with the adherence to antiretroviral treatment. Generally, 
antiretroviral drugs may cause undesirable side effects that set hurdles in maintaining 
good adherence to antiretroviral medication. According to model three of 
adherence/non-adherence as measured by TDM for Nevirapine, two alternative 
medication variables were found significant in this logistic regression model - ‘Use of 
religious treatment’ and ‘Use of dietary supplement’. These two variables had a 
decreasing effect on adherence to antiretroviral treatments. According to results of other 
studies, the role that religion plays in adherence to medical treatment is an intricate and 
varied one; some researchers found that alternative medications (such as religious 
treatment and herbal medicine) have a positive influence on health behaviours and 
health outcomes (Parsons et al., 2006) while others indicated that the use of dietary 
supplement have a negative influence on health behaviours (Chongo, 2011). 
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Factors facilitating adherence to HAART such as the use of alarm and acceptance of 
HIV status were identified as being significantly associated with improving adherence 
to ART. Similar to other studies, these facilitating factors increase the adherence to 
antiretroviral treatments. The use of alarm clock was the primary factor that facilitated 
adherence in our sample. According to Yao et. al., (2010), 69.4% of the study 
respondents stated that using a watch and/or an alarm clock would help them to 
remember the time of drug intake.  
 
The second significant facilitating factor found in the logistic regression was the fear of 
health deterioration; this variable had a positive relationship with adherence to 
antiretroviral treatments. In other words, the fear of their health getting worse would 
encourage patients to be more adherent to the antiretroviral treatments in order to 
improve their health and prolong their lives. The studies of Powell-Cope et. al., (2003) 
and (Fassinou et al., 2004) found that the fear of health deterioration is a significant 
facilitator in adherence to antiretroviral drugs.  
 
Among the reasons of missing medication, only falling asleep during dose time was 
found to have an impact on adherence to antiretroviral treatment. According to the 
logistic regression results of model II, sleeping through dose time is a major cause of 
non-adherence to antiretroviral treatment; thus, patients’ level of adherence to treatment 
would be reduced.  Other similar studies reported falling asleep as a barrier to the 
adherence towards antiretroviral treatment. Among the studies that found this 
relationship are: (Mohammed et al., 2004); (Monreal et al., 2002); and (Stout et al., 
2004). When patients undergoing HAART fall asleep, they tend to miss their dosing 
time and thus will have low adherence level compared to patients who do not fall 
asleep.  
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As for the demographic variables, the age and income level of a patient showed a 
significant association with the adherence to antiretroviral treatments. Patients with 
higher income status have more chances of adhering to their antiretroviral treatments 
compared to patients with lower level of income. The effect of income on the adherence 
to antiretroviral treatments is disputed; some researchers found the association between 
the income status of a patient and level of adherence to antiretroviral treatment (Gallant 
& Block, 1998; Uzochukwu, et al., 2009) whereas others found no association between 
the two (Kgatlwane et al., 2006; Uzochukwu et al., 2009).  
 
Finally, marital status of the patient was found to singly contribute to the level of 
adherence to antiretroviral treatment. As the regression model three of TDM for 
Nevirapine shows, married patients were almost 3 times more adherent to their 
antiretroviral treatment than the unmarried ones. A feasible explanation is that married 
patients may have children and therefore desire to stay alive longer to care for their 
children. Another possibility is that married patients may help to remind each other to 
take their prescribed medications, support each other morally (Uzochukwu et al., 2009). 
 
6.8  Recommendations  
In this chapter, the researcher makes recommendations based on the findings of the 
study. The following recommendations should be considered in an attempt to improve 
the level of adherence to antiretroviral treatment among HIV-positive patients in 
Malaysia. The recommendations are grouped into the following categories: 
Recommendations to the Ministry of Health Malaysia; recommendations to Health care 
professionals such as doctors, pharmacists, counsellors and nurses; recommendations to 
patients, family members and caregivers; and recommendations to Non –governmental 
Organizations (NGOs). 
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6.8.1Recommendations to Ministry of Health Malaysia:  
Based on the findings of this study, the following recommendations are presented in 
order to improve the level of adherence to antiretroviral treatment among HIV positive 
patients in Malaysia. 
- The overall level of adherence to HAART measured by the self-reported ques-
tionnaire in Sungai Buloh Hospital was 81.7%. This may seem high compared to 
the level obtained in other developing countries, however, it is much less than 
the expected 95% adherence level proposed or required by the World Health Or-
ganization (WHO) to avoid treatment failure. This shows that a large number of 
participants do not abide by their medication regimens. They need to be edu-
cated, counselled, motivated and encouraged to take their antiretroviral treat-
ment.  To achieve this target, patients should be informed about HAART usage 
and its adverse effects, given counselling about the disease and most importantly 
the significance of high adherence level. 
- Since first-line antiretroviral treatment is currently available for free in most 
hospitals in the country, the Government should provide second-line treatment at 
a subsidized rate or completely free. This will be of great help for patients who 
have been shifted from the first line of treatment to the second line of treatment 
due to treatment failure. 
- Three methods were used to measure the level of adherence to HAART in this 
study – the self-reported Adherence questionnaire, Therapeutic Drug Monitoring 
(TDM) using the LC-MS/MS machine and pharmacy refill method. Each had its 
advantages and disadvantages. The researcher would like to recommend the 
TDM as a method to measure adherence level as it is more accurate and objec-
tive. The Ministry of Health should encourage major hospitals in the country to 
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conduct regular research and use TDM to determine the adherence level among 
their HIV-positive patients.  
-  Self-reported adherence questionnaire is a method which is simple, fast, easy to 
use and cost effective. It should be recommended to only be used in health fa-
cilities which have not yet measured the level of adherence. This will be good in 
obtaining an estimated level of adherence to HAART due its associated bias.  
- Based on the findings of this study, the researcher will not recommend the 
pharmacy refill method due to its limitations. This method only provides infor-
mation about a patient’s drugs collection records but does not show whether the 
medication has actually been consumed or not.   
- Our findings show more than thirty factors that could predict adherence to 
Highly Active Antiretroviral Treatment (HAART) as measured and confirmed 
by more than one method. These factors were grouped into four groups: reasons 
for missing medications, factors facilitating adherence, adverse effects of treat-
ment and the use of alternative medicine. 
The researcher recommends these significant factors to be compiled in a booklet 
and distributed by the Ministry of Health to all health centres and hospitals in the 
country. This booklet should be used by physicians, pharmacists and nurses to 
inform patients about the predictors of adherence to HAART.  
Patients receiving HAART in any hospital should come together and form a peer 
support group to exchange information and learn from each other’s experiences. 
They can also learn self-care skills from each other e.g how to improve 
adherence such as use of alarm clock as reminders as this strategy has been 
found to increase the odds of adherence marketly. 
- Most patients complained that the distance to travel to hospitals for the purpose 
of obtaining their treatment is too far and costly. This affected their adherence 
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level and to solve this problem, the Ministry of Health should open more treat-
ment centres for HIV-positive patients. 
- The use of religious treatment and herbal medicine by HIV-positive patients on 
HAART was highly significant in our findings. It affected their adherence level 
and because of this, the Ministry of Health should try to bring traditional medi-
cine and Western medicine together and put more light on the importance of ad-
hering to HAART. Patients should be educated about HAART and discouraged 
from combining other alternative medicines with HAART. 
- The Ministry of Health Malaysia and the HIV/AIDS Council should provide full 
support in terms of food, cost of transportation, and cost of second-line treatment 
for poor patients undergoing HAART and cannot afford the treatment. This will 
play a big role in increasing the adherence level since these are big barriers to 
adherence. 
- Waiting time for follow-up and obtaining medication in hospitals is still long as 
indicated by participants in this study. This is due to the shortage of human re-
sources in hospitals and treatment centres in Malaysia, which is a very serious 
and vital problem. Urgent attention is needed if patients’ adherence to medica-
tion is to be improved. For example, few doctors are managing a huge number of 
HIV patients, resulting in their inability to provide quality services. 
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6.8.2 Recommendations to Health care Professionals: 
Medical doctors and pharmacists should take enough time to educate their patients 
about HIV /AIDS, antiretroviral treatment and adherence to their medications.  Patients 
should be informed about the consequences of non-adherence and the required high 
level of adherence to HAART in order to avoid the development of drugs resistance and 
treatment failure. This information may encourage patients to take their medication 
regularly, resulting in high level of adherence.  Health care providers should also take 
time to listen to patients’ problems related to the antiretroviral treatment, side effects, 
social problems as well as psychological problems that they encounter while undergoing 
HAART. Sympathy and respect should be imparted when attending to patients. 
In addition, health care providers should provide psychological support to HIV-positive 
patients. Health care practitioners should explain to patients in a language that they can 
understand and do it with extreme care to improve patient-doctor relationship which is a 
very important factor in improving the level of adherence. 
Doctors should be well-trained to ensure that they are able to identify adverse effects of 
HAART, advise their patients and find proper solutions to such side effects in order to 
avoid patients from stopping to take their medication. Health care professionals such as 
doctors should ensure that their patients are well-educated about the disease and 
HAART before prescribing the medications to them. They should provide detailed 
information and counselling, which should include the following: 
 
 Establishment of a social support team which includes patients and suitable 
health care providers such as counsellor and nurses.  This social support team 
should meet every one or two weeks. The group should hold discussions on 
issues related to their treatment and group members should be given the 
opportunity to learn from each other. They should discuss the importance of 
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adherence to treatment, factors facilitating adherence and factors leading to 
missing HAART medications. 
 Patients should be encouraged to use any kind of suitable reminding devices that 
can help to remind them of their medication time, such as the use of an alarm 
clock which is found to be a very import tool in this study. Use of calendars, 
stop watches and mobile phones as reminders should also be encouraged. 
Patients should know that a high level of adherence to HAART (95% or more) is 
essential for their treatment to work effectively.   
 
6.9 Limitations of the study 
One of the limitations expected in this study was selection bias, which may arise as 
motivated or well patients might be more likely to accept participation and thereby be 
over represented. In addition, social desirability bias may affect the correct 
measurements of variables. This occurs when patients report the behaviour they think is 
correct according to the social norm. In other words, they would report what their health 
care provider wants to hear. This was minimized by engaging a research assistant who 
was not directly involved in the HIV clinic to obtain consent, distribute and collect 
questionnaires. Recall bias is associated with self –reported adherence questionnaire as 
some patients may not remember their medication doses. It was minimized by ensuring 
proper definition and articulation of the research question and improving the quality of 
the questionnaire.  As the questionnaire was sel-administered there would be selection 
biaswith those who are educated and can read and write responding to the question. 
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This is done by ensuring that the questions asked during the interview were clear and 
well-understood by the participants. Another general limitation is the use of many 
different types of questionnaires developed to measure adherence, making comparison 
of results between studies difficult. However this was minimized in this study by 
adopting the AACTG adherence questionnaire that has been used in various multi-
national studies on adherence. Since only adult patients (18 years and above) have 
participated in the study, the results can only be generalized to adults. The reasons for 
non-participation in the study should have been listed in the exclusion criteria but the 
researcher did not included this because it was noted after the study have been 
completed and the author aknoledeged this limitation. 
 
Due to the unavailability of sufficient funds, this study was conducted in only one 
hospital, which could also affect the generalizability of the study. Most of the patients 
came from the out-patients department for treatment and follow-up. We did not include 
patients who were admitted into the wards due to the fact that they were very ill, and in 
general we might miss many patients (this is common in any hospital-based study). 
However, patients in the wards are more likely to be more adherent as they would be 
forced to take their medications. 
 
The researcher acknoledeged limitations in using some vague terms in the questionnaire 
such as using social support in question 20 of the questionnaire, acceptance of ones HIV 
status which may have other meaning –may mean a fatalistic belief i.e ihave HIV/AIDS. 
Using the term efficacy of pills may not be understood as it is a technical term. These 
limitations were noticed after the completion of the study and it was regratable that it 
will not be corrected. 
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The second blood samples collected for the three drugs (efavirenz , nevirapine and 
lamivudine) were less than the requested sample size because ,most of the participants 
did not come back to donate the second blood samples. The research team has send 
SMS massages to remind the participants but only few have shown up. The second 
blood sample was collected with the aim to be used for confirmation and also as a 
backup for the first blood sample. Since the second blood samples were not complete 
the researcher did not analyzed these samples or used them with other results but 
reported them as obtained. 
The researcher did not compare the adherence as measured with pharmacy refill data 
with other methods for measuring adherence such self-reported adherence or TDM 
because it was not one of the objectives of the study and prefer to compare the TDM 
levels with the self reported questionnaire since this was the third specific objective of 
the study.  It was also known that measuring adherence using pharmacy refill data just 
provide information on whether the patients has collected his medication or not but may 
not tell if the patients has swollen the collected tablets.  Based on this the researcher 
concentrated on measuring adherence using TDM and SRA. Therefore, this point may 
be considered for future studies. 
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CHAPTER 7 CONCLUSION 
 7.1 Measurement of Adherence 
In this study, the adherence level was measured using three different methods to ensure 
the accuracy and reliability of the measurement. The first measurement used was the 
self-reported adherence questionnaire. The second was calculation of the adherence 
level based on the online pharmacy records for the Highly Antiretroviral Treatment 
collected by the patients. The final method of measurement of adherence level was 
based on testing drug levels in patients’ blood using the LC-MS/MS machine. Among 
these three methods, the self-reported questionnaire had the highest adherence level 
compared to the other measurements of adherence; pharmacy refill records show the 
second highest adherence level to antiretroviral treatments and the least level of 
adherence was shown by the drug therapeutic measurement method.  
 
The adherence level measured by Therapeutic Drug Monitoring revealed that Efavirenz 
had the highest adherence level among the three drugs; Nevirapine was at the second 
spot, showing a slightly lower level than Efavirenz and patients on Lamivudine had the 
lowest adherence level. Similar results were found in pharmacy refill records which 
revealed that patients on Efavirenz were more adherent compared to those on 
Nevirapine and Lamivudine. The self-reported adherence questionnaire was found to 
show the highest adherence level among all methods of measuring adherence (TDM and 
pharmacy refill records being the other two methods). This could be due to the fact that 
a self-reported adherence questionnaire is subjective and is more likely to report  an 
overestimation. In summary, based on the above measurements of adherence levels, it is 
clearly shown that the level of adherence in Malaysia is much less than the adherence 
level recommended by the World Health Organization (WHO). 
 
  248 
7.2 Comparative analysis of contingency tables 
In this study, a comparison was made between the levels of adherence as measured by 
the four methods (self-reported questionnaire, TDM Efavirenz, TDM Nevirapine and 
TDM Lamivudine) and 48 factors affecting adherence to Highly Antiretroviral 
Treatments (HAART). These factors were classified into the following four groups: 
adverse effects of medications, reasons for missing medications, factors facilitating 
adherence and alternative medications used for HIV treatment. The results of cross 
tabulation analysis were interpreted using the odds ratios and 95% confidence intervals. 
Results indicate that both the self-reported questionnaire and TDM level of Efavirenz 
had the most number of significant variables affecting the level of adherence level to 
antiretroviral treatments compared to the other adherence methods. Each of them had 32 
significant adherence predictors and 11 non-significant predictors of the level of 
adherence to HAART. TDM level of Nevirapine is at the second place with 26 
significant factors and 17 non-significant factors. Finally, TDM level of Lamivudine 
had the least number of significant variables that could predict the level of adherence to 
HAART with 23 significant factors and 20 non-significant factors. 
 
According to the cross-tabulation results, twenty-three factors were found to be strong 
predictors of adherence to HAART based on all four methods of measuring adherence. 
These factors are as follows: rash, itching, diarrhoea, vomiting, fever, use of dietary 
supplement, use of religious treatment, use of acupuncture, use of herbal medicine, use 
of alarm clock, belief in the efficacy of pills, self-efficacy to adhere to medication, 
forgetfulness, cost of treatment too high, being away from home, had many pills, fell 
asleep during dose time, stigma, felt depressed, felt well, and drug collection time was 
too long.  
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This result is interesting and is supported by both logic and the literature; as measuring 
adherence by the level of drug detection in the human plasma using Therapeutic Drug 
Monitoring machine is considered to be close to the gold standard for measuring 
adherence.  
 
7.3 Logistic Regression Analysis 
In this study, 48 determinants of the level of adherence to antiretroviral treatment were 
assessed using four logistic regression models; 19 out of the 48 variables were at least 
found to be significant in one of the four logistic regressions. Model one assessed 
determinants of adherence measured by the self-reported questionnaire. It had the 
highest number of significant variables compared to the other three models with 12 
significant adherence predictors and 7 non-significant predictors. Model two assessed 
determinants of adherence measured by TDM level for Efavirenz, and this model had 
the second highest number of significant variables with 10 significant predictors and 9 
non-significant predictors.  
 
Model three assessed determinants of adherence measured by TDM level for 
Nevirapine. This model had the third highest number of significant variables that could 
predict the level of adherence to HAART, with 8 significant factors and 11 non-
significant factors. Lastly, model four assessed the determinants of adherence level 
measured by TDM level for Lamivudine; this model had the least number of significant 
variables that could predict the level of adherence to HAART, with 7 significant factors 
and 12 non-significant factors. 
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The variables ‘Diarrhoea’ and ‘Vomiting’ (adverse effects to treatment) were found to 
be significant predictors of adherence to HAART by all four models. The use of 
religious treatment as an alternative medication and the use of alarm clock as a reason 
facilitating adherence were found significant in three models (models 1, 2 and 3). 
Falling asleep during dose time as reason for missing medication was found significant 
in models 2, 3, and 4. The four above-mentioned logistic regression models were the 
best-fit models that could explain different measures of adherence to antiretroviral 
treatment. Thus, it is necessary to consider the predictors in order to improve the 
treatment of HIV/AIDS. 
7.4 VALIDATION OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 
(LC-MS-MS) METHOD 
First method was developed and then validated using human plasma free of any 
medications using LC-MS/MS method. Three highly active antiretroviral treatments 
namely efavirenz, nevirapine and lamivudine were tested for in human plasma sample 
of 925 patients. The first blood sample collected from 925 participants was tested for 
detection of the three HAART medications using LC-MS/MS method at 10ng/ml. The 
detected concentrations were transferred into SPSS for analysis. The adherence level 
measured using overall self-reported adherence questionnaire was validated against the 
detected TDM level for the three medications. Even though TDM was objective and 
more accurate, but it was found to be more complex and very expensive. Measuring 
adherence level using SRAQ was cheap, fast and easily conducted, this is very suitable 
and useful for measuring adherence level in developing countries. 
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7.4 Future Research 
 
Based on our findings, research is urgently needed to explore other methods for 
measuring the level of adherence to HAART such as Medication Events Monitoring 
System (MEMS). An investigation on the issue of developing resistance and cross 
resistance leading to treatment failure would be greatly called for. 
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APPENDIX A  
Self Reported Adherence Questionnaire 
 
Instrument No: ------------- 
 
Patient SB NO: ...............         Assessment Date [DD/MM/YYYY]: .................                                            
Administrator: ...................................................................................................... 
 
Introduction: 
My name is Dr Umar Yagoub Mohammed. I’m a postgraduate student in public 
health at the Department of Social and Preventive Medicine, Faculty of 
Medicine   University Malaya, under the supervision of Prof Awang Bulgiba 
Awang Mahmud. I’m conducting a research on factors affecting adherence to 
antiretroviral treatment in HIV positive patients in Hospital Sungai Buloh, 
Malaysia. I would appreciate if you would complete this brief questionnaire, 
which will take about Five to Ten minutes to fill out. Participation in this project 
is completely voluntary. All information that you provide through your 
participation in this study will be kept confidential. Further, you will not be 
identified in the thesis or in any report or publication based on this research. I 
would like to assure you that this study has been reviewed and received ethical 
clearance. Your participation represents available contribution to medical 
research and we thank you in advance for your participation.   
INSTRUCTIONS: 
Please answer the following questions in part one and part two below by ticking 
“✔”. ONLY ONE box for the answer you think is correct. 
Part One: Socio-demographic characteristics. 
1. Gender :     
□--Male         □--Female 
 
2. Religion: 
□--Islam        □--Buddhism      □--Hinduism    □--Christianity    □--Taoism   
□--Others: [Specify]…………............... 
3. Ethnic Group: 
□--Malay          □--Chinese       □--Indian       
 □--Others: [Specify]………................ 
4. Marital status: 
□--Single         □--Married         □--Separated [Married but not living together]    
□--Divorced     □--Widow/widower 
5. Do you have any children?  
□--Yes             □--No 
If yes how many children do you have? -------------------------- 
How many of them are staying with you?  ------------------------ 
6. What is your highest level of education? 
□--No formal schooling  □--Primary school  
□--Secondary School up to Form 3-[PMR/SRP/LCE] 
□--Secondary School up to Form 5 [SPM/MCE/O-Levels]  
□--High School [Form 6/ A--levels/Matriculation]       
□--Diploma   □--Degree      
□--Others: [Specify]…………….................................... 
 
 
Appendix A 
 
 273 
7. Current job status: 
□--Not employed       □--Employed          □--Self employed              
 □—Retired                 □--Retired and re-employed 
8. What is your average monthly income from ALL sources including paid job, 
public assistance/welfare? 
□--Less than RM 1500 per Month   □--RM 1501--- 2500     
□--RM 2501--- 3500       □--RM 3501--- 4500                        
□--RM 4501--- 5500       □--RM 5501--- 6500                   
□--RM 6501 or more 
9- Do you face any the following adverse events (any unexpected, 
unfavourable or dangerous reaction to a drug e.g. Itching) because of your 
HIV treatment in the last 3 month? Please circle 1or 2 in the space below. 
 Adverse efect Yes N 
□-- Vomiting 1 2 
□-- Diarrhoea 1 2 
□-- Loss of appetite 1 2 
□-- Dry Mouth 1 2 
□-- Itching 1 2 
□-- Tiredness 1 2 
□-- Rash 1 2 
□-- Fever 1 2 
□-- Headache 1 2 
 
Part Two: Adherence grading and factors affecting adherence. 
10- Do you currently use medicines that have not been prescribed for you by 
your  
         Your doctor? 
 
□—Yes          □--  No 
 
11- Do you currently drink so much alcohol that it prevents you from taking your   
             HIV medicines?      □—Yes          □-- No 
 
12-Have you ever used any of the following Traditional / Alternative medicine  
      for the treatment of  HIV / AIDS? Please circle 1 or 2 in the space below. 
  Yes No 
 □-- Herbal Medicine (The use of plants) 
 
1 2 
 □--Yoga (is the practice of breathing exercises, postures,  
       stretching exercises) 
 
1 2 
 □--Acupuncture (involves the relatively painless insertion of  
      extremely thin needles into the skin at specific points) 
 
1 2 
 □-- Dietary Supplements (Vitamins, Minerals) 
 
1 2 
 □-- Mind-body Therapies (Meditation uses deep breathing  
       or other focusing techniques) 
 
1 2 
 □--Use of any Religious Treatments ( drinking prayer water, take 
part in  prayer for treatment )  
 
1 2 
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13- When did you start taking HIV medicine for the first time? 
(Modern/Western medicine only).         
  Month …………….....           Year: ………............. 
14- How many different HIV medicines are you taking every day? 
□--2                 □--3           □--4           □--5             □--6             □--7    □--8 
15- How many HIV pills / tablets are you taken per day? 
□--2                 □--3           □--4           □--5             □--6             □--7 
□--8                 □--9           □--10         □--11           □--12                         
16- Answer the question by Circling 1or 2 in the space below  
  Question 
 
Yes     No       
□-- Do you sometimes find it difficult to remember to take your   
medicine? 
 
1 
 
2 
□-- When you feel better, do you sometimes stop taking your 
medicine? 
 
1 
 
2 
□-- Thinking back over the past few days, have you missed 
any of your doses? 
 
1 2 
□-- Sometimes if you fell worse when you take the medicine, 
do you stop taking it? 
 
1 2 
 
17- What is the number of doses [specific quantity of a medicine taken at 
one time] you missed in the LAST 2 [TWO] weeks?   ------------------- 
18- What is the number of doses [specific quantity of a medicine taken at 
one time]  you missed in the LAST 4 [FOUR] weeks? ---------------------- 
19- What is the number of doses [specific quantity of a medicine taken at 
one time] you missed in the LAST 6 [SIX] weeks? -------------------- 
 
Part 3: Factors which facilitate or constrain adherence to HAART 
20 -The following reasons facilitate or help you to adhere to your HIV 
medication. Please circle 1 or 2 for as many reasons as possible in the 
space bellow. 
 Reasons 
 
Yes No 
□ Acceptance of one’s HIV status 
 
1 2 
□ Disclosure (Revealing disease status to people/ friends) 
 
1 2 
□ use of alarm / clock for remembering drug time 
 
1 2 
□ Belief in the efficacy of pills in the treatment 
 
1 2 
□ The needs to care for others 
 
1 2 
□ Social support 
 
1 2 
□ Afraid of my health condition getting worse 
 
1 2 
□ Afraid of developing resistance to drugs and the drug ay 
stop working 
1 2 
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□ To avoid paying for new drugs 
 
1  
□ Self-efficacy and the ability to take and adhere to ART 
 
1 2 
 
 
21-The following are reasons for missing medications. If you have ever missed 
your HIV medication in the last one Month, please circle 1 or 2 for as many 
reasons as possible in the space below. 
 Reasons            
             
Yes No 
□-- Was away from home 1 
 
2 
□-- Was busy with other things 1 
 
2 
□-- Simply forget 1 
 
2 
□--
. 
Had simply too many pills to take 1 
 
2 
□-- Wanted to avoid side effects 1 
 
2 
□-- Did not want other to notice you taking medications 
 
1 2 
□-- Had a change in daily routine.   
 
1 2 
□-- Felt like the drug was toxic / harmful.      1 
 
2 
□-- Fell asleep/ slept through dose time.      1 
 
2 
□-- Felt sick or ill 1 
 
2 
□-- Felt depressed /overwhelmed.                
 
1 2 
□-- Felt well.                     
 
1 2 
□--
. 
Ran out of pills 1 
 
2 
□-- Had problem taking pills at specified times [with meals on 
empty stomach, etc].                           
1 2 
□--
. 
Religious belief.   1 
 
2 
□-- Treatment and drug collection time in the hospital is too 
long 
1 
 
2 
□-- Distance to travel to hospital too long and costly 1 
 
2 
□-- Poor relationship with health provider  
 [Dr, Nurse]. 
1 2 
□-- Cost of treatment too high.                                                                          1 
 
2
□-- Beliefs and preference for traditional medicine. 
 
1 2 
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Appendix B 
SOAL SELIDIK LAPORAN PEMATUHAN SENDIRI 
No. instrumen: ………….. 
 
No. SB Pesakit: ...............         Tarikh penilaian [DD/MM/YYYY]: .................  
 
Pentadbir: ...................................................................................................... 
 
Pengenalan: 
Saya yang bernama Dr Umar Yagoub Mohammed adalah pelajar pascasiswazah di 
dalam Kesihatan Awam di Jabatan Perubatan Kemasyarakatan dan Pencegahan, Fakulti 
Perubatan,Universiti Malaya, di bawah penyeliaan Profesor Awang Bulgiba Awang 
Mahmud. 
Saya sedang melakukan penyelidikan  mengenai faktor-faktor pematuhan  bagi rawatan 
antiretroviral pada pesakit Positif HIV di Hospital Sungai Buloh, Malaysia.  
Saya amatlah menghargai kesudian anda melengkapkan soalan-soalan ringkas ini, yang 
mana hanya mengambil masa lima hingga 10 minit sahaja untuk melengkapkannya. 
Penglibatan anda dalam projek ini adalah secara sukarela sepenuhnya. Segala maklumat 
yang diperolehi daripada penglibatan anda dalam kajian ini adalah di rahsiakan. Untuk 
makluman, identiti anda tidak akan didedahkan dalam tesis ini atau dalam mana-mana 
laporan mahupun penerbitan yg berasaskan kajian ini. 
Saya juga ingin meyakinkan bahawa kajian ini telah pun dinilai dan menerima  
pelepasan dari segi etika. Penglibatan anda akan memberi sumbangan besar kepada 
kajian perubatan dan kami mendahului dengan ucapan ribuan terima kasih 
 
Arahan 
Sila jawab soalan berikut iaitu bahagian I dan II dengan menanda “√” pada kotak yang 
disediakan 
Tandakan pada satu kotak yang anda anggap betul sahaja 
Bahagian I: Ciri-ciri sosio-demografik 
1. Jantina :   
 
□--Lelaki        □--Perempuan 
     
2. Agama: 
 
□--Islam        □--Budha      □--Hindu    □--Kristian    □--Taoism   
 
□-- Lain-lain: [Nyatakan]…………… 
 
3. Kumpulan Etnik: 
 
□--Melayu          □--Cina       □--India       □-- Lain-lain: [Nyatakan] 
 
4. Status Perkahwinan:  
 
□-- Bujang      □-- Berkawin     □--Berpisah[berkahwin tetapi tidak hidup bersama]   
      
□--Bercerai     □-- Janda/Duda 
      
5. Adakah anda mempunyai anak? 
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□--Ya             □--Tidak 
    
Jika ada, berapa ramai anak anda? -------------------------- 
 
Berapa ramai  yang masih tinggal dengan anda? ------------------------ 
 
6. Pendidikan tertinggi anda? 
 
□-- Tiada pendidikan formal        □-- Sekolah rendah 
      
□-- Sekolah menengah sehingga Tingkatan 3 [PMR/SRP/LCE] 
   
□-- Sekolah menengah sehingga tingkatan 5 [SPM/MCE/O-Levels] 
    
□-- Sekolah menengah Atas [Tingkatan 6/A-Levels/Matrikulasi] 
 
□--Diploma   □-- Ijazah Sarjana Muda    □--Lain-lain: [Nyatakan]……………...... 
 
7. Status pekerjaan sekarang: 
 
□-- Menganggur    □--Bekerja           □—Bekerja sendiri         □—Bersara 
     
□-- Bersara dan bekerja semula 
     
8. 
 
 
 
 
 
 
 
 
9. 
Berapa keseluruhan purata pendapatan bulanan anda? Ini termasuk kerja bergaji, 
bantuan awam/kebajikan 
 
□-- Kurang dari RM 1500 sebulan     □--RM 1501--- 2500     □--RM 2501--- 3500 
    
□--RM 3501--- 4500                        □--RM 4501--- 5500       □--RM 5501--- 6500   
 
□--RM 6501 atau lebih 
 
Pernahkah anda mengalami kesan sampingan (sebarang kesan yang tidak dijangka, 
rasa tidak selesa atau tindakbalas berbahaya terhadap ubat tersebut seperti rasa 
gatal-gatal) akibat daripada rawatan HIV anda sepanjang 3 bulan yang lepas? Sila 
bulatkan 1 atau 2 di dalam ruang yang diberikan di bawah 
 
 Kesan sampingan Ya Tidak 
□-- Muntah-muntah 1 2 
□-- Cirit-birit 1 2 
□-- Hilang selera makan 1 2 
□-- Mulut kering 1 2 
□-- Merasa gatal-gatal 1 2 
□-- Keletihan 1 2 
□-- Ruam 1 2 
□-- Demam 1 2 
□-- Sakit kepala 1 2 
 
 
 
 
Appendix B 
 
 278 
Bahagian II: Gred Pematuhan dan faktor-faktor yang mempengaruhi pematuhan 
10.  Adakah anda menggunakan ubat-ubatan yang tidak dipreskipsikan oleh doktor anda  
 
□--Ya          □--  Tidak 
 
 
11. Adakah di kebelakangan ini anda mengambil alkohol berlebihan yg menyebabkan 
anda tidak boleh mengambil ubat-ubatan ? 
             Ubat-ubat HIV  ?      □--Ya         □--Tidak  
 
12. Pernahkah anda mengambil mana-mana ubat-ubatan Tradisional/Alternative berikut. 
Bagi tujuan rawatan HIV/AIDS? Sila bulatkan 1 atau 2 pada ruang yang diberikan di 
bawah 
  Ya Tidak 
 □-- Ubat-ubatan herba (Penggunaan tumbuh-tumbuhan) 1 2 
 □-- Yoga (iaitu mempraktikan latihan pernafasan, kedudukan badan,    
      latihan regangan badan) 
 
1 2 
 □-- Akupunktur (Jarum halus yang dicucuk pada tempat tertentu 
     pada kulit tetapi tidak menyakitkan) 
 
1 2 
 □-- Diet tambahan (vitamin , mineral) 1 2 
 □-- Terapi Minda (Meditasi yang melibatkan pernafasan dalam atau lain 
lain teknik penumpuan fikiran) 
 
1 2 
 □-- Menggunakan mana-mana kaedah rawatan keagamaan (meminum 
air yang telah disembahyangkan, mengambil bahagian di dalam acara 
sembahyang untuk sembuh) 
1 2 
 
13. Bilakah anda mula iaitu pertama kali mengambil ubat-ubatan HIV? (Bagi Moden/ubat-
ubatan Barat sahaja)        
Bulan: …………….                 Tahun:………….. 
14. Berapa jenis ubat-ubatan HIV yang anda ambil setiap hari? 
□--2                 □--3           □--4           □--5             □--6             □--7    □--8 
15. Berapa banyak pil/tablet anda ambil sehari? 
□--2                 □--3           □--4           □--5             □--6             □--7 
□--8                 □--9           □--10         □--11           □--12                         
16. Sila jawab soalan dengan menandakan 1 atau 2 pada ruang yang diberikan 
  Soalan Ya     Tidak      
□-- Pernahkah anda mengalami masalah kesukaran untuk mengingat  
bila seharsnya mengambil ubat-ubatan anda? 
1 
 
2 
□-- Apabila anda merasa lebih sihat, adakah anda kadang kala berhenti 
mengambil ubat-ubatan anda? 
1 
 
2 
□-- Dalam hari yang lepas, adakah anda tertingal mengambil mana-
mana dos ubat-ubatan anda? 
1 2 
□-- Apabila anda merasa semakin teruk apabila mengambil ubat-ubatan 
anda, adakah anda berhenti mengambilnya? 
 
1 2 
 
17. Yang mana satukah bilangan dos [Nyatakan kuantiti ubat-ubatan yang diambil pada satu-
satu masa] anda terlepas pada 2 minggu yang lepas? …………………………….. 
18. Yang mana satukah bilangan dos [Spesifikan kuantiti ubat-ubatan yang diambil pada satu-
satu masa] anda terlepas pada 4 minggu yang lepas? …………………………….. 
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19. 
 
20. 
Yang mana satukah bilangan dos [Nyatakankan kuantiti ubat-ubatan yang diambil pada 
satu-satu masa] anda terlepas pada 6 minggu yang lepas?........................................ 
 
Bahagian 3: Faktor-faktor yang mungkin mengekang pematuhan kepada HAART 
Berikut adalah sebab-sebab yang membantu anda mengikuti arahan kepada ubat-ubatan 
HIV anda. Sila bulatkan 1 atau 2 untuk sebanyak mana penyebab yang mungkin pada ruang 
yg diberikan dibawah 
 Penyebab : Ya Tidak 
    
□-- Penerimaan status HIV anda 1 2 
□-- Mengakui (mendedah status penyakit kepada masyarakat/kawan-
kawan) 
1 2 
□-- Menggunakan loceng / Jam untuk mengingatkan masa mengambil 
ubat-ubatan 
1 2 
□-- Percaya kepada kesan pil yang diambil  semasa rawatan 1 2 
□-- Keperluan untuk memberi perhatian kepada orang lain 1 2 
□-- Sokongan Sosial 1 2 
□-- Risau akan keadaan kesihatan saya bertambah teruk 1 2 
□-- Risau akan berlaku rintangan kepada ubat-ubatan dan kemungkinan 
ianya tidak berkesan lagi 
1 2 
□-- Bagi menglakan membayar ubat-ubatan yang baru. 1 2 
□-- Kesedaran dan kemampuan diri untuk mengambil patuh pada ART 1 2 
 
21. Berikut adalah sebab-sebab mengapa terlepas daripada mengambil ubat-ubatan. 
Sekiranya anda pernah terlepas dalam pengambilan ubat-ubatan HIV pada 1 
bulan yang lepas. Sila bulatkan 1 atau 2 atau sebanyak mana sebab yang 
mungkin dalam ruang yang diberikan dibawah: 
 Penyebab        
      
Ya Tidak 
□-- Tidak berada di rumah (Keluar rumah/berada jauh dari rumah) 1 2 
□-- Sibuk dengan perkara-perkara lain 1 2 
□-- Terlupa 1 2 
□-- Terlalu banyak pil yang perlu diambil 1 2 
□-- Mengelakan kesan sampingan 1 2 
□-- Tidak mahu orang lain mengetahui yang anda mengambil ubat-
ubatan 
1 2 
□-- Perubahan kepada rutin seharian 1 2 
□-- Merasa bahawa ubat-ubatan tersebut meracun/memudaratkan  1 2 
□-- Mengantuk/tertidur ketika masa dos    1 2 
□-- Merasa tidak sihat atau sakit 1 2 
□-- Merasa tertekan/teruja  1 2 
□-- Merasa sihat 1 2 
□-- Kehabisan pil 1 2 
□-- Mempunyai masalah mengambil pil pada masa-masa tertentu 
[masa makan dengan perut kosong, dan lain-lain]                      
1 2 
□-- Kepercayaan agama  1 2 
□-- Rawatan dan masa mengambil ubat hospital terlalu lama 
menunggu 
1 
 
2 
□-- Tempat kediaman terlalu jauh dan memerlukan kos yng tinggi 1 2 
□-- Hubungan yang tidak baik dengan pengamal perubatan [Dok-
tor, Jururawat] 
1 2 
□-- Kos rawatan terlalu tinggi                                                                        1 2 
□- Kepercayaan dan keutamaan kepada ubat-ubatan tradisional 1 2 
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Appendix C 
 
                         自我药物遵守评估问卷 
仪表编号: ------------- 
病人双溪毛糯编号: ........................................................................          
评估日期 [日/月/年]: ...................................................................                                            
执行者: ......................................................................................... 
 
简介：  
我是Umar Yagoub Mohammed 
博士。我是马来亚大学公共卫生部社会和预防医学系Awang Bulgiba Awang 
Mahmud教授的研究生。我正于马来西亚双溪毛糯医院进行一项关于影响爱滋病
阳性患者正确遵守服用抗逆转录病毒治疗药物的因素之研究。问卷填写大约需要
您5至10分钟的时间，您若能协助完成此简短问卷，本人不胜感激。另外，参与
此研究与否，完全出自个人意愿。您所提供的所有信息将会获得保密。此外，您
的身份将不会在任何以此研究为基础的论文或在报告中被发表。我愿向您保证，
这项研究已通过伦理审查和批准。您的参与将为广大的医学研究作出贡献，在此
，我们对您的参与再次表达万分谢意。 
  
说明：  
请回答第一部分和第二部分的所有问题，并在相关选项或您认为正确的一项打勾
“✔”。答案不得复选。 
第一部分： 社会人口特征。   
1 。性别：  
  □ -男性    □ -女性  
 
2 。宗教：   
  □ -伊斯兰教 □ -佛教  □ -印度教 □ -基督教 □ -道教  
  □ -其他：  [请列明] ... ... ... ... ..................  
 
3 。民族：    
  □ –巫裔 □ –华裔 □ -印裔 □ -其他：   
[请列明] ... ... .  
 
4 。婚姻状况：   
  □ -单身  □ -已婚  □ –分居 [已婚但没有生活在一起]  
  □ -离婚  □ –寡妇（丧夫）/鳏夫（丧妻）  
 
 
5 。您有没有孩子？  
  □ -有 □ -无  
如果有，多少位？ .................................................. ..............  
其中有多少位是与您同住？ .................................................. ............  
 
6 。您的最高学历？  
  □ -没受过正规的学校教育 □ -小学  
  □ -中学, 最高到Form 3 - [PMR/SRP/LCE]  
  □ -中学, 最高到Form 5 [SPM/MCE/O-Levels]  
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  □ -高中[Form 6 / A--levels/Matriculation ]  
  □ -文凭  □ -学位   
□ -其他：  [请列明] ... ... ... ... ... ............................. .......  
 
7 。目前的工作状况：   
  □ -没被雇用 □ -就业  □ -自雇  □ -退休  
  □ –已退休，再就业  
 
8 。您每月的总收入 （ 包括工作、公共援助或福利金）  平均为多少？ 
 
  □--每月少于RM1500）     □--RM 1501--- 2500       □--RM 2501--- 3500              
 □--RM 3501--- 4500     □--RM 4501--- 5500       □--RM 5501--- 6500                   
□--RM 6501或以上 
 
 
 
 
  
9 。  您是否（ 面对）任何不良反应（药性副作用）？[在过去3个月因为您的爱滋病治疗，  
是否引起任何意料之外，不利或危险的药物反应如：发痒] 请在以下选择中圈出1或2。  
 药性副作用 有 无 
□-- 呕吐 1 2 
□-- 肚泻 1 2 
□-- 没胃口 1 2 
□-- 口干 1 2 
□-- 发痒 1 2 
□-- 疲倦 1 2 
□-- 红疹 1 2 
□-- 发烧 1 2 
□-- 头痛 1 2 
 
  
第二部分：药量遵守分级及其影响因素。  
10 。  您目前有没有服用不是由您的医生所开的药物？ 
 
 
□ -有 □ -无  
 
11 。  您目前有没有饮用过量的酒导致您无法服用抗爱滋病药品？ 
 □ -有 □ -无  
12 。您可否曾使用以下任何传统药物以治疗爱滋病？请在以下选择中圈出1或2。  
  有 无 
 □—药草(使用植物) 
 
1 2 
 □—瑜伽 （操练呼吸，姿势与伸展运动） 1 2 
 □—针灸（无痛地将针刺入人体特定穴位） 1 2 
 □—营养补助品(维他命，矿物质) 
 
1 2 
 □—身心治疗(深思；深呼吸或其他帮助聚焦的方法) 
 
1 2 
 □—任何的宗教治疗法( 饮符水；祷告医治)  1 2 
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13 
。  
您是什么时候开始服用抗爱滋病药物？ [以现代/西药为准] 。   
                                       
             ... ... ... ................ 年... ... ... ... .... 月  
 
14 
。  
您每天服用多少种不同种类的抗爱滋病药物？ 
□--2                 □--3           □--4           □--5             □--6             □--7    □--8 
15 
。  
您一天服用多少颗抗爱滋病治疗的药丸？ 
□--2                 □--3           □--4           □--5             □--6             □--7 
□--8                 □--9           □--10         □--11           □--12                         
 
16 
。  
请回答以下问题，并在相关选项圈出“１”或“２”。  
  问题 
 
是    否     
□-- 您是否偶尔会觉得很难记得服药？  1 
 
2 
□-- 当您觉得好转时，是否会偶尔停止服药？ 
 
1 
 
 
□-- 回想过去的四天，您是否有错过任何的药物剂量？ 
  
1 2 
□-- 若偶尔当您服用药物后觉得不适，是否会停止服用？ 
  
1 2 
 
 
17 
。  
在过去的两（ 2） 周，  您错过了多少的药物剂量（ 次数） ？ [根据单一时间内医生所建议服用的药物剂量]    
------------------- 
18 
。  
在过去四（ 4） 周，  您错过了多少的药物剂量（ 次数） ？[根据单一时间内医生所建议服用的药物剂量]  ---
------------------- 
19 
。  
 
 
20 
。  
在（过去） 的六（ 6） 周，  
您错过了多少的药物剂量（ 次数） ？[根据单一时间内医生所建议服用的药物剂量] -------------------- 
 
第三部分： 提升或减少抗逆转录病毒治疗 (HAART) 依从性的因素 
以下的理由能帮助您遵守服用抗爱滋病药品。请尽量在所有相关的理由圈出“1”或“2”。  
 理由 
 
是 否 
□-- 对爱滋病患的接纳度 
 
1 2 
□-- 公开透露(将自己的感染状况告知他人/朋友) 
 
1 2 
□-- 以闹钟/时钟记住服药时间 
 
1 2 
□-- 相信治疗中药物的功效 
 
1 2 
□-- 需要照顾他人 
 
1 2 
□-- 社会支持 
 
1 2 
□-- 担心病情恶化 
 
1 2 
□-- 担心对药物产生抗药性，导致无法让药物达到功效 
 
1 2 
□-- 避免为新药支付药费 1 2 
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□-- 自我效能感，抗爱滋病治疗 
 
1 2 
 
 
   
 
 
21 
。以下所列是错过药物治疗的理由。如果您在过去一个月内曾错过任何药物治疗，请尽量在所有相关的
理由圈出“1”或“2”。  
 理由           
             
是 否 
□-- 不在家。  1 
 
2 
□-- 忙于其他事情。  1 
 
2 
□-- 忘了。  1 
 
2 
□--
. 
太多药物需要服食。  1 
 
2 
□-- 为了避免药物的副作用 1 
 
2 
□-- 不想让别人知道您接受药物治疗 
 
1 2 
□-- 日常生活习惯起了改变 
 
1 2 
□-- 觉得药物是有毒/有害的。  
 
1 
 
2 
□-- 睡着了/睡过了服药的时间。  1 
 
2 
□-- 生病或感到不适。  1 
 
2 
□-- 感到忧郁，沮丧/不知所措。  
 
1 2 
□-- 感觉病好了。  
 
1 2 
□--
. 
药丸服食完了。  1 
 
2 
□-- 在特定时间内服药面对困难 [比如，需要饭后服食 或 
空腹服食 等等] 。 
1 2 
□--
. 
宗教信仰。  1 
 
2 
□-- 在医院治疗和领取药物的时间太长。 1 
 
2 
□-- 距离医院太远，交通费用高昂。 1 
 
2 
□-- 与医务人员（医生、护士）的关系不好，无法取得良性交流。 1 2 
□-- 治疗费用太高。  1 
 
2 
□--
. 
相信或优先选择传统疗法 1 2 
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Appendix D 
 
Adherence to HAART in HIV positive patients 
                Data collection form from online records 
                          At Sungai Buloh Hospital     
Instrument No: ------------   Patients S B NO................................                                                                     
Date......................    Part 1  
1- Patients Age in 
Years....................................................................................................... 
2- Date of Birth.........../............./......................./ 
3- Address................................................................................................................... 
................................................................................................................................ 
.................................................................................................................................
............................................................................................................................... 
................................................................................................................................ 
4- Employments Status (e.g. Labour or professional)................................................. 
5- Method of exposure to the HIV virus..................................................................... 
6- CDC HIV 
STAGE....................................................................................................... 
 Pharmacy records of current treatment: 
Treatment was initiated on......../............/...............                        Duration of current 
treatment..................Months 
No                         Drug Name  
 
          Dose Pills No per Dose     Date dispensed    Date Refilled 
1      
2      
3      
4      
4      
5      
6      
 
 
 
 
 
 
Table 2 Measurements:  
No Date           
 
Weight  ( KG ) Height ( M ) BMI           
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Table 3 Investigations done: 
No Date 
                                       
HB WBC CD4 CD8 Viral load    Log-viral load 
1  
 
      
2  
 
      
3  
 
      
4  
 
      
 
Table 4 Liver function tests 
No                   Date Total protein Albumin      ALP     BIL     ALT         AST        GGT 
1         
2         
 
Additional information  
.............................................................................................................................................
.............................................................................................................................................
.............................................................................................................................................
.............................................................................................................................................
.............................................................................................................................................
.............................................................................................................................................
.............................................................................................................................................
.....................................................................  
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Appendix E 
 
Adherence to HAART in HIV positive patients 
                                  Blood sample collection form for TDM  
 
Form No: ....................................                                               
Patient S B NO:-........................ 
Instructions:- 
1-Blood samples should be obtained if patient is on any of the following three 
named HIV drugs Lamivudine, Nevirapine and Efavirenz. 
2- Blood samples should only be collected if patient’s last dose has been taken 
more than 4 hours ago. 
3-Blood samples should be obtained using EDTA or lithium heparin collection      
tubes. 
4-6mls of blood should be collected. 
5-The blood should be centrifuged within 2 Hours of collection. After 
centrifugation, plasma should be placed in a plain tube and then stored in the 
fridge. 
6-Ensure that the Test Request form below is completed fully. 
 
Sample Information:- 
First sample ID:-....................                          Date taken: ....................... 
Time Taken:-.........................                         Time centrifuged: .................. 
No          Drug 
name 
 Dose 
(MG)               
Date of last 
dose 
Time of last 
dose 
No of doses / 
day 
1 Lamivudine     
2 Efavirenz      
3  Nevirapine     
 
Sample collected by:-......................................     Sign:-................................ 
Date:-............................                         Time:-................................ 
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Appendix F 
 
 
Adheren kepada HAART pada pesakit positive HIV 
Borang pengumpulan sampel darah  untuk TDM 
 
No. Borang:…………………………………………….                                       
No. SB pesakit:……………………………….. 
Arahan: 
1- Sampel darah patut diambil jika pesakit sedang dalam pengambilan mana-mana tiga 
daripada nama ubat HIV berikut Lamivudine, Nevirapine and Efavirenz. 
2- Sampel darah hanya diambil jika dos terakhir pesakit telah diambil lebih dari 4 jam 
yang lepas 
3- Sampel darah mesti diambil dengan menggunakan tiub pengumpul EDTA atau 
Lithium heparin.  
4- 6 ml darah patut diambil   
5-Darah tersebut patut diemparkan dalam masa 2 jam selepas diambl. Selepas 
emparan, plasma patut diletakkan didalam tiub kosong dan disimpan di dalam peti 
sejuk 
6- Pastikan bahawa borang permintaan ujian dibawa dilengkap dengan betul 
 
Maklumat sampel:- 
 
ID sample pertama:-....................                      Tarikh diambil: ....................... 
Masa diambil:-.........................                    Masa diemparkan: .................. 
    
No Nama Ubat  Dos (MG)      Tarikh dos 
terakhir 
Masa dos 
terakhir 
Tiada (bilangan) 
dos /hari 
1 Lamivudine     
2 Efavirenz      
3  Nevirapine     
 
Sampel diambil oleh:-...............................    Tandatangan:-................................  
Tarikh :-............................                            Masa:-................................ 
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Appendix G 
Adherence to HAART in HIV positive patients 
Pharmacy Refill Data from Patients online records 
 
Instrument No: --------- Patients S B NO................................  Index visit date  
......../....../..........  
Instructions: 
Please complete the following tables below, starting from the first fill as the most 
recent pharmacy visit and going retrospectively and consecutively until you complete 
the spaces for all the 6
 
refills for each table below. 
 
1-Lamivudine (3TC) 
Refill 
inform 
Refill 
status 
No of pills 
prescribed per 
day 
No of pills 
dispensed 
Date 
dispensed 
(dd/mm/yyyy) 
Days 
b/w 
refills Yes No 
1
st
 Fill       
2
nd
  Fill       
3
rd
  Fill       
4
th
 Fill       
5
th
 Fill       
6
th
 Fill       
Total        
 
2-Efavirenz( Stocrin) 
Refill 
inform 
Refill 
status 
No of pills 
prescribed per day 
No of pills 
dispensed 
Date 
dispensed 
(dd/mm/yyyy) 
Days 
b/w 
refills Yes No 
1
st
 Fill       
2
nd
  Fill       
3
rd
  Fill       
4
th
 Fill       
5
th
 Fill       
6
th
 Fill       
Total        
 
 
 
 
3-Nevirapine (Viramunie) 
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Refill 
inform 
Refill 
status 
No of pills 
prescribed per day 
No of 
pills 
dispensed 
Date 
dispensed 
(dd/mm/yyyy) 
Days 
b/w 
refills Yes No 
1
st
 Fill       
2
nd
  Fill       
3
rd
  Fill       
4
th
 Fill       
5
th
 Fill       
6
th
 Fill       
Total        
 
HAART Treatment was started on 
(DD/MM/YYYYY).............................................                          
Adherence = 
(Pills dispensed/ pills prescribed per day)/days between refills) x 100% 
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Appendix H 
STUDY INFORMATION SHEET 
Please read the following information carefully, do not hesitate to discuss any 
questions you may have with the researcher or your own doctor. 
 
STUDY TITLE: Factors affecting adherence to antiretroviral treatment in HIV 
positive patients a major hospital in Malaysia  
Introduction: We are glad to inform you that we are very committed to the health, 
safety and welfare of HIV positive patients in this hospital undertaking treatment. We 
recognize that Adherence to antiretroviral treatment in HIV positive patients is a health 
and safety issue and acknowledge the importance of tacking the factors affecting 
adherence to antiretroviral treatment.Therefore, we would be most grateful if you could 
participate in this study. The principal investigator for this study is Prof Dr Awang 
Bulgiba the Head of Department of Social and Preventive Medicine, Faculty of 
Medicine, University Malaya. 
What is the purpose of the study? 
We are asking you to take part in this study now to ensure that we can recommend 
measures which will be used to improve patient’s adherence to antiretroviral treatment 
in Malaysia and be used as guidelines by Doctors and Pharmacist for treatment of HIV 
positive in Malaysia. 
What are the procedures to be followed? 
The first part of this study involves you completing a questionnaire which will take less 
than 10 minutes of your time. All information obtained from this study will be 
STRICTLY treated as CONFIDENTIAL. Only the study investigators will have 
access to the confidential data which identifies you by your socio-demographic 
characteristics. Your responses to this questionnaire will remain ANONYMOUS and 
only group data will be presented. It WILL NOT be used as an evaluation of your work 
capabilities. You’ll not be identified in any report resulting from this study. 
Please take the time to complete the questionnaire. Once you have completed the 
questionnaire, please hand over the questionnaire to the study investigators who are at 
your clinic 
The second part of this study involves collecting blood from you which will take only 5 
minutes.  The investigators will collect 3 mls of blood which will be used for test. 
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Appendix I 
 
研究信息表 
 
请仔细地阅读以下信息，如有任何疑问，请别迟疑向研究人员或医生讨论。 
 
 研究标题： 
在马来西亚主要医院的爱滋病呈阳性患者对遵守 
Antiretroviral（抗逆转录病毒）药物正确服用（守时守量）的影响因素  简  
介：我们很荣幸地向您表示，我方非常致力于确保爱滋病患者在这个医院进行治
疗的同时，您的健康，安全和福利也会受到高度的兼顾。我们察觉到 
抗逆转录病毒治疗 
药物药量遵守态度的坚持对患者的健康和安全问题，并认知到必须着手解决影响
对遵守 抗逆转录病毒治疗药物 正确服用方法的因素。 
因此，如果您能参与这项研究，我们将会深深感激。 
这项研究是由马来亚大学医学系，社会和预防医学系系主任Prof Dr Awang 
Bulgiba  教授担任首席研究员 
 
研究目的是什么？  
我们要求您参于这项研究，以确保我们可以采取建议措施以改善马来西亚病人对 
抗逆转录病毒 
疗法的坚持和正确服用方法以作为马来西亚医生和药剂师治疗爱滋病患者的指导
方针。  
 
此研究会遵循什么样的程序？  
这项研究的第 
一部分涉及您填写一份需少于10分钟来完成的调查表。本研究所收集资料将严格
地视为机密。只有调查研究人员才会以您的社 
会人口特征来获得机密数据以进行研究。您对这一份调查表的所有回答将保持匿
名，以及只有以群体方式的资料才会被公布。它不会被用来作为评价您工作能力
的评论表。您的身份将会保密以及不会在任何以这项研究为中心的报告或出版中
曝露。  
 
请花一些时间来完成这份调查问卷。一旦您完成了调查问卷，请将这份调查问卷
交还于您诊所的研究人员。 
 
本研究第二部分涉及5分钟的时间来收集您的血液样本。研究人员将收集您3毫升
的血液样本以充作研究用途与测试。 
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Appendix J 
 
Map and Picture of  
Sungai Buloh Hospital 
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